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Résumé 
Les molécules du CMH présentent une panoplie d'antigènes qui, lorsque 
reconnus par un lymphocyte T spécifique, indique à ce dernier de survivre ou de 
s'activer. Le processus menant à la liaison d'un peptide à la poche du CMH de 
classe II, implique trois molécules accessoires, soit la chaine invariante, DM et DO. 
La chaine invariante replie et dirige les molécules du CMHII jusqu'à la voie 
endosomale. Ensuite, DM échange CLIP, peptide découlant de la dégradation de 
la chaine invariante, pour d'autres ayant une meilleure affinité. Exprimé seulement 
chez certaines cellules présentatrices, DO compétitionne avec les molécules du 
CMHII pour la liaison à DM et ainsi favorise la présentation d'antigènes internalisés 
par des récepteurs membranaires. Ensemble, ces protéines ont un potentiel 
immunomodulatoire pouvant être exploité afin d'augmenter l'efficacité de vaccin 
peptidique. 
DO requiert DM pour arriver à maturité et sortir du RE. Cette interaction, qui 
induit un changement de conformation dans la chaine β de DO, peut être sondée à 
l'aide de l'anticorps monoclonal Mags.DO5. En utilisant cet anticorps, nous avons 
montré que DM stabilise l'interaction entre les domaines α1 et β1 de DO et 
influence son repliement dans le RE. Donc, la conformation qui révèle l’épitope 
Mags.DO5 corrèle avec la migration de DO hors du RE. Afin d'étudier plus 
précisément ce changement de conformation, DO fut contraint à une ronde 
d’évolution dirigée. Des 41 mutants obtenus, 25% se retrouvent à l'interface DO-
DM et 12% se retrouvent à la surface exposée au solvant du domain β1, région 
hypothétique de l'épitope Mags.DO5. De plus, la bibliothèque de mutants a été 
testée pour son habileté à inhiber l'activité de DM. La plupart des mutants montre 
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une activité inhibitrice diminuée, ce qui supporte le model où DO compétionne les 
molécules du CMHII en séquestrant le rôle chaperon de DM. 
Les molécules du CMHII ont l'unique habileté de présenter les 
superantigènes, une famille de toxines virales et bactériennes qui force l'interaction 
CMHII-TCR de façon beaucoup moins spécifique qu'en contexte canonique. Alors 
que la façon dont les superantigènes bactériens s'assemblent avec le CMHII et le 
TCR soit bien comprise, la nature du complexe trimoléculaire découlant des 
superantigènes du virus de la tumeur mammaire de la souris (vSAG) reste mal 
définie. En l'absence d'une structure cristalline, une approche fonctionnelle a été 
choisie pour examiner la relation des vSAGs avec le CMHII et le TCR avec le but 
de dévoiler l'architecture de ce multi-complexe protéique. Je montre que le TCR lie 
parallèlement la chaine α du CMHII et vSAG, ce qui résulte en une interaction 
presque canonique. Puisque différents peptides peuvent être tolérés lors de cet 
ancrage, il semble que vSAG ajuste les interactions CMHII-TCR conventionnelles. 
En outre, mes résultats montrent que vSAG reconnait un épitope conformationnel 
et que cette liaison peut être abrogée par l'extension amino-terminale du peptide 
CLIP, laquelle s'étend en deçà de la niche. Finalement, mes résultats suggèrent 
que les vSAG peut réticuler plusieurs CMHII adjacents et active les cellules T via 
son motif TGXY. 
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Abstract 
MHCII molecules expose a weave of antigens, which send survival or 
activation signals to T lymphocytes. The ongoing process of peptide binding to the 
MHC class II groove implicates three accessory molecules: the invariant chain, DM 
and DO. The invariant chain folds and directs the MHCII molecules to the 
endosomal pathway. Then, DM exchanges the CLIP peptide, which is a remnant of 
the degraded invariant chain, for peptides of better affinity. Expressed in highly 
specialized antigen presenting cells, DO competes with MHCII molecules for DM 
binding and favors the presentation of receptor-internalized antigens. Altogether, 
these molecules exhibit potential immunomodulatory properties that can be 
exploited to increase the potency of peptide vaccines. 
 DO requires DM for maturation and to exit the ER. Interestingly, it is possible 
to monitor this interaction through a conformation change on DOβ that is 
recognized by the Mags.DO5 monoclonal antibody. Using Mags.DO5, we showed 
that DM stabilizes the interactions between the DO α1 and β1 chains and that DM 
influences DO folding in the ER. Thus, the Mags.DO5+ conformation correlates with 
DO egress from the ER. To further evaluate this conformation change, directed 
evolution was applied to DO. Of the 41 unique mutants obtained, 25% were 
localized at the DM-DO binding interface and 12% are at the solvent-exposed β1 
domain, which is thought to be the Mags.DO5 epitope. In addition, I used the 
library to test the ability of HLA-DO to inhibit HLA-DM and sorted for the amount of 
CLIP. Interestingly, most of the mutants showed a decrease inhibitory effect, 
supporting the notion that the intrinsic instability of DO is a required for its function. 
Finally, these results support the model in which DO competes against classical 
MHCII molecules by sequestering DM chaperone’s function. 
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MHCII molecules are also characterized by their ability to present 
superantigens, a group of bacterial or viral toxins that coerces MHCII-TCR binding 
in a less promiscuous fashion than what is observed in a canonical setting. While 
the mechanism of how bacterial superantigens form trimeric complexes with TCR 
and MHCII is well understood, the mouse mammary tumor virus superantigens 
(vSAG) are poorly defined. In the absence of a crystal structure, I chose a 
functional approach to examine the relation between vSAG, MHCII and TCR with 
the goal of uncovering the overall trimolecular architecture. I showed that TCR 
concomitantly binds both the MHCII α chain and the vSAG and that TCR-MHCII 
docking is almost canonical when coerced by vSAGs. Because many peptides may 
be tolerated in the MHCII groove, the pressure exerted by vSAG seems to tweak 
conventional TCR-MHCII interactions. Furthermore, my results demonstrate that 
vSAG binding to MHCII molecules is conformation-dependent and abrogated by 
the CLIP amino-terminal residues extending outside the peptide-binding groove. In 
addition, they also suggest that vSAGs cross-link adjacent MHCIIs and activate T 
cells via a TGXY motif.  
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Preface 
 
 
The family of proteins encoded by the major histocompatibility complex 
(MHC) cluster is at the core of the adaptive immune system of most chordates 
and first appeared in jawed fish. From a teleological standpoint, MHC provides 
the tools to the white blood cells to detect and build up cell-mediated immune 
responses (IR), leading to the elimination of invasive microbes and transformed 
cells. The MHC locus encodes i.a. the classical human leukocyte antigens (HLA), 
a group of membrane-bound receptors that bind and present small peptides to T 
cell receptors (TCR) and the non-classical MHC proteins, which assist peptide 
loading. In homeostatic state, most of the organism’s HLAs are loaded with 
peptides derived from self-proteins and do not trigger T cell activation, a result of 
their thymic education. However, when novel peptides are introduced either by 
transformed cells or alien organisms, T cells become activated and guide the 
adaptive IR according to the threat. 
 
The first description of the MHC is attributed to Jean Dausset in the fifties. 
His rationale came forth after observing that the antibodies (Ab) of a patient 
having received multiple blood transfusions could bind to other individual’s 
leukocytes. The patient’s Abs were generated post-transfusion in response to the 
different HLAs of the donors’ leukocytes, later hypothesized to be carried on a 
single genetic system. Since then, the knowledge pertaining to MHC has evolved 
and was refined by Jan Klein who stated: “MHC is a group of genes coding for 
molecules that provide the framework for recognition of foreign antigens by T 
lymphocytes”. This dogma will be carried throughout my report, while MHC will be 
used to define HLA molecules. 
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To maintain homeostasis, MHC genes play a role in generating an 
appropriate immune response while limiting attacks against host’s cells. This 
intricate equilibrium has put the MHC locus under the magnifying glass of many 
scientists, as it is the main gene cluster associated with autoimmunity. For 
example, the HLA-DQ1 alleles have been linked to asthma, type 1 diabetes, 
multiple sclerosis and celiac disease, to name a few (Jones et al., 2006; 
Trowsdale, 2011). However, it is still ambiguous how these genes are involved in 
autoimmunity etiology. The onset of autoimmunity occurs in the presence of a 
precise immunogenic bound-peptide. Thus, a number of molecular events taking 
place prior to the peptide’s association to MHC molecules influence disease 
outcome. Indeed, limiting the peptide exchange of an antigen presenting cell 
(APC), thereby biasing its peptide repertoire, was reported to prevent type 1 
diabetes in susceptible NOD mice (Yi et al., 2010). Manipulating antigen loading 
through non-classical MHCII molecules constitutes a broad and ubiquitous 
approach to deflect or modulate the presentation of harmful peptides to auto-
reactive T lymphocytes. Inversely, promoting the presentation of a pathogen’s Ag 
strengthens peptide-specific IR. Before undertaking any studies assessing the 
therapeutic role of non-classical MHC molecules, we must first understand how 
they work. To this end, the first section of my work examines the structural and 
functional relationship between the two non-classical MHCII molecules HLA-DO 
and -DM. 
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Presentation of peptides by MHC molecules is not the only way to stimulate 
T cells. Certain bacteria and viruses encode superantigens (SAG), a family of 
proteins with the ability to provoke peptide-independent MHCII-TCR binding. As 
opposed to the very cohesive and specific interaction between peptide-bound 
MHCII and TCR, SAGs bind conserved motifs outside the peptide-binding groove 
leading to very strong polyclonal T cell proliferation/deletion responses. While this 
super-activation may cause food poisoning or toxic shock syndrome, it provides 
microorganisms with a way to elude the adaptive immune system. Recent work 
has shown that mice bearing aggressive T cell lymphoma exposed to bacterial- or 
viral- SAG (bSAG and vSAG) had increased survival rates or underwent complete 
remission, respectively (Mundiñano et al., 2010). These findings suggest that 
under certain conditions, SAGs can be used to treat T cell associated diseases. 
Unfortunately, their use in immunotherapy has remained scarce. While many 
bSAG’s structures have been determined and picture a similar fold, mouse 
mammary tumor viruses (MMTV) viral SAGs’ structure remains unsolved. 
Interestingly, the different MMTVs encode SAGs with distinct TCR variable β chain 
complementarities. This characteristic is appealing and could provide an arsenal 
of therapeutic SAGs specific to diverse T cell populations. Unfortunately, those 
viral SAGs (vSAG) are extremely difficult to manipulate and their mode of action 
remains obscure. Thus, the second part of my study makes use of vSAG7 to 
investigate the mechanism by which this family of SAGs succeeds in cross-linking 
MHCII to TCR and provides a detailed structure-function analysis. 
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This thesis is divided into four sections. In Chapter 1, I describe antigen 
presentation in depth, in terms of its regulation, the molecules implicated and the 
mechanism of peptide exchange in its appropriate cellular context. While I 
discuss both MHC class I and II, the latter is emphasized. I also describe 
antigenic and superantigenic presentation to T lymphocytes, focusing on the 
molecular requirements for TCR docking with MHC and highlighting the SAGs 
structure-function. In Chapter 2, I describe my work regarding the requirement of 
a distinct population of MHCII molecules for successful MMTV SAG stimulation. 
This article entitled “The mouse mammary tumor virus superantigen coerce an 
unconventional MHCII-TCR binding topology” has just been accepted upon 
revision to the Journal of Immunology. In Chapter 3, I present my findings 
pertaining to conformational changes of HLA-DO upon its encounter with HLA-
DM, which assists HLA-DO folding and ER egress. These results were published 
in an article entitled “Evidence for a HLA-DM-induced structural change in HLA-
DOβ” in the scientific journal Immunology. Finally, in Chapter 4, I will discuss the 
issues that corroborate the interplay between antigen presentation, HLA-DO and 
their effect on vSAG presentation and I will then propose several perspectives. 
 
 
 
Chapter 1 : Literature review 
In the forthcoming chapter, I will cover the various aspects of the 
conventional MHC class I and II antigen presentation, including the cellular context, 
the major proteins orchestrating the peptide exchange mechanism and the 
mechanism itself. Next, I will introduce the capability of TCR to bind MHC as well 
as the resulting IRs from a MHCII standpoint. Because SAGs, such as MMTV 
vSAG, also stimulate T cells in a MHCII-dependent fashion, I will describe the 
process underlying its maturation and presentation. Lastly, I will focus on the 
associated-peptide given its central role in the presentation. Although many have 
already covered the Ag presentation, my report will seek to provide a more 
mechanistically oriented description regarding the implicated components and 
pathways. 
1.1. Antigen presentation: the players 
Before describing the molecular events leading to the presentation of 
processed antigens (Ags) to T lymphocytes, it is wise to briefly overview the 
cellular and proteic context of the antigen presentation. Virtually all nucleated cells 
express MHCI molecules, which present the cell cytosolic content in the form of 
peptide-bound MHCI (pMHCI) complexes to CD8+ T lymphocytes. Simply put, this 
segment of the MHC strives to clear the host transformed and virus- or intracellular 
bacteria-infected cells that show modified peptide repertoires. However, pMHCI-
TCR contacts are not sufficient to generate cytotoxic T cells. Indeed, generation of 
such cells requires additional stimuli originating from CD4+ helper T cells following 
MHCII Ag presentation by professional APCs. Macrophages, dendritic cells (DC) 
and B lymphocytes are the professional APCs that present MHCII-bound peptides 
(pMHCII) to CD4+ helper T cells. These Ags originate from exogenous proteins, 
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derived either from extracellular bacteria or parasites and endogenous proteins, 
derived either from the MHCII compartments (MIIC) or other organelles following 
autophagy (Neefjes et al., 2011). All professional APCs rely similarly on lysosomal 
degradation to generate antigenic peptides. Yet, it remains that these leukocytes 
possess specific characteristics, which contribute to the distinctive roles they play 
in the adaptive immune system. For this reason, each APC is briefly described, 
with an emphasis on the Ag-handling facet. 
1.1.1. Macrophages 
Macrophages are involved primarily in the innate immune response, as their 
main function is to endocytose cellular debris and pathogens (Mantovani et al., 
1972). Highly versatile, macrophages have the ability to present many Ags to either 
CD4+ or CD8+ T cells (Geissmann et al., 2010). They are found in nearly every 
tissue and present pMHC complexes locally, especially at inflammation sites 
(Trombetta and Mellman, 2005). However, in response to inflammatory cytokines 
or pattern recognition receptors (PRR), the amount of MHCII and co-stimulatory 
molecules expressed at the surface of macrophages remains low. This results in 
antigen presentation that is generally less efficient than that seen with DCs or B 
cells. Nonetheless, macrophages are the first line of defense against invasive 
microorganisms. 
 
1.1.2. Dendritic cells 
While not as efficient as macrophages at endocytosis, DCs are by far the 
most devoted and skilled APCs to present Ags. Naïve DCs reside in almost every 
tissue, i.a. skin, lungs, gastro-intestinal track, where they have access to various 
antigenic proteins. These leucocytes undergo remarkable transformation upon 
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exposure to cytokines or PRR signal transduction, which lead to downstream 
signaling that influences the longevity of the IR (Joffre et al., 2009). Yet, what 
differentiates them from other APCs is their ability to migrate to lymphoid organs 
upon activation, following chemokine signaling. There, they encounter streams of 
naïve T cells seeking cognate pMHC complexes. Additionally, DCs are extremely 
skilled at crosspresenting Ags, which allow them to present virtually any Ag onto 
both MHCI and MHCII molecules (Delamarre et al., 2003). Contrary to 
macrophages, mature DCs express massive amounts of MHCII and co-stimulatory 
molecules conducive to CD4+ T cell activation. DCsʼ roles in peripheral surveillance 
and centralized Ag presentation in the lymph nodes provide for the most rigorous 
and selective IRs. 
 
1.1.3. B lymphocytes 
Contrary to macrophages and DCs, B lymphocytes discern the Agsʼ tertiary 
structure through cell-surface clonotypic immunoreceptors, named B cell receptors 
(BCR) prior to endocytosis (Batista and Harwood, 2009). The specificity-mediated 
internalization allows B lymphocytes to almost exclusively present peptides derived 
from BCR-cognate ligands. However, given that follicular B cells are confined into 
lymphoid organs, i.e. lymph node and spleen, they do not readily have access to a 
wide spectrum of Ags like macrophages and DCs do. Therefore, Ags are supplied 
to follicles via afferent lymph vessels or transported in situ by DCs. As mentioned 
previously, DCs migrate to lymphoid organs upon activation to present antigenic-
derived peptides to naïve T cells, but also carry undigested Ags ready to be 
presented to B cells (Huang et al., 2005; Platt et al., 2010). In fact, membrane-
associated Ag presentation to B cells has been shown to be more important for 
their activation than soluble Ags (Carrasco and Batista, 2006; Depoil et al., 2008). 
 
 
 
4
In summary, the clustering of proteins onto BCRs initiates strong MHCII 
upregulation, Ag degradation and peptide loading. Then, upon specific MHCII-TCR 
engagement, B lymphocytes proliferate and differentiate into extrafollicular 
plasmablasts or plasma cells.  
Overall, the three professional APCs participate in the activation of CD4+ T 
cells. Despite using similar Ag uptake, which relies on endocytosis or receptor-
mediated endocytosis, each professional APC has very distinct abilities. 
Macrophages are exceptional at endocytosis and digestion, DCs are the most 
specialized to generate pMHC complexes and B lymphocytes are very specific at 
presenting peptides derived from BCR-cognate Ags. Having introduced the cells 
implicated in Ag presentation, I will now introduced the MHCI and MHCII molecules 
in the following subsection before undertaking a more specific description of their 
respective peptide loading process. 
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1.1.4. MHC molecules 
As mentioned earlier, I plan to provide a structural overview of the antigen 
presentation. To this end, I find interesting to begin by introducing the MHC folds 
and inherent characteristics, which are highly relevant given that the subsequent 
sections are rendered according to this information. In Figure 1.1, both class I and 
class II MHCs are pictured. PyMol was used to generate the crystal representation 
and the protein database (PBD) access code is provided in the figure legends 
(http://www.pymol.org; PyMOL Molecular Graphics System; DeLano Scientific, San 
Carlos, CA). 
 
Figure 1.1. MHCI vs MHCII 
Cartoon identifying the important MHC subunits and chains are given beside their crystal structure. 
MHCI HC is salmon, β2M is pink and MHCII α and β chain are green and blue, respectively. (a) 
Ribbon depiction of the MHCI HLA-A2 in complex with the p1049 peptide (1B0G) and (b) the MHCII 
DR3-CLIP complex (1A6A). (c and d) View from the top into the MHC class I and II peptide-binding 
groove. Notice the 310 helix c onnecting the α1 domain β-sheet to the α-helix. The peptides, 
depicted as sticks, are cyan and yellow for MHCI and MHCII respectively. 
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First, MHC class I and II molecules share very much the same structure as a 
result of exon shuffling and gene duplication throughout evolution (Danchin et al., 
2004). Both are highly polymorphic heterodimeric proteins, formed by the assembly 
of either the MHCI α chain (heavy chain, HC) with β2-microglobulin (β2M) or the 
pseudosymmetric MHCII α and β chains. They utilize a similar mechanism to bind 
peptides, i.e. a cleft composed of a β-sheet and two α-helixes forming the floor and 
surrounding walls, respectively. While the MHCI peptidic groove is sealed at both 
ends of the α-helixes junctions and only accommodates short peptides of no more 
than 13 amino acids (aa), MHCII’s extremities remain open and unrestrictive vis-à-
vis peptides length. Among their other disparities, MHCI forms its binding groove 
from a single α-chain, divided into α1 and α2 domains (Figure 1.1a). In contrast, 
MHCII niche is composed of the jointed α and β chains, linked together via the floor 
central anti-parallel β-strands (Figure 1.1b).  
1.1.5. Non classical MHC molecules 
 In addition to classical MHC molecules, 
there is a handful of non-classical class I MHCs 
(or MHCI-like molecules) that share the same 
overall fold and may or may not bind β2M or 
peptides, e.g. T10, T22, FcRn, CD1, MR1, 
MICA, MICB, ULBP (Apostolopoulos et al., 
2008). On the other hand, MHCII includes only 
two non-classical molecules, HLA-DM (DM) and 
HLA-DO (DO) (Busch et al., 2005). They differ 
from classical MHCIIs as they have little to no 
polymorphism and modulate the antigen loading 
rather than presenting antigens. While the 
Figure 1.2. DM, non classical MHCII 
Cartoon and crystal structure of DM 
(1HDM), highlighting the lack of a 
peptide-binding groove 
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crystal structure of both human and mice DM were described fifteen years ago 
(Figure 1.2) (Fremont et al., 1998; Mosyak et al., 1998), the structure of DO has 
just been recently solved in pair with DM by the Stern’s group (personal 
communication, unpublished data). DM structure revealed a stable and closed 
peptide-binding groove, the result of two additional disulfide bonds: one between 
the floor and the α-chain helix and the second between the two distal β-sheets of 
the β-chain. Along with DM, DO is unable to stably bind peptides, most probably a 
result of its inherent groove which differ from the classical MHCII. (Refer to section 
1.3.5. HLA-DO) 
1.1.6. Peptide-binding groove 
A striking feature of MHCs is their 
ability to bind an incredible number of 
peptides and to form very stable 
complexes (Madden, 1995). In order to 
achieve such a feat, MHCs rely on a 
conserved hydrogen bond (HB) network 
and very polymorphic binding pockets. 
Firstly, a collection of HBs and van der 
Waals forces help stabilize any peptides 
that are able to take an extended 
backbone conformation. This network of 
interactions is formed between highly 
conserved MHC residues and the polar 
and charged atoms of the peptide main 
chain, independently of its side chains 
(Figure 1.3).  
Figure 1.3. Hydrogen bond network 
(a) Top view into the class II peptide-binding 
groove (1A6A). Conserved MHCII residues that 
form hydrogen bonds with the bound peptide’s 
main chain atoms are shown as sticks. 
Hydrogen bonds are indicated by dotted lines. 
(b) Molecular epresentation of the panel a 
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Secondly, most of 
the allelic differences 
between MHCs are within 
residues protruding toward 
the peptide-binding groove 
and create pockets with 
different stereochemistry, 
the latter accommodating 
the specific peptide side 
chains (Figure 1.4). In 
addition to charge and 
hydrophobicity, the pocket 
dimension may differ 
depending on the MHC’s side chains’ size and thus also impose restrictions on the 
peptide bound by a particular MHC. Whereas this applies to both MHC classes, 
one has a closed groove and the other is open, causing some divergence in 
binding fashion. 
1.1.7. Associated peptide 
MHCI peptide association is mediated by highly conserved charge 
interactions between the HC (pocket A, B and F) and both ends of the peptide. This 
anchors the peptide’s termini and, in certain instances, allows it to bulge out to 
accommodate longer chains (Figure 1.5, a vs b) (Rudolph et al., 2006; Tynan et al., 
2005). On the other hand, peptide binding to MHCII is not constrained into a closed 
groove and lead to different peptide behaviors, as long as they extend as a 
polyproline conformation. First, this allows the groove to tolerate alternate peptide 
registers, i.e. allows the same peptide to use different anchor residues (Bankovich 
et al., 2004; Mohan et al., 2011; Stadinski et al., 2010). Second, recent work by the 
 Figure 1.4. Groove and pockets 
Surface rendering of a peptide-bound MHCII crystal (1A6A). 
The class II α and β chains are green and blue, respectively. (a) 
Lateral view of the peptide-binding cleft. (b) Top view (90° 
rotation toward the reader of a) of the MHCII groove, in which 
the pocket accommodating the associated-peptide side chains 
are colored in white. The peptide backbone and the residues 
filling the MHCII pocket are yellow. 
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Günther’s group revealed that MHCIIs were able to accommodate a peptide in two 
orientations, a phenomenon that may have been overlooked for two decades 
(Günther et al., 2010). They noticed that shortening the peptide in order to prevent 
HB between the P-2 residue and the 310 helix favored a flipped orientation, the latter 
able to form this bond (Figure 1.5, c vs d) Indeed, the authors pointed out that over 
half of the crystallized pMHCII stemmed from covalently associated single-chain 
peptide-β chains. These results may not reflect the behavior of every peptide, but 
could be applied to pseudo-palindromic peptides like CLIP90-104. Further details 
about the CLIP peptide are given in section 1.3.3. 
 
Figure 1.5. Peptide-binding into MHCs 
Comparison of different canonical and alternative peptide-binding modes. Side view of the crystal 
structure of MHCIs associated with the p1049 peptide (a) and the bulging 13-mer EBV peptide (b) 
(1B0G and 1ZHL). MHCII associated with CLIP in a canonical (c) and flipped orientation (d). HBs 
between the peptide P-2 and the α-chain Phe51 are indicated by dotted grey lines. 
Third, the length of the bound peptide may vary depending on the number of 
peptide flanking residues (PFR) around the 9-mer core. These protruding residues 
have a profound effect on TCR recognition and function (Carson et al., 1997). 
Forth, the peptide may alternatively go through or may already have gone through 
different post-translational modifications (Suri et al., 2006). For example, small 
saccharides, nitrotyrosine, oxidized tryptophan and citrulline (an arginine 
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modification) have been shown to elicit distinct T cell responses when part of a 
given peptide. Overall, by using promiscuous and specific interactions in concert, 
the MHC binding cleft is able to efficiently bind the vast pool of peptides and by 
doing so, permits a certain freedom to the peptide’s sequence, which will have 
distinct effects on the T cell response. 
1.1.8. Peptide-MHC single-chain 
The study of antigen presentation took a 
huge step forward with the advent of innovative 
single-chain (SC) peptide-MHC constructs. 
Designed in the laboratory of John Kappler and 
Philippa Marrack in the nineties (Fremont et al., 
1996; Kozono et al., 1994), this technology 
consists of covalently binding, with a flexible 
linker, the peptide and the MHCII β chain or the 
peptide and the β2M for class I and II, 
respectively. More recently, Mitasksov and 
colleagues even went further by designing a 
single chain trimer (SCT), in which the β2M is 
linked to both the HC and the peptide as shown 
in Figure 1.7b (Mitaksov et al., 2007). Not only do SCs generate an homogenous 
peptide-loaded MHC population, but they also provide a way to express any 
peptide’s sequences, great tools to study peptide-specific T cell responses. With 
the recent discovery of peptides capable of binding the MHCII in a flipped-
orientation, it was recently showed that those flipped-peptide MHCII complexes 
could be generated by linking the peptide to the α chain (Schlundt et al., 2012). 
Such SCs are key to my experimental designs, described in the next chapters.  
Figure 1.6. Single chain MHC 
Schematic of class I and II single 
chains. (a) The peptide is covalently 
linked to the amino-terminal end of the 
MHCII β-chain as a SC dimer (b) The 
peptide is linked to the amino-terminal 
end of β2M, which is also linked to the 
HC at its carboxy-terminal end. The 
linkers are portrayed in light grey.  
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1.2. MHC class I 
Briefly mentioned earlier (1.1.4. MHC molecules), the organism is able to 
clear transformed or infected cells through the action of CD8+ T cells upon 
recognition of pMHCI. Herein, the main pathway orchestrating the generation of 
stable pMHCI in the endoplasmic reticulum (ER) is described in depth, 
emphasizing on the role of the peptide loading complex (PLC). The PLC, shown as 
a cartoon representation in Figure 1.7, is a multi-protein complex composed of 
tapasin (Tpsn), the transporter 
associated with antigen processing 
(TAP), the chaperone calreticulin (CRT) 
and the protein disulfide isomerase 
ERp57 (Garbi et al., 2005; Hughes and 
Cresswell, 1998). Altogether, these 
proteins recruit newly synthesized MHCI 
heterodimers and provide the necessary 
tools for optimal peptide binding.  
1.2.1 Folding and assembly within the PLC  
MHCI heavy chain (HC) is a highly polymorphic glycoprotein containing two 
disulfide bridges, one in the α2 domain, linking the α-helix with the peptide groove 
platform and the other in the α3 membrane-proximal immunoglobulin-like domain 
(Garbi et al., 2005; Kjer-Nielsen et al., 2002). The exact mechanism allowing the 
 Figure 1.7.  Peptide loading complex.  
Multiple interactions contribute to the stability of MHCI peptide-loading complex. Central to the 
PLC is the Tpsn, which transmembrane domain interacts with TAP, forms disulfide bond with 
ERp57 and interact with the α2/3 domain of the HC. CRT binds both the HC α1 domain N-linked 
glycan and ERp57. 
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complete refolding, oxidation and recruitment to the PLC of the HC remains 
elusive. Early after synthesis, the lectin-binding chaperone calnexin (CNX) binds 
the α1 domain monoglucosylated N-linked glycan of the HC, protecting the latter 
from aggregation and favoring its refolding (Helenius and Aebi, 2004). The HC 
disulfide bridges are believed to be catalyzed by ERp57 (Antoniou et al., 2007; 
Lindquist et al., 2001). However, ERp57-deficient cell lines showed normal MHCI 
redox status (Garbi et al., 2006), suggesting that other thiol-oxidoreductases 
contribute to its oxidation. The Ahn’s group demonstrated that protein disulfide 
isomerase (PDI) was also found to associate with the HC as a mixed disulfide 
complex and was controlling the oxidation state of the α2 disulfide bond, essential 
for peptide binding (Park et al., 2006). After refolding, the HC associates with the 
β2-microglobulin (β2M) subunit via its α3 domain, which triggers CNX replacement 
by its soluble homologue CRT (Cresswell et al., 2005; Garbi et al., 2005). 
Furthermore, this interaction stabilizes the MHCI/Tpsn interaction (Wearsch et al., 
2011). Together, β2M and calreticulin maintain the HC stability and promote a 
peptide receptive conformation (Culina et al., 2004; Diedrich et al., 2001; Wearsch 
et al., 2004).  
The recruitment of the MHCI HC-β2M heterodimer to the PLC is mediated 
by Tpsn, a multifunctional transmembrane glycoprotein (Bangia et al., 1999; Garbi 
et al., 2000; Grandea et al., 2000; Lehner et al., 1998; Rizvi and Raghavan, 2006). 
Wether Tpsn binds TAP or MHCI first is currently contested (Chambers et al., 
2008; Cresswell et al., 2005). However, in both situations, the outcome is the same 
and is centered around Tpsn. Tpsn binds TAP through its transmembrane domain 
(Momburg and Tan, 2002), covalently associates with ERp57 by a stable disulfide 
bond (Dick et al., 2002; Peaper et al., 2005) and tethers MHCI with its amino-
terminal domain (Turnquist et al., 2004). This allows ERp57ʼs binding to CRT, 
further stabilizing MHCI interactions within the PLC where it ultimately binds 
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peptide (Figure 1.8)(Santos et al., 2007). The Cresswell’s group has recently 
investigated the stoichiometry of the PLC, reporting that the Tpsn/MHCI ratio varies 
from 2:1 to 2:2 in different conditions (Panter et al., 2012). Their results highlight 
the fact that the PLC may dynamically adapt to variation in the peptide supply as a 
result of viral infection, increasing the number of MHCIs in the PLC. 
 
Figure 1.8: The folding and assembly of the PLC.  
CNX mediates the early folding stage of the HC prior to its association with β2M (1 and 2). The HC 
oxidation happens during this time and PDI and ERp57 facilitates this process (1). Upon proper 
oxidation and pairing with β2M, CNX is replace by CRT (3a). In parallel, newly synthesized Tpsn 
associates with TAP before forming a disulfide bound with ERp57 (3b). Rapidly, HC/β2M/CRT 
subcomplexes join the Tpsn/ERp57/TAP subcomplexes forming the PLC. 
1.2.2. Association/dissociation from the PLC  
Having established the members and the basics underlying the assembly of 
the PLC, one question still remains: what triggers the association and the release 
of MHCI. The incorporation of MHCI within the PLC is a cooperative event between 
Tpsn and CRT, both linked together by ERp57 (Peaper et al., 2005). It was 
hypothesized that Tpsn recognizes only empty MHCI and that the conformational 
change occurring upon peptide binding provokes their dissociation (Hansen et al., 
2005; Sadegh-Nasseri et al., 2008). On the other hand, it is unclear whether the 
dissociation of CRT happens before or after the cleavage of the last glucose by 
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glucosidase II. Given the low affinity of CRT for monoglucosylated glycan (1-2 μM) 
(Cresswell et al., 2005), it is more likely that the CRT dissociates prior to cleavage. 
Out of the PLC, pMHCI will either undergo a round of quality control by UDP-
glucose glycoprotein transferase (UGT) which will re-glucosylate improperly folded 
MHCI or egress to the cell surface (Cresswell et al., 2005). Indeed, in absence of 
this second round of quality control by UGT, the quantity of MHCIs at the plasma 
membrane is reduced, its maturation and assembly are delayed and the peptide 
repertoire differs (Zhang et al., 2011). 
1.2.3. Role of PDI in the PLC  
The fact that two disulfide isomerases are present in the PLC raises the idea 
that they are implicated in the redox state of MHCI, especially since the redox 
status plays an important role in peptide loading (Park et al., 2006; Peaper et al., 
2005). Indeed, in the absence or in the exclusive presence of suboptimal peptides, 
there is an increase of partially reduced MHCI (Park et al., 2006). To verify if 
ERp57 or PDI were implicated in the redox state of MHCI, a search for mixed 
disulfide was conducted. ERp57 was shown as a mixed disulfide complex with the 
HC, but only when not present within the PLC, hence only in the refolding process 
(Lindquist et al., 2001). As part of the PLC, ERp57 was not identified as a mixed 
disulfide with any members except for tpsn (Peaper et al., 2005). In contrast, PDI 
was seen in a mixed disulfide bond with one of the α2 cysteines when part of the 
PLC (Jensen, 2007; Park et al., 2006). Although argued, these observations 
allowed Ahn’s group to suggest that the α2 disulfide is the target of PDI reductase 
activity when the MHCI are empty or loaded with suboptimal peptides (Park et al., 
2006). In contrast, when the MHCI are loaded with optimal peptide, the α2 disulfide 
bond is protected from PDI. This seems to provide another quality control 
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mechanism resulting in the editing of peptide by favoring the ones with greater 
stability before leaving the PLC and being exported to the plasma membrane.  
1.2.4. Functions of the PLC in the peptide loading of MHCI  
As demonstrated by cell lines and KO mice (Garbi et al., 2000; Garbi et al., 
2006; Grandea et al., 2000; Greenwood et al., 1994; Lehner et al., 1998; 
Stepensky et al., 2007), the loss of any PLC members decreases the efficiency of 
MHCI peptide loading with different magnitudes. As a consequence, pMHCI have 
lower stability and cell surface expression. In order to generate a strong and rapid 
CD8+ T cell response, every member of the PLC is required and each plays a role 
in facilitating optimal peptide binding by generating peptide receptive MHCIs and 
by increasing the availability of peptides. The translocation of self or foreign 
degraded proteins from the cytosol to the ER lumen is mediated by the TAP1-TAP2 
complex (Cresswell et al., 2005). Since the MHCI binds only peptides of 8 to 11 
residues, the action the ERAAP or ERAP1 peptidases can be required to trim 
longer translocated peptides prior to or concomitant to binding (York et al., 2006). It 
was proposed by the Ahn’s group, that PDI serves as a peptide carrier and is 
critical for optimal peptide selection (Park et al., 2006). However, it is still 
ambiguous whether this is an indirect effect of the PDI peptide binding pocket 
protecting peptide degradation or if PDI is directly delivering peptide into the MHCI 
groove. Before MHCI can escape the PLC and egress to cell surface, they need to 
stably bind a specific peptide (Garbi et al., 2005). The Figure 1.9 illustrates the 
peptidesʼ journey to the MHCI groove, the egress of pMHCI and their presentation 
to CD8+ T cells (Neefjes et al., 2011; Peaper and Cresswell, 2008; Wearsch and 
Cresswell, 2008).  
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Figure 1.9: MHCI peptide loading and presentation 
The presentation of pMHCI to CD8+ T cell starts by proteasomal antigen degradation and their 
subsequent trimming by a panel of aminopeptidases (1). Those peptides are then translocated to 
the ER lumen (2) and through a tapasin-dependent manner, the loading complex facilitates the 
generation of highly stable pMHCIs (3), leading to the release of loaded MHCIs and CRT from the 
PLC (4). After a transit to the Golgi (5), the MHCIs gain access to the plasma membrane and may 
present its associated-peptide to cognate CD8+ T cells (6). 
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1.2.5. ERp57-Tpsn and peptide exchange  
The physical mechanism leading to efficient peptide loading is still unclear 
and depends on Tpsn. In addition to its supporting role, Tpsn was proposed to be a 
peptide exchange/editor like HLA-DM for the MHC of class II (section 1.3.4) 
(Hansen et al., 2005; Sadegh-Nasseri et al., 2008). Recently, the structure of Tpsn 
was determined by crystallography in complex with ERp57 (Dong et al., 2009) and 
provide the first insights as to what resembles the PLC Figure 1.10. Indeed, Dick et 
al. demonstrated that at steady state, all Tpsn was covalently bound to ERp57 
(Dick et al., 2002). Thus, Peaper et al. suggested that the role previously described 
for Tpsn is a consequence of the Tpsn- ERp57 conjugate (Peaper et al., 2005). 
Briefly, by interacting with the HC α2 domain, Tpsn would stabilize the peptide 
binding groove in a peptide-receptive conformation. Given that Tpsn has a weaker 
affinity for pMHCIs, peptide-loading would initiate the dissociation of the MHCI from 
the PLC (Dong et al., 2009). The biophysical mechanism underlying this process 
remains hypothetical, but seems to be related to the oxidation of the α2 domain. 
 
Figure 1.10: In silico model of the PLC 
Reproduction of the PLC subcomplex model provided by Dong and colleagues (Dong et al., 2009). 
A side view (a) and a top view (b) of the multi-complex shows how the MHCI, Tpsn-ERp57 and CRT 
assemble together (1BOG, 3F8B, IJNH, respectively).  
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1.3. MHC class II 
The molecules derived from the MHCII locus follow the same basic rule as 
MHCI molecules do; i.e. they require the work of many accessory proteins in order 
to present peptides to T cells. More specifically, this pathway relies on the invariant 
chain (Ii) and the non-classical MHCII molecule HLA-DM (DM), two chaperones 
leading to the expression of stable peptide-MHCII complexes (pMHCII) at the 
plasma membrane. Upon synthesis in the ER, Ii associates with MHCII and targets 
the resulting complex to the endosomal/lysosomal compartments, commonly 
termed MIIC, which stands for MHCII compartments (Rudensky et al., 1994). 
There, Ii is sequentially degraded until only the class II-associated invariant chain 
peptide (CLIP) portion remains in the MHCII binding groove (Cresswell and Blum, 
1988). Following Ii degradation, DM facilitates the exchange of CLIP for antigenic 
peptides onto MHCII (Denzin and Cresswell, 1995; Sherman et al., 1995; Sloan et 
al., 1995). The resulting pMHCIIs then egress to the cell surface where they can 
ultimately meet cognate TCRs. A basic model of those events is presented in 
Figure 1.11. Then, the forthcoming subsections describe in further detail the steps 
involving the MHCII chaperones within MHCII’s genesis and the various steps 
encompassing peptide loading. 
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Figure 1.11: MHCII pathway 
General portrait of the MHCII antigen processing and presentation. MHCII chains assemble in the 
ER with Ii. Ii-MHCII complexes transit through the Golgi before gaining access to the MIICs, either 
directly and/or via the plasma membrane. Endocytosed proteins and Ii are degraded by MIICs’ 
resident proteases. The remaining Ii peptide CLIP is then exchanged for an antigenic peptide with 
the help of DM. Finally, MHCIIs egress to the plasma membrane to present their antigenic peptides 
to CD4+ T cells.  
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1.3.1. MHCII isotypes 
To simplify the content, I made used of MHCI and MHCII acronyms to 
describe the MHC molecules, omitting to introduce the MHC isotypes and their 
polymorphism. In human, there are three MHCII isotypes: HLA-DP, -DQ, and -DR 
and so far, over 870 allotypes are identified (European Bioinformatics Institute; 
www.ebi.ac.uk). Most of the polymorphism occurs on the β chain β1 domain and 
those variable residues either protrude toward the peptide-groove or the TCR 
binding site (1.1.6. Peptide-binding groove). Such variations of the side chains 
generate distinct pockets that will accommodate more fitting peptides, increase the 
number of peptides that can efficiently bind MHCIIs. Because of the differences 
between the MHCII allotypes, their relation with Ii or DM can be compromised. For 
example, some allotypes are refractory to DM-mediated peptide exchange and 
others are poor or great binding of the CLIP peptide (Busch et al., 2005).  
1.3.2. Invariant chain: folding, targeting, protecting and editing 
The first steps of Ag presentation begin with the generation of MHCII 
molecules and their association with the invariant chain (Ii). Also called CD74, Ii is 
a type II transmembrane glycoprotein that self-assembles into homotrimers. Ii 
trimerization is driven by both its transmembrane and carboxy-terminal 
trimerization domains (Figure 1.12) (Gedde-Dahl et al., 1997; Jasanoff et al., 
1999a). In human cells, an alternative start codon and exon splicing give rise to 4 
isoforms, named Iip33, -p35, -p41 and -p43, based on their molecular weight 
(Arunachalam et al., 1994). The shortest form of Ii is the most abundant and has 
two major immunological functions. Firstly, it is a MHCII chaperone that assists 
folding, facilitates ER egress and protects the MHCII-peptidic groove from 
premature peptide binding (Matza et al., 2003). Secondly, it is a receptor for 
cytokine and bacteria (Beswick, 2009).  
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While my dissertation mostly revolves 
around Ag presentation, emphasis is set toward 
the participation of Ii in MHCII maturation and its 
influence on the nature of the forthcoming 
associated peptide. The invariant chain’s major 
role is to assist the folding of MHCII and in doing 
so, prevents their self-aggregation. Yet, the 
sequence of events leading to their binding 
remains controversial. To date, the most 
appreciated dogma revolves around a nonamer 
(αβIi)3 composed of three paired MHCII αβ 
heterodimers that associate with a Ii homotrimer 
(Roche et al., 1991a). However, recent data 
suggest that Ii homotrimers would initially bind 
MHCII α chain, thus facilitating the subsequent 
pairing of β chains of the same isotype, as schematized in Figure 1.13. This 
revised theory originates from Kochʼs group, who also pushed the hypothesis that 
once a primary αβ dimer is bound to Ii, a conformation change ensues and 
prevents the binding of additional MHCIIs (Koch et al., 2007). In other words, the 
binding of one MHCII dimer would lock the Ii scaffold into a MHCII-refractory 
conformation generating only αβIi3 pentameric complexes. These results, obtained 
from mouse APCs, do not correlate with those obtained in human, in which 
nonameric complexes were formerly observed (Roche et al., 1991a). Interestingly, 
the human p35 Ii variant includes a RXR ER retention signal that could explain this 
incongruity between both species. A thorough description demonstrating Iip35 
participation in nonameric complex formation is provided in the Annex I. 
 Figure 1.12. Invariant chain 
Schema of Ii. Two motifs facilitate Ii 
trimerization and a di-leucine sorting 
motif directs Ii to the endosomes. The 
glycans at position 113 and 119 are 
also shown. 
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Figure 1.13: Ii association with MHCII 
MHCII chains binding to the invariant chain. Ii self-assembles into a homotrimer (1) prior to the 
binding of a first MHCII α-chain (2). Then, a MHCII β-chain of the same isotype associates with the 
αIi3 scaffold (3). Subsequent cycles of MHCII binding may happen (4), forming heptameric or 
nonameric complexes 
The p35 isoform contains a 16 aa amino-terminal extension that provokes 
the sequestration of Ii trimers in the ER via a RXR motif (Schutze et al., 1994). 
Work by a colleague has demonstrated that this di-arginine motif is masked by 
DRβ cytoplasmic tail upon association with Ii (Khalil et al., 2003, 2005). 
Consequently, in the instance of mixed Ii-trimers, i.e. between the p33 and p35 
isoforms, Ii-MHCII complexes may be retained in the ER until sufficient β chains 
overcome every p35 motif. The period that Ii spends in the ER is then prolonged, 
providing the necessary time for the binding of subsequent MHCIIs, giving rise to 
nonamers (Annex 1). Indeed, it is easy to picture a situation in which MHCIIs, 
outnumbered by Ii (Marks et al., 1990), exit the ER as pentamers before the 
formation of saturated nonameric complexes, a phenomenon that may have been 
overlooked in mouse cells. Overall, Ii assembles into homotrimers and provides the 
scaffold for the efficient pairing of MHCII chains. Then, in the form of partially or 
fully packed Ii3(αβ)x=1-3 complexes, MCHII molecules gain access to the endosomal 
compartments.  
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Guided by two leucine-based motifs within Ii’s cytoplasmic tail, Ii-MHCII 
complexes egress from the ER to the MIIC (Bakke and Dobberstein, 1990). There, 
the increased acidity and presence of proteases allow for Ii degradation, which 
occurs in a highly coordinated fashion. This process frees MHCIIs from Iiʼs scaffold 
and to leave only a small portion of Ii, the class II-associated Ii peptide (CLIP), 
within the peptide-binding groove (Ghosh et al., 1995). The proteolysis steps, 
pictured in Figure 1.14, are as follow: the Ii luminal trimerization domain is cleaved 
first, followed by the trimming of the CLIP extremities, releasing MHCII 
heterodimers from Iiʼs grasp and mediated targeting. A subsequent cleavage 
generates the cytoplasmic fragment, reported to induce NFκB (Matza et al., 2001). 
At this point, newly generated MHCIIs may gain access to the plasma membrane 
to present CLIP. Conversely, as is the case with certain MHCII alleles, CLIP-MHCII 
complexes of short half-life may go through a round of spontaneous peptide 
exchange prior to their transport to cell surface (Jensen et al., 1999). Overall, 
homotrimeric Ii directs MHCII from the ER to the MIICs before being sequentially 
degraded.  
 
 
 
 
 
 
 
Figure 1.14: Ii degradation 
Steps involved in the degradation of Ii. First, the carboxy-terminal trimerization domain is cleaved by 
non-cystein proteases, generating the p22 fragment. Then, cystein proteases remove the 
glycosylated portion to form the p10 fragment before cathepsins S cut the anchored portion, leaving 
the CLIP in the MHCII groove. The amino-terminal is further processed at the intramembrane 
generating a cytosolic fragment (Ii-cyto) with the ability to activate NFκB. 
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Since the eighties, Ii has mostly been viewed as the MHCII chaperone I just 
described. Today, such a role has been shaded by Ii versatility and its novel MHCII 
unrelated functions. Many studies have reported Ii expression in MHCII negative 
leukocytes, gastrointestinal (GI) epithelial cells and various carcinomas (Matza et 
al., 2003), which has led many to hypothesize new Ii roles. Chronologically, 
Shacharʼs group demonstrated that Ii cytoplasmic domain was involved in B cellsʼ 
maturation by activating NFκB (Matza et al., 2001, 2002). Subsequently, Ii was 
found to be the macrophage migration inhibitory factor (MIF) receptor (Leng et al., 
2003). Later, it was identified as H. pylori receptor, a bacterium that exploits Ii in 
order to adhere to GI cells (Beswick et al., 2005). The invariant chain does not 
possess domains capable of prompting signal transduction, but instead pairs up 
with CD44 and CXCR2, which accomplish this task (Bernhagen et al., 2007; Shi et 
al., 2006). A body of work is now available regarding the implication of Ii as a 
receptor and is addressed exhaustively in a recent review by Beswick and Reyes 
(Beswick, 2009).  
Ii has also been shown to interact with CD70, CD1, DM and MHCIs, 
providing either chaperoning or targeting (Alfonso and Karlsson, 2000; Basha et 
al., 2012; Pierre et al., 2000; Sloma et al., 2008; Sugita and Brenner, 1995). 
Altogether, these data are in line with the fact that Ii does not necessarily sits inside 
the MHCII binding pocket. Indeed, Ii is able to bind single-chain peptide MHCIIs 
(Wilson et al., 1998). A body of work by the group of Hammerling, supporting this 
premise, has been put to second rank after the publication of the CLIP-DR3 
structure. 
By protecting the MHCII’s groove and guiding them to the MIICs, Ii influence 
the pool of associated-peptides (Busch et al., 2005). In fact, the repertoire is 
strongly skewed in Ii KO mice, as demonstrated by mixed lymphocytes reactions 
(MLR) and aberrant CD4+ T cell selection (Grubin et al., 1997; Tourne et al., 1995; 
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Viville et al., 1993; Wong and Rudensky, 1996). However, whether it is the different 
Ii isoforms or its ability to bind the MHCII isotypes with different affinities that is 
monitored, Ii’s effect on the peptide repertoire varies. Moreover, upon degradation, 
the residual bound-CLIP peptide also participates in shaping the peptide’s 
assortment to be presented to T lymphocytes. 
1.3.3. CLIP’s mission 
As mentioned earlier, Ii prevents the aggregation of MHCII molecules and 
the binding of resident ER peptides. Following its degradation in the MIIC, this role 
is carried out by the associated-CLIP peptide, which, like a jack of all trades, has 
the ability to fit into any MHCIIs (Busch et al., 2005). To achieve such a feat, CLIP’s 
side chains at position 1, 3, 7 and 9 are hydrophobic and not too bulky allowing 
torsional freedom that results in a promiscuous type of fitting (Figure 1.15). Those 
at positions 4 and 6 are very small and hydrophobic (Pro and Ala) thus adapted to 
avoid steric clash with the high polymorphism of these two pockets (Ghosh et al., 
1995; Lee and McConnell, 1995).  
Given CLIP’s binding fashion, the half-life of CLIP-MHCIIs differs widely 
between MHCII alleles (Sette et al., 1995) and CLIP’s protective effect can be 
compromised when part of short-lived complexes. In fact, there is a strong 
correlation between short half-life, auto-immunity and plasma membrane MHCII 
expression (Busch et al., 2005). Also, either very short- or long-lived complexes 
have debilitating effects on Ag presentation (Busch et al., 2005). Respectively, this 
may cause endogenous peptides to be over-represented on the cell surface, 
leading to auto-immunity or may prevent peptide exchange, leading to a 
homogenous population of CLIP-MHCIIs. Altogether, as a surrogate for peptides, 
CLIP helps restricting peptide exchange to DM+ MIICs, thereby ensuring a efficient 
editing of antigenic peptides (Rinderknecht et al., 2007, 2010). 
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The CLIP-MHCII structures determined so far only show the coreCLIP, i.e. 
residues 87-101, inside DR’s groove and the amino-terminal residues 81-86 could 
not be resolved (Figure 1.15) (Ghosh et al., 1995; Günther et al., 2010). Vogt and 
coworker suggested that this extension, abbreviated herein as CLIP81-86, folds back 
onto DRα α-helix while Neumann and Koch proposed it to interact with the DRβ Ig 
domain (Neumann and Koch, 2006; Vogt et al., 1995). Interestingly, binding to the 
β2 domain was observed only when CLIP was part of full length Ii, meaning that 
the polypeptide may behave differently once cleaved. Also, sequences rich in 
proline, as is the case for this extension, form rigid β-turns and would corroborate 
the former hypothesis.  
 The CLIP81-87 portion has been 
reported to trigger peptide exchange 
via an allosteric self-release 
mechanism (Kropshofer et al., 1995a). 
Such function, mediated by the lysines 
(and the Pro87), seems to stem from 
the binding of those residues to an 
effector site on MHCII α-chain, 
disturbing the HBs of the P1 pocket 
(Chou et al., 2008; Kropshofer et al., 
1995a, 1995b; Narayan et al., 2007; 
Vogt et al., 1995). This extension, later 
renamed helper peptide or Ii-key, has 
also been shown to improve the 
loading of antigenic peptide and was 
further refined by Kallinteris and 
colleagues to the following sequence: 
Figure 1.15. CLIP-MHCII 
Slice of the CLIP-DR3 crystal’s groove (1A6A). The 
MHCII α-chain, in green, is behind the peptide 
while most of the β-chain is sliced off. The CLIP 
side chains occupying the pockets p1, 3, 6 and 9 
are shown in orange sticks. From this viewpoint, 
the CLIP81-86 extension is predicted to flip into the 
plane, onto the α-chain. 
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LRLKLPK (Kallinteris et al., 2006; Perez et al., 2010a; Xu et al., 2012). It has also 
been used in phase I clinical trials against prostate cancer and may prove to be a 
very effective “adjuvant” (Perez et al., 2010b). Overall, the role of CLIP is twofold; i) 
it prevents MHCIIs from collapsing and facilitates its own release. This leads to a 
better editing of antigenic peptide by DM and provides an alternative to counter 
long-lived CLIP-MHCIIs by prompting self-release. As mentioned above (section 
1.1.7), HBs are formed between the 310 helix and the portion of CLIP extending 
further outside of the pocket 1 (Günther et al., 2010). Knowing how important these 
HBs are to keeping CLIP in the canonical orientation, it is possible that the CLIP/Ii 
key extension promotes the peptide self-release by disturbing the 310 region’s HBs 
like DM (Stratikos et al., 2004). 
1.3.4. DM functions 
While the main function of DM is to improve peptide exchange (Vogt et al., 
1996), thus editing a repertoire of stable pMHCII (Kropshofer et al., 1996), DM also 
has the important task of chaperoning empty MHCII and DO (DO: see section 
1.3.5). Empty MHCIIs are very unstable complexes (Stern and Wiley, 1992) and 
depend on DM’s rescue in order to maintain their ability to bind peptides (Denzin et 
al., 1996; Kropshofer et al., 1997a) Based on these observations, one could 
hypothesize that DM only recognizes “peptideless” MHCII. Indeed, DM’s interaction 
with many stable high affinity pMHCII (e.g. DR1-HA) seems to be inexistent and 
thus is dependent on its occupancy state (Anders et al., 2011; Sloan et al., 1995; 
Vogt et al., 1996). To gain insights regarding DM’s mode of action, the Mellins 
group used a mutagenesis approach and identified critical residues on DR3 that 
disrupted its interaction with DM (Figure 1.16) (Doebele et al., 2000; Pashine et al., 
2003). Two of those residues were located in a flexible loop, the 310 helix (Figure 
1.1d), that connects the α-helix to the platform of the MHCII cleft. Therefore, it has 
been suggested that this specific MHCII region undergoes conformational changes 
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upon peptide association/dissociation and that DM recognizes it in the absence of 
a bound peptide (Hansen and Fremont, 2005). A model, proposed by Stern’s group 
suggest that DM recognize a disordered 310 helical region, which does not yet form 
HBs with the peptide backbone (Painter et al., 2011; Stratikos et al., 2004). The 
interesting feature of the 310 helical region nearing the p1 pocket is the presence of 
many highly conserved phenylalanines; three on the 310 helix, three on the 
founding β-sheets and one on the β chain. They are reported to adopt different 
conformation based on the p1-filling residue (Chervonsky et al., 1998). Since it is 
repositioned upon DM contact, the 310 helix could serve as a hinge, disturbing the 
HB network that tethers the peptide (Guce et al., 2012). However, it is difficult to 
conceive that DM can promote peptide release while interacting only with empty 
MHCII.  
 
Figure 1.16: DM-DR binding interface 
Model of the DM-DR (2BC4 and 16A6) binding interface based on the mutagenesis studies by 
Mellins’ group and the ternary structure of DM-DO (Doebele et al., 2000; Guce et al., 2012; Pashine 
et al., 2003; Yoon et al., 2012). A side by side view (a) is given beside a top view (b). The aa 
implicated in DM’s function are shown in light green and light red.  
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In order to understand how DM is able to interact with MHCII and thus 
promote peptide exchange, it is important to consider that the peptide binding to 
MHCII is a dynamic and cooperative event in which both the MHCII and the peptide 
fold together, the latter highly pH-sensitive (Sadegh-Nasseri and Germain, 1992; 
Yaneva et al., 2009). This allows a transient state between partially and completely 
bound peptide in function of pH. Consequently, because of the intrinsic behavior of 
MHCIIs, DM is able to interact with pMHCIIs that are not completely bound but still 
display DM binding (Schulze and Wucherpfennig, 2012). The interaction between 
DM and MHCII leads to the opening of the MHCII groove into a more favorable and 
receptive conformation for peptide binding and facilitates this cooperative refolding 
(Figure 1.17). Evidence suggested that the appropriate filling of the P1 pocket is 
the triggering event for pMHCII to adopt a DM resistant form (Chou and Sadegh-
Nasseri, 2000; Narayan et al., 2007; Sadegh-Nasseri et al., 2008, 2012). However, 
another study based on multiple MHCII alleles and peptides has shown that 
interactions along the entire length of the peptide binding groove contribute to DM 
susceptibility (Belmares et al., 2002). This likely suggests that the P1 model may 
be an oversimplification that only applies to certain MHCII alleles. Indeed, 
promiscuous fitting at the P9 pocket has been shown to also affect DM mediated 
peptide exchange synergically to P1 (Stern L., personal communication). Overall, 
DM’s functions are likely a consequence of its capacity to generate open, peptide-
receptive MHCIIs. This open conformation increases the peptide exchange rate 
and allows MHCII to screen multiple peptides, favoring the ones inducing the 
conformational change required to mask DM’s binding epitope and that have 
greater kinetic stability. However, the physical mechanism underlying DM function 
remains unclear partly because of the lack of a solved crystal structure MHCII-DM 
complex.  
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At the same time that DM promotes peptide exchange, it also edits the 
peptide repertoire (Busch et al., 2005; Kropshofer et al., 1997b; Lazarski et al., 
2005; Vogt and Kropshofer, 1999). In a recent report, it was demonstrated that 
antigenic epitopes presented by MHCIIs in the presence of DM are more likely to 
engender CD4+ T cell response in the context of a virus infection (Yin et al., 
2012a). Furthermore, these complexes are more refractory to DM-mediated 
dissociation, a correlate of their longer half-life (t1/2), which is a distinguishing 
feature for T cell recognition. This study is doubly elegant, as it shows that the 
biophysics property of a pMHCII population does not always reflect the T cell 
response that it engenders, nor the immunogenicity (Lazarski et al., 2005). 
pMHCIIs’ immunogenicity can be classified in two groups; one is refractory to DM 
and the other is sensitive (Kremer et al., 2012). Thus for the APC, it is essential to 
control the contribution of Ii, DM and DO to give rise to both types of pMHCII 
complexes and preserve homeostasis. 
The group of Wucherpfenning just crystalized the DR-DM ternary complex, 
using a partially filled DR molecule (Pos et al., 2012). To succeed, they covalently 
linked a small peptide that occupied the DR pocket only from P4, thus allowing DR 
to display a DM-sensitive form and leading to strong binding between those two 
molecules. Also, to prevent DM from releasing the bond peptide and keep the 
complex stable, the peptide is trapped by a disulfide bond between the p5 residue 
and the α chain residue V65, which is mutated to a cysteine. Interestingly, the 
structure is very similar of the DO-DM complex isolated by Guce and colleagues 
and also implicated the 310 helix to fold back into the peptide-binding groove, 
exchanging the αW43 P1-filling residue for αF51 (Guce et al., 2012).  
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Figure 1.17: Peptide exchange 
In DO+ cells, DM-DO complexes egress from the ER to the MIICs (1), in which the increased acidity 
provokes their dissociation (2). There, spontaneous peptide release and loading occurs due to 
continuous peptide motion and provides a pool of MHCIIs with partially-bound peptide, susceptible 
to DM binding (3). DM-binding site is pictured as a slot on the cartoon’s MHCII α-chain. Next, DM 
facilitates the release of the remainder of the peptide (4) while the resulting DM-empty MHCII 
complexes can bind new peptides with very rapid kinetics. Weak MHCII binders will go through 
many cycles of peptide editing by DM, until strong binders induce its dissociation. These stable 
pMHCIIs may be displayed on the cell surface for many days depending on the APC. In parallel, 
DM also rescues empty-MHCII before they collapse (5). 
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1.3.5. HLA-DO 
In contrast to DM, which promotes peptide exchange, a second MHCII-like 
molecule hinders this effect. DO is a non polymorphic heterodimer which directly 
interacts with DM (Liljedahl et al., 1996). Upon synthesis in the ER, DO does not 
efficiently bind Ii (Karlsson et al., 1991; Liljedahl et al., 1996), like the MHCIIs, and 
refolds poorly. Therefore, in order to avoid rapid degradation, DO associates with 
DM, thereby enabling its proper folding and exit from the ER (more detail in chapter 
3). Finally, in the endosomal compartments, DO prevents DM from exchanging 
peptide.  
The manner by which DO impedes DM activity is just starting to unfold, but 
still remains a matter of debate. Most current theories regarding DO mechanism 
claim that the DO-DM complex remains associated along the endosomal pathway 
where DO partially or totally inhibits DM function in a pH-dependent manner 
(Alfonso et al., 1999; Brocke et al., 2002; Van Ham et al., 1997; Hammond et al., 
1998; Jensen, 2007; Kropshofer et al., 1998, 1999; Liljedahl et al., 1998). 
Therefore, this model argues that DM is greatly inhibited in the early endosomal 
compartments, but only partially in the late, more acidic ones. A strong argument 
for this model was the presence of trimolecular complexes containing DO, DM and 
MHCII, and immunoprecipitation of DO by MHCIIs (Hammond et al., 1998). A 
second hypothesis is that DO is an empty MHCII and that it has higher affinity than 
MHCII for the DM binding site. This paradigm is supported by the concept of DM 
function per se, which binds and chaperones empty MHCIIs, and by other indirect 
evidences: firstly, DO shares more than 60 % homology with MHCIIs; secondly, as 
for DR, the same conserved glutamic acid (α40) on DO is essential for DM 
interaction (Deshaies et al., 2005); thirdly, in the absence of Ii, DM is able to rescue 
MHCII to exit the ER (Serradell et al., 1999). Based on these observations, it has 
been suggested that DO is a permanently empty MHCII that monopolizes DM 
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chaperoning capability, thereby preventing DM from associating with MHCII. 
Although a common misbelieve, acidification in the later stage of the endosomal 
pathway is not what inactivates DO or dislocate it from DM. In the MIICs, DO-DM 
complexes remain associated in the limiting membranes while DR-mediated 
peptide exchange occurs in the vesicles (Lith et al., 2001; Zwart et al., 2005). In 
addition, the interaction between DM and DO is very tight (personal communication 
- SPR experiments) and never dissociate, as it is the case with empty DR1 (Anders 
et al., 2011). Whether a ligand, only present in the MIICs, has the ability to bind DO 
and initiate a conformational change that liberates it from DM or whether those DO-
bound DM molecules are doomed remains to be investigated.  
Recently, in a fruitfull collaboration, the Stern and Mellins groups were able 
to co-crystalize DM and DO together (Guce et al., 2012). The ternary complex 
corresponds with initial mutagenesis studies supporting the competition model and 
suggesting molecular mimicry (Deshaies et al., 2005; Doebele et al., 2000). In light 
of their results, whether the previously observed interaction between DO and 
MHCIIs or DO-DM-MHCIIs are genuine remain to be confirmed, interactions that 
could be mediated by the transmembrane domains or other accessory proteins. In 
addition, knowing that empty MHCIIs tend to collapse, those trimolecular 
complexes may either be intrisic to their occupancy state or the tip of a yet to be 
discovered function of DO toward MHCIIs. On another note, van Lith and co-worker 
previously reported that DO could egress to the cell surface with the MHCI HC 
(Van Lith et al., 2003). This peculiar association is mostly observed in 
overexpression system and yet, no role has yet been proposed. Thus it remain 
possible DO escape ER-quality control once stabilized by MHCI HC in a manner 
similar to DM. Conversely, as mentionned previously, empty MHC molecules tend 
to aggregate (Arimilli et al., 1999; Ruffet et al., 2003).  
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1.3.6. Peptide editing by DO 
The foregoing section 1.3.4 briefly introduced the impact of DM on the 
MHCII presentation. This will now be further developed including the role of DO, to 
provide a broader outlook. Until now, the role of DO on IRs is vague and it is 
surprising that giving all the recent structural data its function has not gotten 
clearer. Interestingly, the expression pattern of DO is quite unique and mostly 
confined to B cells, thymic epithelial cells, and certain types of primary DC, but not 
monocyte-derived DC, upon maturation stimuli. Many studies have suggested that 
DO could differentially select certain peptide epitopes, but the experimental model 
chosen could always be criticized and do not reveal its purpose (Alfonso et al., 
2003a, 2003b; Liljedahl et al., 1998; Perraudeau et al., 2000). In a recent paper, 
Gu and coworkers stress the point that DO favors presentation of exogenous Ags 
while reducing autoimmunity (Gu et al., 2012). In this recent article, they confirmed 
that the concentration of CLIP-MHCIIs at the cell surface of DO-/- B cells is 
significantly lower than on wt cells. Thereby, peptide exchange is more extensive 
on MHCIIs in the absence of DO. What was really striking, however, was that DO-/- 
produced higher titers of auto-reactive-Abs, a skewed CD4+ T cell repertoire and a 
propensity to auto-immunity. Thus, DO edits qualitatively the different self-peptides 
that are presented to CD4+ T cells. 
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1.3.7. Ways to load peptides onto MHCIIs 
 
 
 
 
 
Figure 1.18: Ways to manipulate MHCII peptide loading 
Manipulate the pMHCII populations with DMY (Pezeshki et al., 2011) 
Increase the potency of peptide vaccines with Ii-Key (Gillogly et al., 2004; Humphreys et al., 2000; 
Perez et al., 2010a, 2010b; Xu et al., 2012) 
Increase peptide loading with peptide bound to J10 compounds (Call et al., 2009) 
Single-chain peptide-Ii-MHC construct to load peptides (Thayer et al., 2003a) 
mAb-SAG hybrids as cancer vaccine or peptide carrier (Dohlsten et al., 1994; Han et al., 2011; Loh, 
2006) 
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1.3.8. SAGs binding to MHCIIs 
In addition to binding small antigenic peptides, MHCIIs are also the ligand of 
a family of small proteins called superantigens (See Section 1.5. Superantigens). In 
contrast to the former, SAGs do not interact with MHCII’s peptidic groove but rather 
bind solvent-exposed residues located onto MHCII α-helixes. They bind relatively 
non-polymorphic regions and thus can be presented by numerous MHCII alleles. 
SAGs binding mechanism is hypothesized to rely on MHCII overall structure rather 
than conserved-residue interaction and supported by the affinity hierarchy of SAGs 
toward the different MHC isotypes (DR > DQ > DP), (Li et al., 1998a). In addition, 
little to no structural alterations were observed from crystallized SAGs, whether 
alone or as part of a complex, supporting the idea that they are dependent of the 
MHCII conformation (Fraser and Proft, 2008).  
A decade of data on quaternary structures and in silico models has provided 
insights on strategies used by SAGs to bind MHCIIs and are depicted in Figure 
1.19. So far, three major mechanisms have been identified. SAGs may bind a) 
MHCII α-chain, b) an epitope composed of the α-chain and the associated-peptide 
or c) the β-chain’s HIS81 through coordination of a zinc ion (Sundberg et al., 2007). 
A handful of SAGs also have the ability to cross-link or oligomerize MHCIIs by 
using both α and β-chain binding sites. Yet, the magnitude of the oligomerization 
remains unknown (Bueno et al., 2007). In addition to the bSAGs’ three binding 
modes, the SAG Mycoplasma arthriditis-direved mitogen (MAM) binds the MHCII 
orthogonally, contacting the α-chain, the peptide and the β-chain (Figure 1.19d) 
(Zhao et al., 2004). More details about SAGs are provided in sections 1.4.7 and 
1.5, which describe how they cross-link TCR in order to activate T cells and 
summarize their features, respectively. First, however, a look at the TCR is called 
for.  
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Figure 1.19: SAG binding strategies onto MHCII 
Different modes by which SAGs interact with MHCIIs. (a) Interaction with MHCII via the α-chain and 
the associated-peptide (TSST-1, 2TSS). (b) Interaction of SAG with the α-chain (SEB, 1SEB). (c) 
Interaction of one SAG molecule with two MHCIIs; one via the β-chain using the high-affinity zinc 
site, the other via the α-chain (SEA, 1L05 and 1HXY (SEA was superimposed over SEH in the 
SEH-MHCII complex (Petersson et al., 2002))). (d) Binding of the SAG using the MHCII α-, β-chain 
and the peptide altogether (MAM, 1R5I). As usual, MHCII α- and β- chains are green and blue and 
the associate-peptide is yellow. 
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1.4. T cell receptors 
Exploring the influence of associated-peptide or SAG on antigen 
presentation obliges a thorough structural and biophysical understanding of the T 
cell response. This cellular response depends on a highly sensitive and educated 
multi-receptor complex (Figure 1.20), composed of the T cell receptor (TCR) and 
CD3 chains to spot the insanely vast pMHC repertoire (Rudolph et al., 2006). 
Taken separately, TCRs serve the purpose of recognition while the many 
monomorphic CD3 components that participate in signal transduction alongside the 
CD4 and CD8 co-receptors. Much like MHCIIs, each TCR chain is composed of a 
αβ heterodimeric ectodomain anchored to the plasma membrane by a 
transmembrane region, followed by a small cytoplasmic tail (Davis and Bjorkman, 
1988). The ectodomain is composed of variable and constant Ig-like folds 
analogous to Abs and are very specific pMHC ligands. TCR’s ability to recognize 
pMHC appears to have occurred 400 millions years ago and is mediated via the 
TCR complementary determining regions 
(CDR) (Scott-Browne et al., 2011). Herein, 
most of the listed data reflect αβ TCRs 
associated with classical MHCs. These 
data may not govern the engagement of αβ 
and γδ TCR to non-classical MHC 
molecules, which seem to use a 
combination of canonical and unique 
Figure 1.20. TCR-CD3 multireceptor complex 
A handful of interactions allows the CD3/TCR multimeric complex to form. The transmembrane 
domains of the TCR and CD3 chains contain nine conserved charged residues that link the CD3 
subunits in this manner: α-ε-δ, β-ε-γ and α-ζ-ζ. For simplicity, these exact contacts are not preserved 
in the 2D cartoon depiction. 
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strategies (Wucherpfennig et al., 2010).  
1.4.1. TCR variability / Variable regions 
In order to extend the finite genomic information into extremely diverse 
receptors, the immune system recombines and edits germline-encoded segments 
(Morris and Allen, 2012). In a process that is developmentally regulated (thymic 
selection), T lymphocytes generate the TCR by recombining the V(D)J segments of 
the locus encoding the ~80 TCRβ, and the VJ segments of the locus encoding the 
~60 TCRα chains (Davis, 1990; Wilson et al., 1988). In human, the Vα region is 
classified into 22 subfamilies, 15 of those containing a single member. The Vβ 
region, for its part, is classified into 20 subfamilies and only 7 contain a single 
member. The Jα and Jβ regions include 46 and 13 gene segments of 16 to 25 and 
15 to 17 aa, respectively. In addition, there are two Dβ regions that account for the 
addition of 3-4 aa to the Vβ CDR3 (Wilson et al., 1988). Since they do not go 
through recombination and editing, the TCR CDR1 and CDR2 loops preserve the 
germline-encoded information for interacting with MHCIIs (see also section 1.4.7). 
In contrast, the high diversity of the CDR3 loops linked to the V(D)J gene 
rearrangement allows for the TCR’s ability to recognize the limitless pool of 
antigenic peptides (Bridgeman et al., 2012). 
1.4.2. Complementary determining regions 
Structurally, CDRs are flexible loops formed by the antiparallel β sheets 
junctions of the distal TCRs’ Ig domains (Figure 1.21). The seemingly symmetrical 
TCR α and β chains, held together by a cystine bridge, draw both CDR3s at the 
reflection axis, i.e. the center of the heterodimer (Bentley et al., 1995; Garboczi et 
al., 1996; Garcia et al., 1996). This positions the CDR1 loops next to the TCR 
center and the CDR2 loops at the edge of the receptor. It is also noteworthy that 
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there are multiple interchain contacts between the TCR’ CDRs. These interactions 
can occur between the two CDR3s loops or between the residues of the CDR3 and 
those of the CDR1 and CDR2. Reflecting those interchain contacts, different CDR 
rotamers exist for a given chain when paired with distinct partners (Gras et al., 
2010; Pellicci et al., 2009). Thus, TCR’s plasticity stems partly from the CDRs’ aa 
variability.  
 
Figure 1.21: Complementary determining regions 
Overview of the TCR structure and CDRs. (a) A cartoon depiction of the TCR is shown beside the 
crystal structure of the HA1.7 TCR (1FYT). TCR α and β chains are colored cyan and teal, 
respectively. (b) Top view of the TCR, as if the reader is the pMHC. The CDRs are magenta, purple 
and red for the alpha chain and yellow, orange and lime for the β chain. (c) A 90° angle rotation 
toward the slate showing the lateral face of the TCR. The CDR3s are at the center of the 
heterodimers while the CDR2 are distal.  
1.4.3. TCR flexibility 
Probably the most impressive feature of TCRs is the ability to recognize the 
massive quantity of peptide-associated MHC complexes with limited genetic 
polymorphism. It is commonly accepted that this limitation can be overruled by the 
TCR’s structural flexibility. Interestingly, this characteristic was formerly 
hypothesized to be a mechanism to explained thymic selection following the 
determination of the first TCR-MHC structure in 1996 (Garcia, 1998). More 
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recently, studies have revealed that TCR V-domains may adopt alternate 
conformations to fit both MHC classes differentially independently of the positive or 
negative selection (Gascoigne, 2011; Stadinski et al., 2011; Yin et al., 2011). Other 
structural data have also indicated that the same TCR successfully engages 
distinct pMHCs and does so using exclusive strategies (Colf et al., 2007). 
Alternatively, there are also examples of distinct TCRs capable of binding the same 
pMHC in a different manner (15-16 du review 2011). Furthermore, it is reported 
that by differentially combining α and β chains, TCRs may vary their plasticity in 
order to bind a larger pool of pMHC (Stadinski et al., 2011). The following schema 
(Figure 1.22), inspired by Gascoigne’s, offers a simplified mechanism behind this 
plasticity. 
 
Figure 1.22: TCR flexibility 
This schematic illustrates how the same TCR can give rise to three different conformers. (a) The 
closed conformer is the structure that has been most often encountered in TCRs, whether bound to 
ligand or free. Rotation in the J region of the V domain relocates the CDR1 and CDR2 out and away 
from the other chain’s CDRs and is possible for both Vα and Vβ domains (a and c). This rotation, in 
the range of 8° to 12° relative to their position in the closed conformer, results in the CDR’S distal 
residues to move by about 4Å. The CDRs’ open conformers are superimposed on the CDRs’s 
closed conformer, shown in paler hues.  
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1.4.4. Docking onto pMHC and geometry 
 Much as MHCs are capable 
of binding countless peptides within 
their peptidic groove, TCRs 
recognize the entire pMHC 
repertoire with their CDR loops. The 
growing TCR-pMHC structural 
database has provided insights on 
how they associate with MHC and 
inspired a stereotyped docking 
model, portrayed in Figure 1.23 
(Garcia and Adams, 2005; Garcia 
et al., 1996; Marrack et al., 2008a; 
Rudolph et al., 2006). TCR’s 
orientation over pMHC is diagonal, with a variable angle of around 45° in reference 
to the peptide (Figure 1.24a) (Wilson and Garcia, 1997). This angle brings the Vα 
and Vβ on top of the carboxy-terminal portion of the MHCII β and α chain 
respectively. In contrast, when docked onto MHCI, the TCRα chain is positioned 
over the HC’s α2 domain, equivalent to the MHCII β helix (Bridgeman et al., 2012). 
It is generally the CDR3 loops and MHC-associated peptide that command 
variations in the TCRs’ angle and pitch (Marrack et al., 2008a). Besides, being 
somatically generated, it is these loops that are fine-tuning TCR’s reactivity 
(Rubtsova et al., 2009). More like a guideline, this general docking orientation does 
not apply to every resolved pMHCs, e.g. MBP85–99-HLA-DR2b with the Ob.1A12 
TCR, which use an unconventional topology (Figure 1.24b) (Hahn et al., 2005; 
Wucherpfennig et al., 2009). 
Figure 1.23. CDRs docking on MHC 
Lateral view of the TCR on top of pMHCII (1FYT). The 
CDR loops of the Vα and Vβ domains are positioned 
over the amino-terminal and carboxy-terminal halves 
of the peptide, respectively. TCR’s interaction with the 
peptide is mostly done by the central CDR3 loops.  
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 At first glance, this 
canonical orientation 
seems to be defined by the 
TCR’s CDR1 and CDR2 
loops that bind conserved 
residues on the MHC α-
helixes while the CDR3 
loops interact with the 
associated-peptide 
(Bridgeman et al., 2012; 
Cuendet et al., 2011; 
Wucherpfennig et al., 1993, 
2010). However, as the 
thermodynamics of every pMHC-TCR is unique it is hard to believe in such a strict 
model (Miller et al., 2007) Accordingly, it has been suggested that this TCR polarity 
was the result of a stoichiometric pressure from the multiple surrounding co-
receptors, such as CD3, CD4/CD8 (Ding et al., 1998). Given that those two 
viewpoints are not mutually exclusive, it is well accepted that TCRs have 
designated CDRs interacting exclusively with the peptide or MHC chain within the 
boundary of the overall quaternary structure (Wucherpfennig et al., 2010). Few 
exceptions have been observed that did not entirely fit this canonical rule. Among 
them, Wucherpfening’s group have reported a pMHCII-TCR complex interacting 
exclusively with the peptide and CDR3s while CDR1s have also been listed as 
peptide binder in conjunction to the CDR3s (Hahn et al., 2005; Rudolph et al., 
2006). The canonical geometry will be further developed in section 1.4.7, which will 
cover the evolutionary relation between pMHC and TCR. Yin and coworkers were 
recently able to crystalize the ternary complex between a pMHCII, TCR and CD4 
Figure 1.24. Unconventional docking 
Structural comparison of TCR docked onto pMHCIIs. (a) Top 
view of the canonical human antimicrobial HA1.7–HA–DR1 
complex (1FYT). MHC chains are white and the peptide is dark 
grey; TCR α-chain	   is cyan and β-chain is teal. (b) The human 
autoimmune Ob.1A12–MBP–DR2b complex (1YMM).  
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(Yin et al., 2012b). This feat was possible by increasing the affinity of CD4 for the 
MHCII using in vitro directed evolution and yeast display and is shown in Figure 
1.25. Having described how TCRs dock onto pMHC molecules, it is now easier to 
explain how this recognition is transduced into T cells activation. 
 
Figure 1.25:  TCR-CD3-CD4 complex 
Ternary complex between the CD4, MHCII and CD4. (a) Schematic of a docked pMHC with the 
TCR-CD3 multireceptor complex and CD4. (b) Ribbon formatted crystal structure of the MS2-3C8 
TCR, MBP-DR4 and CD4 complex and the CD3 γδ and γε subunits (3T0E).  
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1.4.5. Biophysics of activation 
The comparison of pMHC-associated TCR crystal structures portrays a 
frozen state that explicitly shows their plasticity. However, despite their extreme 
value, these structures remain far from the reality of membrane-associated 
receptors within the cellular laminar flow. Biophysics experiments have provided a 
collection of hypothesis as to how T-cells are activated and were compiled into a 
comprehensive table (Table 1.1) (Bridgeman et al., 2012).  
Theory Definition 
Kinetic Proofreading 
(McKeithan, 1995) 
    The ability of a T-cell to discriminate between agonist and non-specific 
peptide–MHCs (pMHCs) based on kinetic parameters required for 
sequential downstream phosphorylation steps  
 
Serial Triggering 
(Valitutti et al., 1995) 
    The ability of a small number of pMHCs to achieve a high T-cell 
receptor (TCR) occupancy via serial engagement of the same TCR  
 
Germline-encoded Codon Theory 
(Feng et al., 2007) 
    The theory that germline-encoded codons permit specific TCR 
variable-domain recognition of certain MHC molecules  
 
Induced Fit Model 
(Boniface et al., 1999; Savage et 
al., 1999) 
    A thermodynamic mechanism by which TCRs ‘scan’ the pMHC to 
‘search’ for complementarity – this structural reordering may be 
transmitted along the entire length of the TCR, inducing a conformational 
change that may trigger TCR signaling  
 
Conformational Change Model 
(Gil et al., 2002; van der Merwe and 
Dushek, 2011) 
    A model to explain TCR activation based on the premise that ligand 
engagement by the TCR induces a conformational change in the 
TCR/CD3 complex that permits linkage to T-cell signalling  
 
Permissive Geometry Model 
(Minguet and Schamel, 2008) 
    A refinement of the conformational change model, based on the 
premise that dimeric/multimeric pMHC binding promotes rotation of the 
ab TCR subunits with respect to each other – this rotation induces a 
scissor-like movement of the CD3 chains, permitting their 
phosphorylation  
 
Aggregation Models 
(Van der Merwe and Dushek, 2011) 
    Models of T-cell activation based on the premise that pMHC 
engagement induces aggregation of co-receptor in the vicinity of TCRs 
(co-receptor heterodimerization) and/or aggregation of TCR complexes 
(pseudodimer aggregation)  
 
Kinetic Segregation Model 
(Davis and Van der Merwe, 1996) 
    A model that explains the progression of TCR signaling based on size 
exclusion of phosphatases from the vicinity of activated TCRs  
 
Table 1.1: T cell activation theories 
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Before taking a side as to which T cell activation theory is the best, facts 
pertaining to the binding biophysics should be introduced. First, there is a hierarchy 
of TCR binding affinities toward their respective cognate ligands; pMHCI cognate 
TCRs bind with more affinity (KD = 32 µM) than pMHCII cognate TCRs (KD = 
92 µM). Second, it is also suggested that the affinity of TCRs is generally weaker 
for self or degenerated-self pMHCs compared to foreign peptides, which explain 
partly why tolerance ensues preferentially to an immune response (Bridgeman et 
al., 2012; Cole et al., 2007). However, it is now clear that the T cell mediated 
response is not a direct correlate of the binding affinity and should account for 
other parameters, i.e. half-life, on- and off- rates. By comparing self and foreign 
Ags, a striking relationship between the origin of the associated peptide and these 
biophysical parameters becomes apparent: TCR binds i) self-pMHC with weaker 
affinities, faster off-rates and slower on-rates and ii) foreign-pMHC with higher 
affinities, slower off-rates and faster on-rates (Bridgeman et al., 2012). These 
dynamics allow for multiple binding and serial triggering of events that may arise 
with as little as 10 pMHCs (Manz et al., 2011; Purbhoo et al., 2004).  
Structural and biophysical studies hint at an active rather than static model. 
Moreover, transposing these data to a cellular and multireceptor context in respect 
to the recent studies relative to CD3 and pMHC-induced signal transduction 
suggest that TCRs are anisotropic mechanosensor, i.e. direction matters (Adams 
et al., 2011; Husson et al., 2011; Kim et al., 2009; Li et al., 2010; Wang and 
Reinherz, 2011). For example, using a very elegant approach, Kim and colleagues 
demonstrated that MHC-coupled beads could only activate T cells after a tangential 
force was applied using optical tweezers (Kim et al., 2009). This model fits very 
well the laminar flux within which APCs and T cells come across and is 
schematized in Figure 1.26.  
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Overall, one can picture a pMHC-TCR docking scenario that stems from the 
TCR’s plasticity, allowing TCRs to distinguish and “mold” ligands in fast, serial 
events. Yet, this recognition happens as a whole, i.e. TCRs do not discriminate the 
associated-peptide from its ligand. As cells are not bouncing into each other but 
are rather crossing paths, the accumulation of pMHC-TCR punctual bindings 
induces a lateral force that is detected by the CD3 multi-complex. As mentioned 
earlier, the kinetics of this interaction is influenced by many parameters. This way, 
self and foreign pMHCs engender a distinct “pressure” against the TCR-CD3 
complex, which results in either T cells’ survival or activation.  
 
Figure 1.26: Anisotropism model 
Initial ligation of the TCR by pMHC (docking) constitutes a detachable mechanosensor that, as a 
result of continued T cell scanning, transmits an external torque (bending) into initial signaling 
(circling arrows) via the rigid components of the TCR complex prior to dissociation.  
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1.4.6. Downstream TCR signaling and T cell activation 
MHC-TCR engagement is only the first step to what will lead to an intricate 
signaling cascade. Thorough descriptions of the TCR signal transduction and T cell 
activation has been recently reviewed and thus, I will abridge them and offer only 
the essential background material (Morris and Allen, 2012; Smith-Garvin et al., 
2009). At the immunological synapse, the MHCs interact with the TCR 
multireceptor complex and the CD4 or CD8 co-receptors. This engagement is 
transduced by conformational changes within CD3 and leads to its 
phosphorylation, either directly or with the help of the Lck kinase, the latter 
associated to CD4/8. The synapse promotes TCR signaling and the recruitment of 
the transmembrane adapter protein LAT and generates a local stoichiometry 
favoring a phosphorylation cascade, which ultimately activates phospholipase C-γ1 
(PLC-γ1). Then, PLC-γ1 hydrolyses PIP2 to form inositol triphosphate (IP3) and 
diacylglycerol (DAG). IP3 then induces Ca2+ flux-mediated signaling, leading to NF-
AT activation, while DAG recruits Ras and PCK-θ at the plasma membrane.  
On one side, the Ras pathway leads to the phosphorylation of Erk, which 
activating the transcription factor Elk1, and to the expression of the activator 
protein-1 (AP-1) (Genot and Cantrell, 2000). On the other side, PCK-θ regulates 
the transcription factor NF-κB by triggering the phosphorylation, ubiquitination and 
degradation of IκB, which prevents NF-κB from gaining access to the nucleus 
(Vallabhapurapu and Karin, 2009). Altogether, these transcription factors act 
synergically to control the fate of the T cell. For example, NF-AT co-expression with 
AP-1 leads to IL-2 production and activation, while NF-AT alone leads to anergy. 
Figure 1.27 schematizes the signaling pathways participating in T cell activation.  
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Figure 1.27: TCR signaling 
pathway 
(1) The white boxes represent the 
major members of the proximal 
signaling complex: Lck, LAT, 
ZAP-70 and PLC-γ1 that initiate 
the signaling cascade and the 
hydrolysis of PIP2. (2) Binding of 
IP3 to its receptor triggers a Ca2+ 
flux from the ER and cell 
membranes and activates NF-AT. 
DAG recruits PKC-θ and RasGRP 
to the plasma membrane, which 
prompts NF-κB’s activation (3) and to the positive feedback loop responsible for Ras activation (4), 
respectively.  
 It is noteworthy that at the immunological synapse, cosignaling is crucial for 
T cell activation and depends on the concomitant binding of CD28 and CTLA-4 to 
CD80/86 (Smith-Garvin et al., 2009). Once the signaling cascade is in motion, 
multiple outcomes are possible depending on the MHC class of the APC that the 
naïve T cell encounters. From this meeting stems a pronounced clonal expansion 
generating numerous T cells with a wide range of effector functions such as 
cytotoxity and cytokine production (Jabbari and Harty, 2006; Kallies, 2008; O’Shea 
and Paul, 2010). According to the cytokines’ profile, these T cells will differentiate 
into many subtypes as part of the adaptive arm of the immune system.  
1.4.7. MHC-TCR co-evolution 
Aside from the structure-function, one of the most interesting question 
regarding TCRs is whether or not they co-evolved with MHC molecules (Marrack et 
al., 2008a, 2008b). This is even more relevant given that, although a conserved 
TCR docking mode has been put forth, no ubiquitous determinants were found to 
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define it. While the TCRβ CDR2 loop has often been linked to interact in a pairwise 
manner with MHCs, this does not stand as a general rule. Many crystals have 
confirmed that CDRβ residues Y46, Y48 and E54 engage with a variety of pMHC 
ligands (Feng et al., 2007; Garcia et al., 2009; Sim et al., 1996; Stadinski et al., 
2011). Indeed, these residues have been shown to interact with the highly 
conserved MHCII α-chain residues K39, Q57 and Q61, providing crucial support to 
the pairwise co-evolution model (Burrows 2010, Rudolph 2006). 
Despite this peculiar MHC class restriction attributed to the CDR1 and CDR2 
loops of the V domains, the docking mechanism remains unclear. A handful of 
groups with results supporting the co-evolution dogma have also identified aa of 
the TCR Vβ8 and Vα4 that confer intrinsic ability to bind certain MHC alleles, even 
in the absence of a bound-peptide or with reactivity against both MHC classes (Dai 
et al., 2008; Marrack et al., 2008a, 2008b; Yin et al., 2011). Accordingly, these 
results also pointed out that the CDR2 loops are partly responsible for this 
recognition. In the same vein, a very recent report from Scott-Browne and 
colleagues suggest that the features controlling the TCR specificity for MHC 
stemmed from a common ancestor over 400 million years ago and was conserved 
throughout evolution (Scott-Browne et al., 2011). Elegantly, they generated many 
chimeric TCRs with sequences of highly divergent species and showed that these 
TCRs have yet retained their ability to bind MHCs. This report is in line with the 
Nobel Laureate Neils Jerne’s premise, which hypothesizes the evolutionary 
selection of the TCR variable regions toward MHCs (Jerne, 1971).  
A recent report by Stadinski et al. stresses the fact that TCR specificity for 
pMHC ligands is not driven by germline-encoded pairwise interactions. Notably, 
they described a single TCR Vβ using alternate strategies to bind pMHC when 
paired with different Vα (Stadinski et al., 2011). The authors argue that since CDR1 
and CDR2 loops have the flexibility to bind their ligands in many ways, this could 
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not fit a pairwise co-evolution model. Accordingly, the Mariuzza group just 
demonstrated that the CDR3 loops can markedly alter those evolutionarily selected 
contacts (Deng et al., 2012). Besides, reports from the Singer group have provided 
very interesting results showing that deletion of either CD4/8 or thymic selection 
allowed TCRs to recognize Ags in an Abs-like fashion, independently of MHC 
ligands (Van Laethem et al., 2007; Tikhonova et al., 2012). Additionally, Baker and 
colleagues have put forth the hypothesis that TCR’s binding is mostly orchestrated 
by the associated peptide and less so by conserved MHC motifs (Gagnon et al., 
2005).  
Altogether, TCR bias toward MHC may well be a combination of conserved 
evolutionary feature, thymic selection and co-receptors pressure (Collins and 
Riddle, 2008; Garcia, 2012; Garcia et al., 2009; Marrack et al., 2008a). While it is 
outside the scope of my thesis to answer this question, it remains that TCR 
engagement with MHC is a very central factor to consider in evaluating how SAGs 
are able to manipulate this mechanism for their own purpose. Based on the co-
evolution premise and CDR2β’s key role, the McCormick’s group recently proposed 
that this loop is the critical determinant for bSAGs’ function (Nur-ur Rahman et al., 
2011). As many pathogens mimic or exploit conserved motifs/interactions to elude 
the immune system, SAG binding to a TCR region described to be evolutionarily 
linked to MHC recognition adds to this viewpoint pros’ list. 
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1.4.8. TCR relationship with SAGs 
In order to activate T cells, SAGs elicit a biochemically distinct MHC-TCR 
engagement and signaling (O’Rourke 
et al., 1990; Sundberg et al., 2007). As 
a general rule, SAGs bind a cognate 
TCR Vβ domain (Figure 1.28a-c), 
which prompts a massive proliferation 
and deletion of T cell expressing SAG-
specific Vβ elements, creating holes in 
the repertoire (Biasi et al., 1994; 
Penninger et al., 1995; Wahl et al., 
1993). This “repertoire hole” is what 
led to their identification in the mouse 
almost forty years ago (Festenstein, 
1973). 
Figure 1.28: SAG docking onto TCR 
SAG-TCR interaction is shown beside the 
CDR-binding imprints. (a) Interaction between 
TSST-1 and the TCR CDR2β and FR3β 
regions (2IJ0). (b) Interaction between SEB 
and the TCR CDR2β, FR3β and HV4β regions 
(1SBB). (c) Modelization of the interaction of 
SEA with the TCR CDR1β, CDR2β, CDR3β 
and HV4β regions (1L05 and 1KTK (SpeC 
was used as a reference for SEA 
superimposition)). (d) Binding of the SAG 
MAM use most of the distal TCR interface, 
including the Vα (2ICW). (e) Interaction of 
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SEH with the TCR Vα and CDR3β (2XNA).  
The first effect of SAG presentation is a strong polyclonal T cell expansion 
(Acha-Orbea et al., 1993a). However, in addition to Vβ, specific Vα repertoire 
skewing is also described (Aude-Garcia et al., 2000; Smith et al., 1992a; Vacchio 
et al., 1992). Interestingly, recent data pertaining to Staphylococcus enterotoxin H 
(SEH) and MAM have demonstrated that SAG-mediated TCR engagement can 
also stem from Vα binding (Figure 1.28d and e) (Saline et al., 2010; Wang et al., 
2007). However, this does not explain how Vβ-specific SAGs could also give rise to 
Vα skewing, which is the result of direct TCR-MHCII interaction. Altogether, SAGs 
bind TCRs differently, either recognizing the overall conformation, for least specific 
SAGs, or forming very specific HBs between SAG and the CDRs’ aa lateral chains 
(Sundberg et al., 2007). As a consequence, this limits/broadens the number of Vβ 
a given SAG can bind and thus affects its potency.  
The fate of SAG-activated T cells differs from that of T cells activated by 
conventional Ags and bypasses conventional Ag processing and presentation. 
Whereas conventional Ag could activate a small 0,0001% of the naïve T cell, up to 
20% of the those cells could be activated by a given SAGs (Ford and Burger, 1983; 
Fraser and Proft, 2008). SAGs ability to activate that many T cells is explained by 
their ability to predominantly bind non-variable region of the TCR (Acha-Orbea and 
MacDonald, 1995). The greater potency of the response initiated by SAGs leads to 
both proliferation and cytokine release and ultimately results in activation-induced 
cell death, while those T cells that survive become unresponsive or anergic (White 
et al., 1989). Interestingly, SAG presentation activates both CD4+ and CD8+ T 
cells although CD4 is reported to enhance T cell response by increasing the overall 
avidity of the interaction (Thibodeau and Sékaly, 1995). Given the MHCII interface 
used for SAGs binding, CD4 should proficiently interact with the MHCII β2 domain 
although the possibility remains that this instead occurs on an adjacent SAG-free 
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MHCII. CD4-deficient cell lines or mAb blockage of CD4 also result in T cell 
activation by SAGs, suggesting that the downstream activation cascade also 
functions without contribution from CD4 (Bueno et al., 2007). Given CD4/8’s role in 
localizing Lck to the proximal TCR signaling complex and the role of Lck in initiating 
the canonical signaling, the phosphorylation of CD3 must be induced directly by 
TCR ligation. This may occurs when a high degree of cross-linking is attained at 
the immunological synapse (Stanners et al., 1995). Alternatively, it was proposed 
that SAGs could bypass this pathway by binding additional ligands or co-receptors. 
The Madrenas group proposed a Lck-independent pathway that relies on the 
induction of PLC-β by the heterotrimeric G protein family member Gα11 (Bueno et 
al., 2006). Figure 1.29 
depicts this alternative 
pathway. 
Figure 1.29: Alternative TCR 
signaling pathway 
SAG-mediated T cell activation 
via Gα11-dependent PLCβ 
activation. The question mark 
highlights uncertainty over 
whether it is triggered by a high 
degree of cross-linking at the 
proximal TCR signaling complex 
or by an unidentified G protein 
coupled receptor. 
In addition to SAG-MHCII binding to the TCR multireceptor complex, 
costimulation and late downstream events are important for the T cell fate. As 
opposed to canonical Ag presentation, which relies on CD28/CTLA-4 costimulation, 
that mediated by SAG is less dependent on this mechanism, but costimulation can 
intensify the response (Vella et al., 1997). Interestingly, the effect of these 
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costimulatory molecules can vary and go from T cell response attenuation to 
dependency, depending on the system used (Fikri et al., 2002; Krummel et al., 
1996). Clearly, Ags and SAGs have distinct ways to activate T cells and much 
remains to be deciphered. Whether unidentified receptors are implicated in this 
response remains to be verified but seems likely given the participation of G 
proteins in signaling and the ability of a handful of bSAGs to stimulate T cells 
independently of MHCII ligands (Avery et al., 1994; Bueno et al., 2006). It is 
noteworthy that the ability of distinct SAGs in activating either TCR signaling 
pathway may differ. 
Recently, Arad and colleagues suggested that SEB could bind to the 
costimulatory molecule CD28, which is constitutively expressed on naïve T cells 
and binds B7 ligands on APCs (Arad et al., 2011). The CD28 binding site on SEB, 
which is relatively conserved among bSAGs of this family, is located on the 
opposite side of those of the TCR and MHCII, and fits in a model including CD28 
(Figure 1.30). The downstream signaling cascade stemming from CD28 
engagement remains to be elucidated. It will also be of interest to evaluate how 
CD28 impacts the presentation of other SAGs. 
 
Figure 1.30: SEB binds CD28 
SEB-mediated MHCII-TCR engagement 
complex showing the possibility of CD28 
binding. The region 150-161 of SEB is 
colored red and corresponds to the CD28 
binding interface. The model is based on the 
SEB-MHCII and SEB-TCR co-crystals (1SEB 
and 1SBB). To easily portray the possibility of 
such multimeric complexes, CD28 structure 
was added and oriented as if bound to the T 
cell membrane. 
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1.5. Superantigens 
I have begun this chapter by presenting SAGs in relation to MHCII and TCR, 
yet neglecting to present them properly. Now, I describe the diversity and potent 
immunostimulatory role of these mitogens and offer a structural overview of the 
topology underlying TCR-MHCII engagement. SAGs are a group of toxins, 
commonly known for their implication in food poisoning and toxic shock. They are 
small 15 to 30 kDa byproducts of different pathogenic microorganisms, such as 
bacteria, viruses and protozoa (Thibodeau and 
Sékaly, 1995). For most of their existence, SAGs have 
been described as molecules with the ability to 
polyclonally activate T cell bearing specific TCR Vβ 
elements. This dogma, however, has been challenged 
in the recent years and now includes specific Vα 
elements of the TCR. SAGs possess structural 
features allowing to concomitantly bind the MHCII and 
the TCR outside of the usual Ag-binding site (Figure 
1.31). The most characterized bacterial SAGs 
(bSAGs) and viral SAGs (vSAGs) are those of 
Staphylococcus aureus and Streptococcus pyogenes, 
and those encoded by the MMTVs, respectively. Paradoxically, whereas bSAGs 
have very well characterized structure/function but a poorly defined role, vSAGs 
have a well-defined role but structural knowledge is lacking.  
The contribution of SAGs in the bacterial life cycle is vague. An 
immunosuppressant role has been put forth, whereby bSAGs allows the bacteria to 
colonize their host, thus providing the bacteria with an evolutionary advantage. 
Alternatively, the SAG-mediated inflammation may stimulate bacterial growth 
Figure 1.31. Ag vs SAG 
Comparison of conventional Ag 
MHCII-TCR topology (a) vs an 
example of the one coerced by 
SAG (b) 
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(Marrack et al., 1993; Stow et al., 2010). That many distinct SAGs are known to 
bind the different MHCII allotypes and the TCR V elements suggests that their 
diversity has been compelled by a need to stimulate as many T cells as possible 
and that they are crucial for the bacteria (Fraser and Proft, 2008). Yet, 20 years 
after their identification, the roles of S. aureus and S. pyogenes toxins remain 
hypothetical, but all the same, come with their share of side effects for the host. 
Indeed, they are associated with the onset of Kawasaki disease, atopic dermatis 
and chronic rhinosinusitis (Xu and McCormick, 2012). Moreover, in mouse models, 
bSAGs were shown to increase the severity of a model of multiple sclerosis (EAE) 
and rheumatoid arthritis (Torres and Johnson, 1998). 
On the other hand, vSAGs’ role in the MMTV cycle is well understood. By 
using SAGs to recruit T cell help, MMTV exploits the immune response in order to 
instigate the infection in long-lived memory B cells and plasma cells (Acha-Orbea 
et al., 2007). Also, by causing a vSAG-specific Vβ T cell deletion, the occupying 
virus prevents subsequent infection from other MMTV bearing vSAGs with the 
same Vβ specificity (Golovkina et al., 1992). Figure 1.32 portrays the role of vSAG 
in MMTV’s infection cycle. Notably, recent findings by the Golovkina group show 
that MMTV transmission requires additional stimuli from the commensal microbiota 
(Kane et al., 2011). MMTV infection often leads to breast cancer, although its 
etiology seems independent of the encoded vSAG (Acha-Orbea and MacDonald, 
1995). Interestingly, MMTV-like sequences were found in human breast 
carcinomas and encoded functional vSAGs (Wang et al., 2004). It was also 
reported that MMTV can infect human cells and thus arose the hypothesis that, like 
in mouse, this virus was a tumorigenic factor (Indik et al., 2005). However, a recent 
epidemiology report that reviewed 85 original studies pertaining to this field 
concluded that no significant relationship exists between human breast cancer and 
the presence of MMTV-like sequences (Joshi and Buehring, 2012). 
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Marginal knowledge about SAGs encoded by other viruses, such as those of 
HERV-K18, is available and remains controversial (Azar and Thibodeau, 2002; 
Sutkowski et al., 2001; Woodland, 2002). However I will not discuss these SAGs in 
this work.  
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Figure 1.32: Transmission and infection cycle of MMTV 
The exogenous MMTV transmission is milk-borne; virions contained in ingested milk first infect DCs 
(1) then spread to B and T cells in the Peyer’s patches and ultimately, with the help of its vSAG (2), 
to other lymph nodes and lymphoid organs. A rapid T cell proliferation follows, providing help to B 
cells and recruiting additional lymphocytes (3), leading to a pool of infected cells. These cells gain 
access to mammary glands (4), a mucosal-associated lymphoid tissue (MALT), in which the virus 
replicates (5) and is later shed via the milk (6). Because of the vSAG, a slow and almost complete 
deletion of cognate Vβ T cells follows the infection (7). As a result of the virus’ multiple integration in 
lymphocytes (8) and mammary gland epithelial cells, tumorigenesis may arise to varying degrees 
(9). Germline transmitted, endogenous MMTVs cause thymic negative selection of vSAG-cognate T 
cells (I) leading to deletion (II). Most of endogenous viruses are unable to produce infectious 
particles.  
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1.5.1. Bacterial superantigens 
More than 30 bSAGs are expressed by S. aureus and S. pyogenes. They 
are classified into five distinct evolutionarily groups and, according to their 
sequence, are hypothesized to share the same tertiary structure. However, as 
presented above, they bind MHCII and TCR using different strategies. Table 1.2 
highlights the major characteristics of the subgroups whereas Figure 1.33 shows in 
sillico models of SAG-MHCII-TCR ternary complexes.   
 Toxins Strain MHCII binding mechanism 
Group I TSST-1 S. aureus Binds MHCII α chain through a low affinity N-
terminal domain that is peptide-dependent 
(Kim et al., 1994) 
Group II SEB, SEC, SpeA S. aureus,  
S. pyogenes 
Bind MHCII α chain through a low affinity 
binding domain, independently of the 
associated-peptide (Jardetzky et al., 1994) 
Group III SEA, SED, SEH S. aureus Bind MHCII like group II and group IV and can 
cross-link MHCIIs (Mehindate et al., 1995; 
Petersson et al., 2002) 
Group IV SpeC, SpeG, SpeK S. pyogenes Binds MHCII β chain H81 through coordination 
with a Zinc ion (Li et al., 2001) 
Group V SEI, SEK, SpeI S. aureus,  
S. pyogenes 
Bind MHCII similarly to group IV, but posses an 
additional loop important for TCR interaction 
(Günther et al., 2007) 
Table 1.2: Overview of bSAGs classification 
Because Streptococcus enterotoxins often resemble those of 
Staphylococcus, I will concentrate my effort in describing the latter regarding the 
ability of groups I, II and III to bridge MHCII to the TCR, which covers the three 
existing binding strategies and will briefly highlight the main features of the groups 
IV and V.  
 
 
 
62
 Sole member of the group I, TSST-1 
concomitantly binds to the MHCII α chain 
and C-terminal end of the associated-
peptide (Kim et al., 1994). Consequently, 
its presentation is highly dependent on the 
bound-peptide sequence and is completely 
null in situation where the C-terminus 
protrudes outside the groove (Hogan et al., 
2001; Wen et al., 1997a). Moreover, TSST-
1 Vβ specificity is very strict and linked to 
an aa insertion in the CDR2β loop (Moza et 
al., 2007). Finally, TSST-1 engagement is 
devoid of MHCII-TCR contacts (Figure 
1.33a). 
 
Figure 1.33: SAG-mediated T cell activation 
complexes 
Different strategies used by SAGs of groups I, II and 
III to bridge MHCII and TCR together. (a) Model of 
the TSST-1-mediated T cell activation complex 
based on the TSST-MHCII and TSST-TCR co-
crystals (2TSS and 2IJ0). (b) Model of SEB-
mediated T cell activation complex based on the 
SEB-MHCII and SEB-TCR co-crystals (1SEB and 
1SBB). (c) Model of the SEA-mediated T cell 
activation complex based on the SEA-MHCII and 
SpeC-TCR co-crystals (1L05 and 1KTK (SpeC was 
used as a reference for SEA superimposition)).  
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More promiscuous than TSST-1, the group II member SEB binds a broader 
range of Vβs and its successful presentation depends on extra Vα-MHCII β chain 
interactions (Figure 1.33b) (Sundberg et al., 2007). This SAG binds both the MHCII 
and TCR in a conformation-sensitive fashion, interacting with the main chain of 
these molecules (Fields et al., 1996; Li et al., 1998b).  
 Members of group III, which includes SEA, have the notable ability to cross-
link MHCIIs (Figure 1.33c). Remarkably, they bind MHCIIs in two ways, using 
distinct binding sites (Thibodeau et al., 1997). The first is similar to that used by 
group II SAGs and the second, which relies on a Zn ion and the MHCII βHIS81, 
also characterizes the group IV SAGs. Little structural information is currently 
available on how group III SAGs engage TCRs. However, given the respective Vβ 
and Vα skewing stemming from SEA and SEH presentation and lack of competition 
for the TCR between those SAGs, it is conceivable that the member of this group 
differentially bridge TCRs and would benefit to be reclassified accordingly 
(Petersson et al., 2003; Saline et al., 2010). Finally, group V behave similarly but 
also posses a loop extension crucial for T cell activation, by contacting the apical 
loop of the TCRβ FR4 region (Brouillard et al., 2007; Günther et al., 2007). 
 
Figure 1.34: Overlay of bSAGs 
A superimposition of groups I, II and III 
SAGs indicate very similar tertiary 
structure. Most changes are located in 
the connecting loops and the area 
delimited by a circle. Absent from 
SEA, ordered on SEB and highly 
ordered (β-sheets) on TSST-1, this 
region interacts with the TCR, MHCII α 
chain or associated-peptide, 
respectively. 
 
 
 
64
In addition to the SAGs classified into the five classic groups is the MAM 
SAG, which possesses a unique fold and binding strategy (Figure 1.35). In the 
case of MAM SAG, MHCII-TCR engagement stems from its concomitant 
association with the membrane distal interface of the receptors and prevents any 
contact between the two (Wang et al., 2007). MAM has also been reported to form 
zinc-dependent homodimers, which would allow MHCII cross-linking (Zhao et al., 
2004). 
Figure 1.35: MAM-mediated T 
cell activation complex 
Ribbon depiction of the ternary 
complex between MHCII, MAM 
and TCR (2ICW). MAM-mediated 
bridging reveals a near-
perpendicular topology between 
the MHCII and TCR. (b)  90° 
CCW rotation of (a), highlighting 
the perpendicular binding.  
 
 
Altogether, the many bSAGs have evolved to activate T cells using different 
architecture, using many tweaks that allow them to modulate their potency and 
thus their impact on the immune response (Sundberg et al., 2002). 
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* note that I did not use the word protein here as, at the time, the possibility was that Mls could 
also be lipidic 
1.5.2. Viral superantigens 
Faceless for almost 20 years, the superantigens of MMTV (vSAGs) were 
initially described as the minor lymphocyte stimulating (Mls) antigen by Festenstein 
(Festenstein, 1973). They were documented as MHC unrelated genes that led to 
strong mixed leukocyte reactions in mice strains with identical MHC (Acha-Orbea 
and Palmer, 1991). The name “superantigen” was offered by Kappler and Marrack 
in an effort to explain the function of these potent stimulatory factors*, unrelated to 
bSAGs, that could bind MHCIIs and stimulate T cells in a Vβ-specific manner 
(Marrack and Kappler, 1990). As a consequence of Mls antigens, responsive T 
cells are deleted, creating holes in the T cell repertoire (Acha-Orbea et al., 1993b). 
It is only in the early nineties that three groups concurrently linked the deletion of 
specific T cell Vβ subsets to a gene within the mouse genomic mtv sequence 
(Acha-Orbea et al., 1991; Choi et al., 1991; Woodland et al., 1991). The next years 
were very prolific and shed light on the nature of these type II transmembrane 
glycoproteins (Figure 1.36) encoded by the MMTV long terminal repeat ORF 
(Acha-Orbea and MacDonald, 1995). Grouped in seven families, there are over 50 
described vSAGs that are encoded either by the endogenous mtv loci or 
exogenous viruses (Acha-Orbea et al., 2007). They share about 85% overall aa 
homology and have a hallmark variable 21 to 38 C-terminal stretch that correlates 
well with their Vβ specificity (Acha-orbea, 1995; Acha-Orbea and Palmer, 1991).  
 
Figure 1.36: Schematic of vSAG polypeptide 
General features of the type II vSAG polypeptides: up to five N-linked glycosylation sites, the 
membrane cleavage site (MCS), the proximal cleavage site (PCS) and the optional distal cleavage 
site (DCS), which is only present on certain vSAGs.  
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As I mentioned earlier, the structure-function of vSAG is ill defined. The first 
major finding pertaining to vSAG was its TCR binding interface. Pullen and 
colleagues noticed residues of the solvent-exposed lateral face of the TCR Vβ (red 
and pink in Figure 1.37) that impaired vSAG stimulation but not conventional Ag 
presentation (Pullen et al., 1990). Interestingly, most of the vSAG-inactivating Vβ 
mutations tested did not affect bSAGs presentation, which suggest that vSAGs and 
bSAGs have non-overlapping binding site. Moreover, introduction/deletion of N-
linked carbohydrates can prevent/restore presentation of vSAG, respectively. 
 
Figure 1.37: TCR-vSAG binding interface 
vSAG7 critical residues for T cell activation include 
the Vβ8.2a V17, T18, N22,, T24 D51, E70, N71, 
which are part of the FR3 and HV4. In contrast to 
bSAGs, vSAG7 do not bind the CDRs. The TCR is 
shown as if the MHC was below. 
 
A further article by Pullen and coworkers revealed a TCR Vβ residue (T24) 
that affected both the presentation of OVA peptide and vSAG (Pullen et al., 1991a). 
This result suggests that this mutation disrupted an essential TCR-MHCII contact. 
Of note, this threonine is part of the CDR1, region implicated in canonical 
MHC/peptide (Figure 1.23) binding and the fact that it affects both OVA and vSAG 
presentation will be further discussed in the forthcoming chapters. Overall, vSAGs 
bind the TCR Vβ at the lateral, solvent-exposed β-pleated sheet. 
While the TCR binding site was being defined, Winslow et al. succeeded in 
isolating vSAGs and identified B cells as expressing this 45 kDa glycoprotein, only 
present on the cell surface as a 18.5 kDa processed fragment (Winslow et al., 
1992). Processing at the PCS (Figure 1.38) is indeed essential to unlock vSAG 
stimulatory function, even though the two resulting fragments may remain non-
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covalently associated after cleavage (Krummenacher and Diggelmann, 1993; Park 
et al., 1995; Winslow et al., 1994a). I will refer those two fragments as the N-vSAG 
and C-vSAG throughout this work. 
Figure 1.38: vSAG maturation 
First, up to 5 N-linked glycan are co-
transnationally added to the immature vSAG 
polypeptide. The maturing vSAG then transit 
to the Golgi where it is cleaved at the MSC 
and PCS, generating the N-vSAG and C-
vSAG (also 18kDa or mature vSAG) moieties. 
Some vSAG family members contain an 
additional cleavage site, which renders C-
vSAG inactive if processed. Processing at the 
PCS is essential for vSAG ability to activate T 
cells. 
1.5.3. vSAG presentation 
 The association of vSAG with MHCIIs is probably the most enigmatic aspect 
underlying the ability of these SAGs to mediate the T cell signaling complex. 
Indeed, the vanishingly small quantity of vSAG produced, even upon super 
expression, remains a major obstacle in characterizing and defining the biophysics 
of vSAG (Krummenacher and Diggelmann, 1993). Earlier studies described N-
vSAG to interact with the MHCII β chain at the βHis81-dependant SEA binding 
interface (Figure 1.19) and suggested a second biding site elsewhere (Mottershead 
et al., 1995; Torres et al., 1993). The second site, used by C-vSAG, overlaps the 
one of SEA on the MHCII α chain (Figure 1.19) (Delcourt et al., 1997a). 
Interestingly, it was also proposed that vSAG binds the MHCII groove similarly to Ii 
(Hsu et al., 2001). The three proposed binding modes are depicted in Figure 1.39. 
C-vSAG binding to the MHCII α chain leads to TCR engagement and T cell 
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stimulation (Grigg et al., 1998a; Winslow et al., 1994b). The C-vSAG moiety also 
have the ability to be intercellularly transferred from MHCII- cells to MHCII+ APCs, 
in what is called the paracrine transfer (Delcourt et al., 1997a). 
 
Figure 1.39: Proposed vSAG-
MHCII binding modes 
N-vSAG binds to the MHCII β 
chain and C-vSAG bind to the α 
chain. Conversely, N-vSAG may 
bind to the MHCII groove like Ii 
before being processed. 
 
An interesting feature of vSAGs, is their ability to bind both human and 
mouse MHCIIs (Labrecque et al., 1993a). The different alleles have distinct vSAG 
presentation capability and follows a hierarchy in which I-E > I-A >>> I-Aq and DR > 
DQ > DP and where I-E and DR are the best presenters (Kappler et al., 1988; 
MacDonald et al., 1989; Subramanyam et al., 1993). As I mentioned previously 
(1.3.8. SAGs binding to MHCIIs), this phenomenon seems to indicate that C-
vSAGs associate with MHCIIs in a conformational manner.  
The question as to whether immature vSAGs associate synergically to 
MHCII upon synthesis is being challenged. Reports have argues that both can bind 
in the ERs (Hsu et al., 2001) and other observed MHCII-vSAG interaction only at 
the cell surface between mature MHCII and C-vSAG (Grigg et al., 1998a). In the 
second model, vSAGs traffic independently of MHCIIs and finally associate at the 
cell surface with mature, SDS-resistant pMHCII complexes. Also, given the 
dependency of human HeLa cells to only present vSAG after being transfected with 
Ii and DM (or CIITA), interaction between vSAG and MHCIIs depends on the 
bound-peptide and occurs at the cell surface (Azar et al., 2005b).  
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1.5.4. The associated-peptide influence 
I mentioned earlier that the group I SAG directly binds the associated-
peptide and therefore, its presentation is directly affected by nature of the latter. In 
the case of TSST-1, it is the peptide C-terminus end that impacts its binding and 
thus, many inherent pMHCIIs do not allow presentation (Wen et al., 1996). In their 
study, Wen and colleagues conducted a thorough saturation mutagenesis of a 
peptide, evaluating each residue in their ability to present TSST-1. Interestingly, 
whereas most substitution did not affect the ability of the pMHCIIs to promote 
TSST-1 presentation, C-terminal PFRs sterically blocked its binding and hampered 
presentation (Wen et al., 1997b).  
In the case of vSAGs, the nature of the associated-peptide correlates with 
the ability of pMHCII to present vSAG. However, the part of the peptide (N- or C-
terminus) or whether it is a direct binding or indirect effect, reflected on the MHCII 
comformation, remains to be elucidated and is more thoroughly discussed in the 
next chapters.  
1.5.5. Interplay between MHCII maturation and SAG 
Given the apparent correlation between the associated-peptide and SAGs 
presentation, one must ask if non-classical MHCIIs can influence their presentation 
by differentially altering the MHCII peptide repertoire. Indeed, It was previously 
shown that DM-deficient human cells could not present TSST-1 or vSAGs (Azar et al., 
2005b; Lavoie et al., 1997). Similarly, presentation of these SAGs by cells from H2-
DM-deficient mice was inefficient (Golovkina et al., 2001; Hogan et al., 2001; Tourne et 
al., 1997). As mentioned above, DM edits the peptide repertoire by exchanging CLIP 
for a variety of peptides with better kinetic stability (Schulze and Wucherpfennig, 
2012). Thus, in the absence of DM, MHCIIs display a different peptide repertoire in 
which associated-CLIP peptides are overrepresented. Given the ability of DO to inhibit 
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DM, it is possible that similarly to DM-deficient cells/mice, DO affect SAG presentation. 
Accordingly, a recent report by a colleague just acknowledged a role for DO in SAGs 
presentation (Pezeshki et al., unpublished data). His data indicate that both SEA and 
TSST-1 are favorably presented following DO over-expression in contrast to SEB and 
vSAG7, which were both unaffected. Based on these results, it is tempting to link this 
effect to the increased abundance of CLIP-MHCII complexes. However, while DM-
deficient cells failed to present TSST-1, its inhibition by DO did not lead to a 
presentation defect, as it should have been expected if its presentation was tied to the 
CLIP peptide. Therefore, intricacies resulting from the MHCIIs maturation are perhaps 
reflected in SAG presentation more that by the nature of the bound-peptide. Overall, 
DO effect on the tested bSAGs can sometime be counterintuitive, much like it is with 
conventional Ag presentation (1.3.6. Peptide editing). What is therefore very interesting 
is the possibility that there is a co-evolutionary relation between an “invariant pMHCII 
complex” that ensure efficient SAG presentation given their inherent expression 
(Rudensky et al., 1991). 
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1.6.  Problematic, Hypothesis and Objectives 
Even though the mouse mammary tumor virus superantigens were the first 
ones identified, they remain poorly defined. Indeed, vSAGs are produced in 
vanishingly small quantities, which rendered structure/function studies quite a 
challenge. Stemming from the work of Azar et al., which reported that vSAG 
presentation was restored upon Ii and DM expression in defective human cell lines, 
I aimed to further characterize the contribution of the MHCII-bound peptide in vSAG 
presentation (Azar et al., 2005). Also, I aspired to unveil the architecture of the T 
cell signaling complex mediated by vSAGs, which I hypothesized unlike any of 
those mediated by bSAGs.  
Interestingly, while both Ii and DM impact vSAG presentation, DO does not 
(Pezeshki, 2012). One would think that overexpressing DO would inhibit DM and 
reduce its peptide exchange activity, and thus would lead to ineffective vSAG 
presentation. However, the function of DO is quite remarkable in that it is following 
the Schrödinger’s paradox. Indeed, depending of the experimental system used to 
witness its effect, the observed results are often antipodal. Thus, to better 
understand DO, we directed our efforts in figuring out its biophysics. Starting from 
the idea that DO was an inherently unstable molecule, we conducted experiments 
to monitor its conformation upon DM binding, event leading to its stabilization. 
Furthermore, a point mutation, engineered by a previous laboratory member, 
induces a similar conformation change that unfetters DO from DM and allow DO 
egress to the plasma membrane, independently of DM (Deshaies et al., 2005). 
Knowing that a single aa substitution had such an effect on DO, I undertook to 
screen a library of randomly mutated DO to reveal other aa that could further 
stabilize this molecule.  
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vSAGs were proposed to bind MHCIIs like Ii (Hsu et al., 2001). However, 
given the utmost importance of a peptide-filled MHCII “state” for vSAG 
presentation, this proposal fell short at explaining how vSAG could bind the peptide 
groove concomitantly to a peptide. Interestingly, co-expressing two SCDs, one 
consisting of vSAG bound to MHCIIβ and the other consisting of Ii bound to 
MHCIIα, led to structurally-sound CLIP-MHCIIs, indicating that Ii and vSAG do not 
have overlapping binding site. Of note, It was recently proposed that Ii trimers 
could only bind a single MHCII heterodimer and that this interaction would lock the 
Ii scaffold, preventing binding of additional MHCIIs (Koch et al., 2011). This report 
contradicts seminal work in which nonameric complexes were observed (Roche et 
al., 1991b). Also, the fact that the two SCDs properly assembled suggested that 
high order complexes arose. Thus, we used the Ii-SCD to indubitably prove the 
existence of nonameric Ii-MHCII complex.  
The articles presented in the forthcoming chapters recount these 
experiments.
 
 
 
Chapter 2 : Functional analysis of the MMTV 
superantigen 
Experimental design: JSF, NHS and JT 
Performed experiments: JSF70%, LG25% YS3% and DYD2% 
Writing: JSF90% and JT10% 
 
 
 
 
 
 
 
 
 
 
74
 
  
75 
Unconventional Topology between the TCR and MHC Class II Molecule is 
Coerced by MMTV Superantigens 
 
 
Jean-Simon Fortin,*§1 Laetitia Genève,*1 Naglaa H. Shoukry,¶ Georges A. Azar, *2 
Younes Souheil,¶ Bader Yassine-Diab,¶ Rafick Pierre Sékaly, ‡ Daved H. 
Fremont§ and Jacques Thibodeau*† 
 
* Laboratoire d’Immunologie Moléculaire, Département de Microbiologie & 
Immunologie, Université de Montréal. Montréal, QC, Canada. 
§Department of Pathology & Immunology, Washington University School of 
Medicine, St. Louis, MO, United States 
¶Département de Médecine, Université de Montréal and Centre de Recherche du 
Centre Hospitalier de l’Université de Montréal (CRCHUM), Montréal, Québec, 
Canada. 
‡Division of Infectious Diseases, Vaccine and Gene Therapy Institute - Florida 
(VGTI-FL), Port Saint Lucie, FL, United States 
 
† Corresponding author: Jacques Thibodeau,  
Laboratoire d’Immunologie Moléculaire, Département de Microbiologie & 
Immunologie, Université de Montréal, CP 6128, Succursale Centre-Ville, 
Montréal, QC, Canada, H3C 3J7 
Tel : (514) 343-6279; Fax: (514) 343-5701;  
 
 
 
Running title: Structure-function analysis of the MMTV superantigen 
 
  
76 
ABSTRACT 
Mouse mammary tumor virus (MMTV) superantigens (vSAG) are 
notorious for defying structural characterization and a consensus has yet to be 
reached regarding their ability to bridge the TCR to MHCII molecule. In this study, 
we determined the topology of the T cell signaling complex mediated by vSAG by 
examining the respective relation of vSAG7 with the MHCII chains, MHCII-
associated peptide and TCR. We used various covalently linked peptide-MHCII 
complexes to demonstrate that vSAG presentation is tolerant to variation in the 
protruding side chains of the peptide, but sensitive to a protruding N-terminal 
extension. An original approach in which vSAG was covalently linked to either 
MHCII chain confirmed that maturing vSAG binds the MHCII β chain outside the 
peptide binding groove. Also, whereas mature vSAG binds to the MHCII α chain 
in a conformation-sensitive manner, immature vSAG binds the β chain. Because 
both vSAG moieties remain non-covalently associated after processing, our 
results suggest that vSAG crosslinks MHCII molecules. Comparing different T 
cell hybridomas, we identified key residues on the MHCII α chain that are 
differentially recognized by the CDR3β when engaged by vSAG. Finally, we 
describe a highly conserved TGXY motif responsible for vSAG-mediated T cell 
activation. Our results reveal a novel SAG-MHCII-TCR architecture in which 
vSAGs coerce a near-canonical docking between MHCII and TCR that allows 
eschewing of traditional CDR3 binding with the associated-peptide in favor of 
MHCII α chain binding. Our findings highlight the plasticity of the TCR 
complementary determining regions. 
 
 
Keywords: Mouse mammary tumor virus/superantigens/antigen 
presentation/MHC class II/T-cell receptor. 
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INTRODUCTION 
Superantigens (SAGs) are bacterial or viral proteins that have the ability to 
stimulate up to 20% of the total T cell population, bypassing conventional MHC 
class II (MHCII) antigen processing and presentation (1). SAG-activated T cells 
undergo a strong proliferation phase that is followed by either anergy or deletion 
(2). In contrast to canonical MHCII-TCR docking, which relies on the intimate 
binding of the complementary determining regions (CDRs) to the MHCII α-helixes 
and associated-peptide, TCR bridging to MHCII by SAGs relies on distinct 
strategies (3). On the one side, they commonly bind to the TCR CDR2, 
framework region 3 (FR3) and hypervariable region (HV4) that are within a 
specific variable (V) family (4). On the other side, they either bind i) the MHCII α 
chain, ii) a binding interface composed of the MHCII α chain and associated-
peptide, iii) the MHCII βHis81 residue through coordination of a zinc ion or iv) the 
entire MHCII membrane-distal surface spanning the α, β chain and the 
associated-peptide (4, 5). Moreover, a handful of SAGs have the ability to 
crosslink or oligomerize MHCII molecules by using both the MHCII α and β chain 
binding sites (6). SAGs of viral origin have yet to provide a clear picture in terms 
of their ability to compel such interactions.  
 
 The best-characterized viral SAGs (vSAG) are those encoded by the 
mouse mammary tumor viruses (MMTVs). Contrary to other SAGs, vSAGs are 
produced by the host cell machinery and must undergo post-translational 
modifications in order to stimulate T cells (7). First, a precursor polypeptide 
forming a type II transmembrane protein of 37 kDa is modified by the addition of 
up to five N-linked glycans (8). Then, the 45 kDa glycoprotein transits to the Golgi 
where it is cleaved at two specific R-X-X-R dibasic motifs, resulting in the N-
vSAG and C-vSAG (also called 18 kDa) moieties. After processing, both N- and 
C-terminal domains remain non-covalently associated and detached from the 
membrane (9). This maturation allows cells to shed vSAGs, even if devoid of 
MHCIIs, a feature called paracrine transfer (10). Finally, by binding both MHCII 
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and TCR, the C-vSAG domain is responsible for cognate T cell stimulation (11, 
12). Within this fragment is the most polymorphic region of the MMTV SAGs, the 
C-terminal 21 to 38 residues responsible for Vβ specificity (13). Extensive TCR 
mutagenesis has revealed that the TCR-binding site of C-vSAG includes the TCR 
Vβ FR3 and HV4 (14–18). Interaction with MHCIIs, in contrast, is puzzling and 
has been reasoned from competition experiments in which vSAG and the 
staphylococcal enterotoxin A (SEA) compete for binding on both the α and β 
chains (10, 19).  
 
 The molecular basis for successful T cell stimulation by vSAG7 is an 
interesting conundrum. Our group and others have described vSAG presentation 
to be influenced by the peptide repertoire (12, 20, 21). However it is unknown 
whether this characteristic is linked to vSAG binding to MHCII or TCR recognition 
of the vSAG-bound MHCII complex. Conflicting evidence of vSAG binding to the 
MHCII α, β chains or peptide-binding groove exists in the literature and none 
provides a consensual model on how they successfully generate the T cell 
signaling complex (10, 19, 22, 23). In the present study, we aimed to determine 
the topology of the vSAG-MHCII-TCR complex by examining the respective 
relationship of vSAG7 with the MHCII chains, associated-peptide and TCR. To 
this end, we used a panel of covalently linked peptide-MHCII molecules, point 
mutants and MHCII-vSAG single chain (SC) constructs. Altogether, our results 
define a novel MHCII-SAG-TCR architecture. 
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MATERIAL AND METHODS 
 
Plasmids and mutagenesis 
The vSAG7 sequence was codon optimized using GeneOptimizer™ (Invotrogen). 
pBUD-DRα, and -DRβ have been described elsewhere (24). Lumenal portions of 
DRα (aa 1-191) and DRβ (aa 1-199) were linked to the lumenal part of vSAG7 
(aa 667-322) or Ii (a 72-297) by the PCR overlap extension method (25). The 
chains were joined by a small glycine-serine linker (G3-S-G3) introduced in DR 
chains, Ii and vSAG7 by complementary overlapping primers. DRα mutants, 
peptide-linked DRβ (26), HASCT, SCDΔCt and HASCTΔCt were generated by 
the PCR overlap extension method using the Phusion polymerase (NEB). The 
resulting cDNAs were cloned into pCDNA3 vector (Invitrogen).  
 
Antibodies and reagents 
The following antibodies were used: VS7 (mouse monoclonal antibody (mAb) 
IgG1 to the C-terminal end of MMTV7 SAG) (27), L-243 (mouse IgG2a mAb) and 
ISCR3 (mouse mAb IgG2b) bind a specific DRα conformational epitope (28), 
XD5 (mouse IgG1 mAb to a linear epitope in the β1 domain of all class II 
molecules) (29), BU45 (mouse IgG1 mAb to the C-terminal portion of human Ii) 
(30) and CerCLIP.1 (mouse IgG1 mAb to the N-terminal portion of CLIP) (31). 
The anti-DRα (rabbit anti-serum against the DRα chain) and anti-DRβ (rabbit 
anti-serum against the DRβ*0101 chain purified from SDS-PAGE; R.P. Sékaly, 
unpublished). The anti-SEA mAb was a kind gift of Dr W. Mourad (University of 
Montreal) (32). SEA was purchased from Sigma Aldrich (St-Louis, MO). 
 
Cell lines and transfections 
Human epithelial HEK 293T, HeLa DM.5 and HeLa CIITA cells (21), and murine 
DAP cells were culture in DMEM (Wisent) with 5% fetal bovine serum (FBS; 
Wisent) while Kmls.13.11 and Kmls 12.6 T cell hybridomas (33) were cultured in 
DMEM with 10% FBS. CTLL-2 (ATCC TIB-214; American Type Culture 
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Collection) and HA1.7 TCR+ Jurkat cell line, CH7C17 (34), were cultured in RPMI 
(Wisent) with 10% FBS and 4 µM of β-mercaptoethanol. HeLa and DAP cells 
were transfected with the fusion proteins using lipofectamine LTX reagent 
(Invitrogen) according to the manufacturer’s instructions. The cells were selected 
for resistance against geneticin (500 µg/mL; Wisent) and sorted by flow 
cytometry, using a FACSVantage SE (BD). HEK 293T cells were transfected 
using the calcium phosphate method as described previously (35) using 8 μg of 
plasmid DNA. Cells were harvested and analyzed 48 h post-transfection. 
 
Flow cytometry 
Cells were incubated in PBS with the primary Ab for 30 min on ice. Cells were 
washed twice with PBS and incubated a further 30 min with the Alexa fluor-488-
coupled goat anti-mouse IgG Ab (Invitrogen) for 30 min on ice. After two more 
washes, cells were analyzed by flow cytometry using a FACScalibur (BD 
biosciences). Alternatively, cells were incubated for 1 h with SEA (1µg/ml) on ice 
and washed twice with PBS prior to the addition of Abs. Intracellular stainings 
were performed as mentioned on fixed, permeabilized cells (4% 
paraformaldehyde, 0.05% saponin).   
 
T cell stimulation assays 
vSAG7-expressing APCs were co-cultured at a 1:1 ratio with 5x104 T cell 
hybridomas for 18h at 37°C. IL-2 production was determined by the ability of the 
co-culture supernatant to sustain the proliferation of the IL-2-dependent T cell line 
CTLL-2 and measured by [3H]thymidine incorporation (47). For indirect 
presentation, APC (donors) were co-cultured with BJAB cells (acceptors) and 
responder T cell hybridomas at a ratio of 1:1:1. 
 
Immunoblot 
Stable or transfected cells were lysed for 30 min on ice at a density of 2x107 cells 
per mL in 1% (v/v) Triton X-100 in lysis buffer (20 mM Tris-HCl, 150 mM NaCl) 
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and Complete Protease Inhibitor (Roche). Heated (65°C) or boiled total protein 
extracts were then separated by SDS-PAGE (10 %) under reducing conditions, 
unless mentioned otherwise. Samples were transferred to Hybond-ECL 
nitrocellulose membrane (Amersham Biosciences). Membranes were blocked for 
1 h with 5% (w/v) dry milk in TBS-T (TBS with 0.1% (v/v) Tween® 20). The 
following steps were also performed in TBS-T with 5% dry milk. Primary antibody 
to DRα, DRβ and vSAG7 were incubated for 1 h at room temperature. 
Membranes were washed three times for 10 min and incubated for 1 h with HRP-
conjugated secondary antibodies (BIO/CAN Scientific) followed by three more 
10-min washes. Bands were visualized by the BM Chemiluminescence Blotting 
Substrate (Roche). For endo H sensitivity, 500U of endoglycosidase H (NEB) 
were added to the protein extract and incubated for 1h at 37°C. Samples were 
analyzed on SDS-PAGE as above.  
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RESULTS 
 
The MHCII associated-peptide influences vSAG7 presentation 
 It was previously shown that DM-deficient human cells could not present 
the toxic shock syndrome toxin-1 (TSST-1) or vSAGs (21, 36). Similarly, 
presentation of these SAGs by cells from H2-DM-deficient mice was inefficient 
(37–39). DM edits the peptide repertoire by exchanging CLIP for a variety of 
peptides with better kinetic stability (40). Thus, we wondered whether the 
accumulation of CLIP-MHCII complexes observed in DM negative cells was 
responsible for the lack of vSAG7 presentation. We used the well-characterized 
DM-negative T2-DR3 cell line (41). In these cells, over 90% of the DR molecules 
are loaded with CLIP, a phenotype that is lost upon transfection of DM (42). As 
shown in Figure 1A, whereas T2-DR3 cells failed to present vSAG7, T2-DR3-
DM+ cells led to strong T cell proliferation, similar to that observed with DM-
proficient BJAB and COX B cell lines. Of note, in this experiment, vSAG was 
provided by co-culturing APCs with the class II-negative DAP-vSAG7+ cell line 
(10). These results suggest that CLIP-DR3 complexes do not support vSAG7 
presentation.  
 
 We next aimed to determine how the CLIP peptide could affect vSAG7 
presentation. Considering the MHCII associated-peptide, vSAG presentation can 
be influenced by: i) the peptide’s flanking residues (PFR) extending outside the 
groove, ii) the peptide’s protruding side chains or iii) a peptide-induced MHCII 
conformational change. To discriminate between these possibilities, we 
generated cell lines displaying distinct homogenous pMHCII populations by 
transfecting DRα with various peptide-DRβ fusion proteins (43). The mouse DAP 
cells were chosen as model APCs as they are easily transfected and allow 
vSAG7-specific T cell stimulation upon co-transfection of MHCIIs and vSAG (44). 
Once stable peptide-DR1 DAP cell lines were obtained, we transiently 
transfected vSAG7 and monitored proliferation of mouse vSAG7-responsive T 
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cell hybridomas (45). We used two different hybridomas bearing Vβ6 regions 
cognate for vSAG7. Because vSAG7 expression is low, we co-expressed a 
reporter GFP to monitor transfection efficiencies and plotted MFI in bar graphs 
below or beside histograms of all cell lines.  
 
Firstly, we tested whether the PFRs of CLIP were affecting vSAG 
stimulation. We hypothesized that the hallmark N-terminal extension of CLIP 
would affect vSAG7 presentation based on analyses of CLIP peptides found in 
T2-DR3 cells, which all bear 4 to 6 PFRs (46, 47). We generated cell lines 
expressing MHCIIs charged with either longCLIP81-101 or coreCLIP87-101 peptides, 
herein named lCLIP and cCLIP, respectively (Fig. 1B). To ensure that the 
quaternary structure of the different complexes was not disturbed by the peptide, 
we used two different mAbs: L243, which binds a conformational epitope on DRα 
chain and XD5.117, which binds a linear epitope on DRβ chain (29, 48). Figure 
1C shows for each cell line the MHCII cell-surface expression and the MFI of the 
reporter GFP (lower panels). Both cell lines expressed similar amount of MHCIIs 
and were similarly receptive to DNA upon the subsequent transient transfection 
of vSAG7 and GFP. 
 
After vSAG7 transfection, cells were incubated with the Vβ6+ T cell 
hybridomas Kmls 13.11 or 12.6. As shown in Figure 1D, vSAG7 presentation by 
lCLIP-DR was inefficient compared to cCLIP-DR, the latter giving rise to strong T 
cell response. Interestingly, we also observed a decrease in L243 mAb reactivity 
with the lCLIP-DR1 transfectant (Fig. 1C), better portrayed by the graph in Figure 
1E showing normalized MFI for L243 over XD5. The reduced L243 reactivity for 
lCLIP-MHCII complexes can either stem from an MHCII conformation alteration 
or steric hindrance between the CLIP81-86 extension and L243. This result 
suggests that vSAG7 presentation is sensitive to variations in pMHCII that are 
also sensed by the mAb L243. However, it is hard to pinpoint whether it is one of 
these effects, or a combination of both, that account for the reduction in 
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stimulatory capacity of vSAG7. On the one hand, it was reported that the L243-
like 14-4-4S mAb, specific for mouse MHCII, competes against vSAG7 on I-Ed 
(49). Likewise, the Staphylococcus enterotoxin B (SEB), which binds to the 
MHCII α chain and competes with L243, is also affected by lLCIP (50, 51). On 
the other hand, superimposition of the crystal structures of DR1 bound to either 
CLIP86-101 or CLIP90-101 showed conformational alteration in the loop connecting 
the third and forth strands of the MHCII β-sheet platform that includes lysine α39 
(52). Mutation of K39 abolishes L243 and SEB binding but does not affect vSAG 
presentation (53). Therefore, although there is a known conformational change 
between CLIP-MHCII variants, it is unlikely to affect vSAG7 presentation. 
Together these results suggest that the reduced vSAG7 stimulation observed 
when presented by lCLIP-DR1 is due to steric hindrance of vSAG7 by terminal 
PFRs of CLIP. Also, the above-described data corroborate the notion that vSAG7 
binds to the MHCII α chain (10).  
 
Secondly, we sought to evaluate the contribution of TCR-contacting 
peptide residues by comparing the capacity of peptides with distinct protruding 
side chains to present vSAG7. To this end, we employed a covalently linked 
hemagglutinin HA(307-319) peptide (HADR1). We selected this peptide over CLIP 
given the availability of the HA peptide-DR1-HA1.7 TCR structure and the 
responsive modified Jurkat cell line expressing the HA1.7 TCR (thereafter simply 
referred to Jurkat) (34, 54). Our rationale was to be able to distinguish both the 
conventional and vSAG presentation in the same setting, using different T cells. 
In addition, to minimize adverse effects linked to the bound-peptide’s primary 
sequence, we performed the same assays using another peptide supporting 
vSAG presentation, the tetanus toxin peptide (TT829-842). Like the HA-DR1, TT-
DR1 has great kinetic stability and also fills the P1 pocket with a tyrosine, thus 
providing a system to test the exclusive contribution of peptide protruding side 
chains (Fig. 1B) (55, 56). The TCR contacting side chains of these two peptides 
were interchanged, resulting in the backbone (b) HAb and TTb variants, and 
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involved a charge reversal at P-1 (K-Q), a change of a small residue (V) to a 
bulkier one (I) at P2, and finally a change from a negatively charged residue to a 
highly hydrophobic one (K-F) at P8. If any of the peptide protruding side chains 
were implicated in specific vSAG7 contacts, one should expect to see differential 
stimulation between these peptides, independently of the T cell Vβ specificity. 
The stably transfected HAβ and TTβ constructs (Fig. 1F, H) were then tested for 
their capacity to stimulate T cells (Fig. 1G, I). Every variant successfully 
presented vSAG7, suggesting that a peptide’s protruding side chains are not 
critical for vSAG7-mediated response (Fig. 1G, I). Conversely, presentation of 
HAb failed to stimulate Jurkat T cells (Fig. 1J) as specific TCR contact residues 
have been modified (54). All covalently-linked peptides (except lCLIP) supported 
strong vSAG7 presentation, ruling out a role for the peptide’s C-terminal linker 
and thus, PFR at this end. Altogether, these results suggest a model in which 
vSAG7 presentation is tolerant to the nature of the peptide’s protruding side 
chains, but sensitive to peptides bearing an N-terminal extension.  
 
N-vSAG7 has an overlapping binding site with SEA on the DRβ chain 
 The above-described data support the notion that C-vSAG7 binds to the 
MHCII α chain. However, it has been proposed that the vSAG7 polypeptide has 
two binding site on MHCII, one of which shares the same interface as SEA on the 
β chain or binds the peptide-binding groove (19, 22, 23). Maturing vSAGs are 
composed of two domains that remain non-covalently associated upon 
processing. C-vSAG participates in MHCII-TCR bridging but the role of N-vSAG 
is less clear. To gain insight on the role of the latter, we designed two single 
chain polypeptides in which the luminal domain of either DR chain is linked to 
that of vSAG7. These straightforward single chain dimers (SCDs) were inspired 
by a similar SC between MHCII and Ii (57). Such SCDs were made possible 
because HLA-DR and vSAG7 are type I and type II proteins, respectively, 
allowing fusion of the C-terminus of DR chains to the N-terminus of vSAG7. The 
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resulting DRα and β-based fusion molecules were named αSCD and βSCD, 
respectively and are depicted in Figure 2A. For brevity, when a SCD is 
mentioned in an experimental setting, it is always co-transfected with its 
matching complementary wild type DR chain partner, e.g. DRα+βSCD is referred 
to βSCD. 
 
 First, we characterized the interaction between the SCDs and their 
complementary MHCII chain partner. For these experiments, we used HEK 293T 
cells given their high transfection efficiency. As shown in Figure 2B, the αSCD 
apparently failed to associate with DRβ upon transfection, as judged by the lack 
of L243 surface staining and unusual degradation pattern (Supplemental Fig. 1). 
In contrast, the βSCD properly associated into heterodimers with DRα, trafficked 
to the plasma membrane and was recognized by a panel of conformational mAbs 
(Fig. 2B). Using the anti-C-vSAG7 mAb VS7, we also observed MHCII-bound 
vSAGs at the cell surface (Fig 2B, right panel). Altogether, these results indicate 
that only the βSCD can generate ordered complexes and allow vSAG surface 
expression.  
 
 Next, to confirm that vSAG7 behaved like the wt vSAG when part of the 
βSCD, we verified whether it still competed the binding of SEA. We transfected 
HEK 293T cells with either wt DR or βSCD and performed SEA binding assays 
monitored by flow cytometry. Figure 2C shows the DR (left panel) and SEA (right 
panel) staining profiles, which reveal weak SEA binding to cells expressing 
βSCD. Once normalized for MHCII surface expression, we noted a two-fold MFI 
reduction for βSCD compared to the wt or βIi-SCD controls (Fig. 2D). These 
results indicated that the vSAG moiety on DRβ prevented SEA binding. However, 
as SEA has a minor low affinity binding site on the MHCII α chain, the possibility 
remained that the observed competition was due to the presence of vSAG7 on 
DRα (58, 59). To test this, we performed the same experiment using a DRα 
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mutant that is unable to bind SEA (DRαK39A) (58). As shown in Fig. 2E, 
competition is observed whether βSCD is associated with wt MHCII α chain or 
K39A mutant. Moreover, truncating C-vSAG from βSCD, generating the 
βSCDΔCt, resulted in a similar reduction of SEA binding, confirming that N-
vSAG7 and SEA have an overlapping binding interface (Fig. 2F). The high SEA 
concentration and affinity for βHis81 are factors likely to favor displacement of 
some of the vSAG7 molecules and could explain why competition was not total. 
Likewise, processing of the vSAG7 moiety is observed and could favor its 
dissociation from the β chain (Supplemental Fig. 1). These data confirmed that N-
vSAG has an overlapping binding site with SEA on the MHCII β chain.  
 
vSAG7 does not bind the MHCII peptide groove 
 Our results described so far define the binding site of C-vSAG7 and N-
vSAG to the MHCII α and β chain, respectively. Thus, it was difficult to envision a 
model where vSAG7 interacted with both DR chains at once. The Huber group 
proposed that a segment of MMTV vSAGs (called the MIIPBM, MHCII peptide 
binding motif) interacts with the MHCII peptide-binding groove upon synthesis in 
the ER (23). The CIIPBM motif is part of N-vSAG and could bridge both vSAG 
segments through the MHCII cleft. To verify whether vSAG7 occupies the MHCII 
groove, we designed a new construct, HA-single chain trimer (HASCT), in which 
the HA peptide was appended to the βSCD N-terminus (Fig. 2A). Based on the 
Hsu et al. premise, our rationale was that N-vSAG7 would prevent HA binding to 
the groove. Figure 3A shows the surface DR expression for both βSCD and 
HASCT in comparison to wt DR and HADR. Interestingly, DR surface staining 
was increased in both transfectants expressing the linked-HA peptide. These 
data corroborate well with the MHCIIs increased stability when optimal peptide 
occupies the groove (26). Soluble versions of DRβ and HAβ (sβ and sHAβ) 
chains were used as controls and ruled out transmembrane (TM) domain-
mediated bias between the TM-devoid βSCD and controls. L243 MFI ratios of sβ 
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and βSCD against sHAβ and HASCT, respectively, showed a 4-fold increase in 
expression when HA was fused to DRβ (Fig. 3B). That the tethered HA peptide 
increased expression of DR is incompatible with a model in which vSAG would 
occupy the binding groove.  
 
 To confirm that the HA peptide was lodged inside the groove and not 
displaced by the immature vSAG7 polypeptide, we tested the complex for SDS 
sensitivity. Indeed, HA-DR1 complexes resist SDS-denaturation and migrate as 
compact peptide-loaded heterodimers under non-boiled conditions (60). Cell 
lysates obtained from the transfectants presented in Figure 3A as well as a βIi-
SCD control were analyzed by SDS-PAGE. XD5 mAb was used to probe the 
resulting immunoblots. As expected, in absence of HLA-DM, neither Ii- nor 
vSAG7- SCDs formed compact complexes with DRα (Fig. 3C, lane 4 and 6). In 
contrast, when HA was linked to either DRβ or βSCD (lane 2 and 8), compact, 
SDS-resistant heterodimers were observed, confirming that the HA-peptide was 
present in the groove.  
 
  To unequivocally prove that vSAG7 did not bind to the MHCII cleft, we 
tested whether the HASCT could induce both Jurkat and vSAG-specific T cell 
responses. To this end, we moved from the HEK 293T to HeLa cells, the former 
being unable to present vSAG (21). Of note, although the molecular basis of this 
defect remains obscure, HeLa cells are unable to present vSAGs unless 
transfected with CIITA or treated with IFN-γ (21). This provided a useful system to 
evaluate the presentation of HA independently of vSAG in absence of CIITA and 
of both HA and vSAG7 in the presence of CIITA. We transiently transfected our 
various β chains into either HeLa or HeLa CIITA+ cells and assessed the 
response of Jurkat or Kmls 13.11 cells. As expected, vSAG7 presentation only 
occurred in the presence of CIITA, whether from the SCD and SCT (Fig. 3E). 
Surprisingly, HeLa cells transfected with HASCT failed to stimulate Jurkat cells in 
contrast to the control sHAβ (Fig. 3D). The lack of HA presentation can be 
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attributed to either an MHCII conformation flaw or to the vSAG moiety of the 
HASCT hampering proper TCR docking. We argue for the latter alternative 
because the tested mAbs did not distinguished the HASCT from the sHAβ control 
(Fig. 3A) and in the presence of CIITA, HA presentation was restored (Fig. 3D). 
However, that Jurkat failed to respond to the HASCT in CIITA-negative cells was 
puzzling. This is not due to degradation of the SCT-HA peptide and its 
subsequent association to endogenously expressed MHCIIs as the DRβ*0102 
allele in the homozygous HeLa CIITA+ cells does not present HA307-318 to Jurkat 
T cells (61) and therefore must arise from the HA-DR1 moiety of the SCT. One 
explanation is that in presence of a pool of MHCIIs, C-vSAG is transferred from 
the processed SCT onto the endogenous pMHCIIs (supporting vSAG 
presentation), thus revealing HA to the HA1.7 TCR bearing Jurkat T cells. The 
implications of this finding are discussed below.  
 
vSAG7 presentation relies on MHCIIα-TCR interactions 
 To better pinpoint the C-vSAG7 binding site on DRα and investigate the 
TCR binding topology, we generated an array of mutants of the α-helix lining the 
peptide groove. Most mutants were modeled from DQ2 and IAq, which present 
vSAG poorly and span aa63 to 68, the interface associated with SEB binding 
(13). Figure 4A shows the point-mutants on the HA-DR1 cartoon depiction 
(Protein data base (PDB): 1FYT) as well as DRα residues implicated in L243 
mAb binding (28, 54). Flow cytometry analysis of the resulting stable DR 
expression in DAP cells is given in Figure 4B assessed by L243 and XD5 
staining. As above, stable cell lines were transiently co-transfected with vSAG7 
and the reporter GFP. Then, cells were co-cultured with Kmls 13.11 and Kmls 
12.6 T cells and IL-2 production was measured. In an effort to minimize the effect 
of the cells’ intrinsic associated-peptides, we co-expressed each DRα variant 
with the HADRβ chain. In addition, this allowed us to monitor the stimulation of 
HA-specific Jurkat cells, which could be impeded by the α chain mutations (Fig 
4D). As predicted from the HA-DR1-HA1.7 TCR co-crystal (54), only mutation of 
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TCR contact residues α64, 65 and 67 abrogated presentation of HA to Jurkat 
cells.  
 Noteworthy, the reactivity of L243 was strongly decreased towards DR 
mutants α63 and α67 (Fig. 4B). This is best portrayed by the bar graph in Figure 
4C, showing L243 MFI over the MFI of the conformation-insensitive XD5 mAb. 
Surprisingly, those same DR mutants had a dramatically reduced ability to 
present vSAG7 (Fig. 4E and F) suggesting again overlapping binding regions 
between L243 and vSAG. As the side-chain of α63 points laterally, the weakened 
stimulation observed with both hybridomas by the αI63E MHCII mutant cell line 
suggests that C-vSAG7 binding is somehow affected by this mutation. Indeed, a 
less obstructive mutation, αI63A, restored vSAG7 stimulation (Supplemental Fig. 
2A and 2B).  
 Interestingly, while DRαA64R allowed a strong Kmls 13.11 stimulation, 
Kmls 12.6 failed to respond (Fig. 4E and F). This result indicates a TCR 
recognition effect unrelated to vSAG7 binding and highlights the importance of 
specific DRα-TCR contacts for efficient T cell stimulation. In line with this, it 
became difficult to evaluate whether the effect of DRα K67A on vSAG 
presentation is actually linked to a weakened association between vSAG and 
DRα or to a TCR recognition defect. Indeed, DRα K67 is characterized by a lack 
of both L243 reactivity and inefficient presentation of HA peptide to Jurkat cells, 
making both outcomes plausible (Fig. 2C and D). Although weak, the stimulatory 
response observed exclusively with the Kmls 13.11 hybridoma suggests that 
TCR recognition is a factor.  
 
 The solvent exposed DRα α-helix is used by SEB to bridge TCRs (62). The 
fact that vSAG7 presentation implicates DRα-TCR interactions demonstrates that 
the topology of the ternary complex is different from the one involving SEB. 
Interestingly, only the DRα mutant A64R cell line was unable to support SEB 
presentation (Supplemental Fig. 2C). The highly conserved A64 is buried inside 
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the SEB-DRα interface and the Arg substitute is likely to sterically hinder SEB 
association, probably reflecting the effect of I63E on vSAG7 presentation. 
Overall, it is apparent that the mechanism leading to TCR recognition of the 
vSAG-MHCII complexes differs from SEB and canonical peptide-MHCII 
recognition. 
 
vSAG7 mediates TCR activation through a conserved T-G-X-Y motif 
The specific interactions between the TCR and the MHCII α chain suggest 
the existence of conserved vSAG-TCR contacts. Given the numerous responsive 
Vβs for all vSAGs, it is unlikely that the TCR interaction is solely based on the 
polymorphic vSAG C-terminus as it would severely impede the likelihood of a 
cognate partnership. Interestingly, an alignment of MMTV SAGs and MMTV 
SAG-related domain from other viruses (e.g. herpesvirus) revealed a conserved 
T-G-X-Y motif (Fig. 5A), located at residues 226-229 of C-vSAG. Such a motif 
has been shown to be crucial for γ-aminobutyric acid (GABA) binding to the 
GABAA receptor and mutagenesis analysis identified that GABA binding depends 
on the threonine and the tyrosine (63). Based on this fact, we mutated the 
tyrosine 229 to a Phe and assessed the ability of vSAG7-YF to stimulate different 
T cell hybridomas. Figure 5B indicates that the Y229F mutation introduced either 
in full length or SC vSAG7 abrogated the activity. The TGXY motif could impact 
vSAG activity in many ways. On one hand, it could perturb C-vSAG binding to 
MHCIIs or its overall structural integrity. Both these hypotheses are refuted by the 
fact that the mutation did not affect surface expression of MHCIIs nor vSAG7 
(Fig. 5C and D). On the other hand, the tyrosine 229 could be implicated in direct 
TCR contact. Supporting this mechanism is the presence of a similar motif, 
LGNY, on a SEB contacting loop that interacts with the HV4 region of the TCRβ. 
Accordingly, mutation of the Tyr on SEB prevents its presentation (64, 65). 
Furthermore, Digglemann and coworkers described the region of C-vSAG 
bearing the TGXY motif as part of the TCR-interacting domain (66). These results 
suggest that in addition to highly polymorphic regions responsible for Vβ 
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specificities, vSAG binding also relies on conserved vSAG-specific TCR 
interactions. 
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DISCUSSION 
 
 The data presented herein define how vSAG7 bridges MHCII to the TCR. 
C-vSAG binds the MHCII α chain in a conformation-sensitive manner at the 
interface formed between the α-helix and the β-sheet platform. We demonstrated 
that, when coerced by vSAG, the TCR recognizes the MHCII in a near canonical 
manner, which constitutes a unique topology among those previously described 
for SAGs. Next, our results suggest that maturing N- and C-vSAG7 bind the 
MHCII β and α chains, respectively, on distinct MHCIIs. Finally, we identified a 
conserved motif in MMTV vSAGs, responsible for TCR binding independently of 
the TCR Vβ specificity. Based on our results and those of others, we propose a 
model in which the N- and C-terminal domains of a single vSAG crosslink two 
MHCIIs and bridge only specific TCR bearing Vβ elements that can be skewed 
as to recognize the MHCII α chain instead of the associated-peptide (Fig. 4G). 
 
C-vSAG7 binding to the MHCII α chain is influenced by the associated-
peptide 
 Presentation of vSAG7 requires that MHCIIs be filled with a diverse peptide 
repertoire (12, 21, 38). Here, we demonstrated that a single peptide supports 
vSAG7 presentation. However, the MHCII associated-peptide must meet certain 
criteria in order to be part of a permissive pMHCII. By comparing cell lines 
expressing either cCLIP-DR1 or lCLIP-DR1, we showed that the CLIP81-86 PFR 
inhibits vSAG presentation (Fig. 1D). Interestingly, it was previously described 
that CLIP N-terminal extensions also interfered with SEB binding to MHCII (51). 
Based on the crystal structures of CLIP-DR3 and CLIP-I-Ab, the CLIP81-86 N-
terminal extension is disordered thus failing to discern whether it prevents vSAG 
binding by steric hindrance, electrostatic repulsion or if this effect is a hallmark of 
the CLIP81-86 sequence (67, 68). Future studies will address this issue by 
characterizing the impact of N-terminal extensions on various peptides. 
Nevertheless, knowing the profound effect of PFRs on canonical and TSST-1 T 
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cell responses (39, 69, 70), and that DM favors the binding of peptides that tightly 
fit the groove, our findings point to N-terminal peptide trimming as a major 
determinant for vSAG presentation (40, 71). These results explain why DM-
deficient cells, either murine or human, are unable to present vSAG7 as they are 
predominantly charged with CLIP peptide bearing a 4-6 amino acids extension 
(46, 47, 72). It was reported by Hsu et al. that a DM-negative B cell line was able 
to present vSAG7 (23). However, as opposed to T2 cells expressing a single 
MHCII (DR3) or our DAP cell lines (DR1), the proportion of the various alleles of 
DR, DQ or DP that are bound to CLIP at steady state or which form of CLIP is 
bound is unclear in the DM- model.  
 
 It is unclear whether the previously reported need for peptide diversity 
reflects a direct contribution of the peptide’s sequence to part of the vSAG 
binding site, or an indirect negative effect echoed in the MHCII conformation. The 
findings presented herein support the latter hypothesis. It is unlikely that vSAG7 
interacts with the MHCII bound-peptide’s protruding side chains because severe 
changes in charge or size between those of HA, TT and CLIP did not affect their 
ability to activate Vβ6 and Vβ8.1 bearing T cells (Fig. 1 and Supplemental Fig. 
2D). While we did not conduct a thorough saturation mutagenesis of the 
peptides, our observation of DRα-TCR contacts portrays a setting in which 
vSAG7-peptide interactions are improbable (see below). 
 
 Our results suggest that C-vSAG7 binds to the lateral interface formed by 
the solvent-exposed DRα α-helix/β-sheet junction (Fig. 4A), an area highly 
susceptible to peptide-induced conformational changes (73). That HA-DR1αI63E, 
but not HA-DR1αI63A reduced L243 mAb reactivity and reduced vSAG7 
presentation capabilities point to an MHCII conformation defect (Fig. 4C-D and 
S3). It was previously reported that mice expressing Eα-bound I-Ab as the sole 
pMHCII were unable to mount vSAG7 specific responses, supporting the 
conclusion that a diverse MHCII peptide repertoire was required (38). In light of 
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our results, we can speculate as to why this pMHCII failed to present vSAG. The 
Eα(52-68) peptide bears no N-terminal PFRs and the C-terminal linker between 
the peptide and the MHCII β chain does not influence vSAG presentation. Thus, 
as previously presented by the authors, the inability of Eα-I-Ab to successfully 
present vSAG must be due to its intrinsic conformation (38). Indeed, whereas the 
25-9-17 mAb binds a panel of peptide-bound I-Ab, Eα-I-Ab was not recognized 
(74, 75). One possibility is that vSAG7 binding is affected by the αF24 residue, 
reported to be pushed outward by the bulky p1-filling Phe of Eα, at the C-vSAG7 
binding site (76). While we did not observe an effect of a Y-A substitution at the 
p1 HA residue (Supplemental Fig. 2E), it would be interesting to determine if a 
bulkier amino acid (e.g. Trp) substitution would reduce vSAG7 presentation 
accordingly. Altogether, these results indicate that the interface formed on the 
DRα α-helix/β-sheet junction is paramount for vSAG7 binding and that its 
presentation is vulnerable to both peptide-mediated conformational changes and 
N-terminal PFRs. 
 
TCR engagement by vSAG7 is unique among SAGs 
 Most of the SAG-mediated T cell signaling complexes outline a typical 
interaction between the TCR Vβ and the SAG, where the Vα sometimes 
participates in MHCII β chain binding (4, 77, 78). Consequently, Vβ-MHCII α 
chain contacts are sterically precluded by the bound bacterial SAGs (bSAGs). 
Given the lack of an MMTV vSAG crystal structure, it is challenging to predict 
how vSAGs force MHCII-TCR association. Previous analyses of the response of 
mature peripheral T cells against vSAGs have clearly established that non-Vβ 
components of the TCR are involved in the pMHCII-vSAG7 complex recognition 
(79–82). The Vα chain was shown to be an important part of the complex and a 
skewed repertoire in responding cells has been identified (83, 84). Within a given 
Vα family, reactivity was seen with only certain Vβ subfamily members (84, 85). 
Thus, the variations in the CDR regions, especially CDR3, are likely to affect the 
capacity of these TCRs to bind the MHCIIs and might be at the origin of many of 
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the reported cases of MHCII allelic/isotype restriction (33, 49, 84, 86).  
 
 Based on these facts and our results demonstrating that DRα A64R and 
K67A mutant cell lines differentially stimulated distinct hybridomas bearing the 
same Vβ, it is clear that the TCR-MHCII contacts are imperative to vSAG7 signal 
transduction (Fig. 4E-F). Moreover, these findings highlight direct MHCII α chain-
TCRβ contacts and would imply that vSAG7-mediated TCR engagement 
resembles that of conventional peptides, as hypothesized by the Marrack and 
Kappler group following their discovery that the TCR βT24Y mutant abrogated 
both conventional Ag and vSAG presentation (14, 87). Along the same lines, our 
MHCII α 64 and 67 mutants were also unable to trigger HA-specific activation of 
Jurkat cells (Fig. 4D). Based on the crystal structure of HA-DR1-HA1.7 TCR, 
DRα A64 and K67 are bound to the CDR2β D51 (54). However, one must be 
cautious in unifying these results. Indeed, as we have shown with our many 
different peptide-MHCII combinations, the peptide’s protruding side chain did not 
affect vSAG response by the tested hybridomas, as would be expected in a 
traditional pMHCII-TCR setting (Fig. 1). Furthermore, mutations at residue α65 
and α68, which are also implicated in TCR binding (54), had no effect on the 
ability of MHCIIs to present vSAG7 (Fig. 4D and E). Thus, it is fitting to picture a 
near canonical docking between MHCII and TCR that is coerced by vSAG. Such 
architecture allows eschewing of traditional CDR1/3 binding with the associated-
peptide in favor of MHCII chain binding as proposed by Nguyen et al. (88). These 
Vα-MHCIIβ and Vβ-MHCIIα contacts remain to be verified biochemically (89). 
 
 A large body of literature suggests that the β chain junctional region could 
influence TCR recognition of vSAGs (80, 90–92). Especially relevant was the 
demonstration by many groups that Vβ6 thymic deletion is incomplete in vSAG7+ 
mice and that Vβ junctional diversity regulates vSAG reactivity (92, 93). At first 
glance, the need for a diverse peptide repertoire and the importance of Vβ 
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junctional diversity may seem paradoxical. As many peptides support vSAG 
binding, we do not expect skewing in CDR3. However, our results point to the 
existence of non-permissive peptides regulating vSAG binding and to 
unconventional interactions between MHCII and TCR. In order words, there may 
be extra pressure on CDR3s to have more intimate contacts with the MHCII 
chains than during canonical peptide recognition. Indeed, thymic positive 
selection does not directly influence the fine specificity of T cells toward MHCII 
and it has been suggested that TCR/MHCII interactions taking place during vSAG 
presentation are unconventional and linked to TCR recognition of haplotype-
specific MHCII residues (80, 88). This is in line with the recent demonstration by 
Kilgannon et al. that three out of eight Vβ6+ T cells, although all specific for the 
same pMHCII (K5-IAd), did not respond to vSAG7 (93).  
 
 A recent report by Stadinski et al. stresses the fact that TCR specificity for 
pMHC ligands is not driven by germline-encoded pairwise interactions. Notably, 
they described a single TCR Vβ using alternate strategies to bind pMHC when 
paired with different Vα (94). The authors argue that since CDR1 and CDR2 
loops have the flexibility to bind their ligands in many ways, this could not fit a 
pairwise co-evolution model. Accordingly, it demonstrated that the CDR3 loops 
can markedly alter those evolutionarily selected contacts (95). Canonical CDR-
pMHCII contacts can differ under different pressures, supporting a model in 
which vSAG enforces such unconventional docking. 
 
vSAG7 moieties bind distinct MHCIIs 
 Given that vSAG7 N- and C-terminal moieties bind respectively the MHCII 
β1 and α1 domains, one must ask how such binding is possible while remaining 
non-covalently associated. We propose a model where C-vSAG binds the α 
chain of an adjacent MHCII, while still bound to N-vSAG, the latter attached to the 
β chain. In other words, unable to reach the α chain of its MHCII partner in cis, C-
vSAG interacts with another MHCII in trans. This model highly resembles the 
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manner in which SEA crosslinks MHCII molecules via a low affinity binding site to 
the α chain and the Zn-dependent binding site on the β chain (96, 97). In the 
context of the SCT, our results showing that HA presentation to Jurkat cells is 
null in endogenous MHCII- as opposed to MHCII+ cell lines strongly support such 
a model (Fig. 3D). Indeed, we speculate that in the absence of surrounding 
endogenous pMHCIIs, both vSAG7 moieties remain associated with the parent 
MHCII, blocking the groove and preventing the TCR from recognizing the HA-
peptide. Also, as each MHCII is covalently linked to vSAG, it is possible the C-
vSAG prevents any approaching vSAG from contacting the α chain in trans. In 
contrast, in Hela CIITA cells, C-vSAG7 will find numerous vSAG-free 
endogenous MHCII α chains to associate with, freeing the MHCII membrane-
distal region for the HA-1.7 TCR binding. Future studies will address the 
biochemical basis for vSAG binding to two distinct MHCII molecules. 
 
Highly conserved TCR binding motif in vSAGs 
 Our results indicate a more intricate vSAG7 presentation than previously 
acknowledged. vSAG stimulatory activity is paired to the TCR interaction of DRα, 
a structural aspect that will likely modulate its potency in terms of the responding 
T cell repertoire and the strength of the signal. Additionally, vSAG recognition of 
specific TCR vβ elements is mediated through its C-terminal 30 or so highly 
variable amino acids, complicating speculation as to how this family of vSAGs 
could mediate such a broad immune response without a conserved binding 
scheme. Interestingly, the chemical baicalin (BA), shown to block GABA binding 
to its receptor in the nervous system, also blocked T cell stimulation by TSST and 
SEB, suggesting a conserved mechanism between those two bSAGs, MMTV 
vSAG and GABA neurotransmitter linked to the TGXY motif (98, 99).   
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Conclusion 
 Our observation that conserved DRα residues are implicated in the 
recognition of the vSAG-peptide-MHCII by the TCR suggests that T cell activation 
is influenced by the polymorphic CDR3β region, linked to the recognition of the 
MHCII α chain. To our knowledge, this represents a novel SAG-mediated MHCII-
TCR architecture. According to a recent study by Nur-ur Rahman et al. 
suggesting that the TCR CDR2β is the critical determinant for the functional 
recognition of bSAGs, it is clear that the topology of vSAG differs from those 
previously described (100). As both the MHCII allele and associated-peptide 
influence the potential interaction between MHCII and TCR, a given TCR could 
only recognize a fraction of the vSAG-pMHCII complexes (80). MMTV vSAGs are 
expressed at very low density on the cell surface and still remain highly potent T 
cell activators. This expression pattern is of great importance as it mimics the low 
density of conventional antigenic peptide-MHCII complexes, critical for T cell 
activation (101, 102). 
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FIGURE LEGENDS 
 
Figure 1. vSAG7 presentation is dictated by the MHCII associated-peptide. 
A) vSAG presentation by DM+ and DM- B cell lines following vSAG transfer from 
the vSAG7+ DAP cell line (10). Presentation is monitored by the stimulation of 
Vβ6 and 8.1 bearing T cell hybridoma Kmls 13.11 and KR3+. BJAB (DR3) is 
used as a positive B cell control and COX is a DR3+DM+ B cell line. B) 
Sequence alignment of different peptide constructs covalently linked to DRβ used 
to assess vSAG presentation. Peptides are aligned according to the residue 
filling the P1 pocket. Asterisks above the sequences mark the protruding side 
chains at positions P-1, P2 and P8. MHCII cell surface expression of DAP cells 
transfected with DRα and cCLIP- or lCLIP- (C), HA- or HAb- (F), or TT- or TTb- 
(H) stained with either L243 or XD5 anti-DR mAbs. The MFI values for cell 
surface expression are shown are shown in the lower right corner of each 
histogram and are colored according to the legend. Bar graphs below the 
histograms represent the MFI of the GFP control plasmid co-transfected with 
vSAG7, to monitor the transfection efficiency. L243/XD5 MFI ratio of the two CLIP 
variants, cCLIP87-101 and lCLIP81-101 are shown in E. Transfected cell lines from C, 
F and H were used as APC to stimulate Kmls 13.11, Kmls 12.6 hybridomas or 
Jurkat T cells (D, G, I and J). All data are representative of at least three 
independent experiments. 
 
Figure 2. The N-terminal domain of vSAG7 overlaps SEA binding site on 
the MHCII β chain. A) Schematic representations of SCD and SCT are shown. 
The C-terminus of DR1 β chains were covalently attached to the N-terminus of 
vSAG7 by flexible GLY-SER linker. Peut-être ajouter que la meme chose est faite 
avec α In the SCT, a peptide was appended to the N-terminus of the β chain 
according to Kozono et. al (26). The linkers between DR and either the peptide, 
vSAG7 or Ii are represented as light grey boxes. B) L243 and VS7 cell surface 
staining of HEK 293T cells transfected with the αSCD or βSCD and the 
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appropriate complementary DR chain or a wt DR and vSAG7 control. L243 and 
VS7 mAbs recognize a conformational epitope on DRα and the C-terminal end of 
vSAG7, respectively. C) HEK 293T cells were transiently transfected with wt DR 
and vSAG7, DRα and the vSAG7-SCDs or Ii-βSCDs. 48h post-transfection, cells 
were harvested, split and incubated on ice with L243 or SEA for 3h. After 
washing, bound SEA was detected by flow cytometry using an anti-SEA mAb. 
These staining profiles are representative of at least five independent 
experiments. D) The MFI were plotted as a ratio where the error bars represent 
the standard deviation to the mean of three stainings on independent populations 
of transfected cells. E) Same as D, but using DRα K39A mutant, which prevents 
SEA binding to the α chain. F) Same as D, but using a truncated version of the 
vSAG7-SCDΔCt, devoid of the C-terminal domain. All data are representative of 
at least three independent experiments. 
 
Figure 3. vSAG7 binding to MHCII α and β chains occurs on distinct MHCII 
molecules. A) Cell surface expression of MHCII on HEK 293T cells transfected 
with DR or SCD (right panel) and HADR or SCT (left panel) stained with the L243 
mAb. B) The MFI of the transfectants bearing the HA peptide were plotted as a 
ratio against the ones without HA. The error bars represent the standard 
deviation to the mean of three stainings on independent populations of 
transfected cells. C) Compact SDS-resistant and -sensitive form of DR were 
assessed by immunoblot (IB) analysis of total protein extracts (boiled or heated 
to 65°C) from the transfectants in A. Ii-SCDs were used as control. The IB was 
revealed with the anti-DRβ mAb XD5. The two compact complexes are marked 
with I or II (lane 2 and 8) and schematized next to the gel. D) Comparison of HA-
specific T cell stimulation between endogenous MHCII positive or negative HeLa 
cells transfected with different MHCII β chains. HeLa MHCII positive cells 
expressed DR2, contrary to the transfected DR1. E) Same as D but comparing 
vSAG7 specific T cell stimulation. All data are representative of at least three 
independent experiments. 
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Figure 4. Residues on the MHCII α chain act in tandem with vSAG to 
engage TCRs. A) Cartoon depiction of the MHCII with a close-up on the peptide-
binding groove that highlights DRα α-helix spanning mutants (pink) and the L243 
mAbs binding site (red), depicted as sticks. The α, β chains and peptide are 
green, blue and yellow, respectively. B) MHCII cell surface profiles of DAP cell 
lines transfected with HADRβ and different DRα mutants as stained with L243 
and XD5 mAbs. The MFIs are shown in the lower right corner of each histogram 
and are colored according to the legend. Co-transfected GFP protein was used to 
monitor the transfection efficiency of vSAG7 and MFI are shown as bar graphs 
next to histograms. C) L243 and XD5 MFI ratios derived from B. Cell lines from B 
were transfected with vSAG7 or a mock control before monitoring Jurkat (D), 
Kmls 13.11 (E) and Kmls 12.6 (F) T cell proliferation. All data are representative 
of at least three independent experiments. G) Model of vSAG7 binding to MHCII 
and TCR in which the multiple binding regions between vSAG7, both MHCII 
chains and the TCR are highlighted. The N-vSAG and C-vSAG moieties remain 
non-covalently associated after processing and lead to the cross-linking of MHCII 
molecules. Binding of C-vSAG7 to the MHCII α chain is conformation-dependent 
and abrogated by a peptide N-terminal extension. The TCRβ CDR3 binds the 
MHCII α chain specifically instead of the peptide whereas vSAG binds the FR3 
and HV4 region of the Vβ. The exact nature of Vα binding to the MHCII β remains 
to be fully characterized (103). 
 
Figure 5. A conserved TGXY motif is central to vSAG7’s activity. A) 
Sequence similarity among 18 MMTV vSAG proteins or vSAG-like domains. The 
height of a particular position is proportional to the frequency of the 
corresponding residue type between the aligned sequences and to the sequence 
information in the alignment and its given bits (104).  The residue numbering is 
based on the vSAG7 protein, genebank ID: M90535.1. The letters T, G and Y of 
the motif are colored a lighter shade of grey. B) Functional assay of transiently 
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transfected HeLa CIITA cells with multiple β chains against the vSAG7-reactive 
Kmls 13.11 T cell hybridoma. C) L243 cell surface expression profiles of DRα 
transiently co-transfected with either the βSCD or the Y229F mutant. D) Ratios 
between DR and vSAG MFI were plotted from the transfectants in C and the error 
bars represent the standard deviation to the mean of three independent 
experiments. 
  
  
119 
Figure 1 
     
  
120 
Figure 2 
 
 
 
 
 
 
 
  
121 
Figure 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
122 
Figure 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
123 
Figure 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
124 
 
 
 
 
125
 
Chapter 3 : HLA-DM-induced structural change in 
HLA-DOβ 
Experimental design: FD, DAD, JSF and JT 
Performed experiments: FD45%, DAD30% and JSF25% 
Writing: DAD40%, JSF30% and JT30% 
 
 
 
 
 
 
 
 
 
 
126
 
 
 
 
 
 
 

peptide exchange.21 The mutual recognition would
involve fine structural changes in both molecules. A DM-
susceptible, flexible isoform of DR may arise from
changes induced by inadequate peptides and from pro-
tonation of histidine a33 at low pH.22,23 For DM, many
experiments also suggest that protonation in the endocy-
tic pathway results in minor, reversible structural changes
exposing hydrophobic regions of the heterodimer.24–26
Ullrich et al. used 8-anilino-1-naphthalenesulphonic acid
(ANS), a fluorescent dye binding to hydrophobic protein
patches, to demonstrate subtle pH-induced changes in
purified DM and DR molecules.25 Since the interaction of
DM with DR reduces ANS binding to both molecules, it
was postulated that the surface of contact is comprised of
pH-sensitive regions on both proteins.7,24,25 In line with
this hypothesis and with the critical role of the peptide
N-terminal region, Mellins and coworkers recently
proposed a model for the DR–DM interaction based on
elegant functional mutagenesis data.27,28
Another non-classical MHC-related molecule, HLA-DO
(DO), was shown to accumulate in MIIC-like compart-
ments.29 DO was first described as a DM inhibitor since
its overexpression in class II transactivator-transfected
cells increased the fraction of classical class II molecules
bound to the CLIP fragment.30,31 However, mouse B cells
proficient or deficient in H2-DO do not exhibit dramatic
variations in the levels of CLIP bound to I-Ab.32–34 It was
proposed that H2-DO promotes the presentation of anti-
gens internalized by membrane immunoglobulins by
selectively inhibiting the activity of H2-DM in early endo-
cytic compartments rich in proteins internalized by fluid-
phase endocytosis.33 This hypothesis is consistent with an
active inhibitory role of DO in vitro at mildly acidic pH
(early endosomes) and to a poor inhibitory potential at
low pH (MIIC and lysosomal compartments).33 Also, this
model is consistent with results obtained using spleno-
cytes from mice with a targeted mutation in the H2-DOA
genes and which showed slightly increased efficiency in
the presentation of soluble antigens.33 Accordingly, anti-
gen-presenting cells from H2-DO- or DO-overexpressing
transgenic mice showed reduced presentation of exo-
genous antigens.32,35 Others suggested that DO stabilizes
DM and promotes stable MHC–peptide complexes when
physiological conditions are met.36 Interestingly, the
recent demonstrations of DO expression in specific DC
subsets argue against a specific role in B cells in the con-
text of the surface immunoglobulin antigen uptake.37–39
Still, it is now accepted that H2-DO and DO ‘modulate’
MHC class II antigen processing.32,34,36,40
In human B lymphocytes, as opposed to their mouse
counterpart, the majority of DO molecules was found
associated with DM30,36,39,41 and this association allows
DO to egress the ER.29,42 The lack of a recognizable
di-basic ER retention motif (RXR or KKXX) suggests that
the assembled DOab heterodimer is improperly folded in
the absence of DM and most probably unstable. Misfold-
ing of newly synthesized proteins is known to induce
retention and aggregation in the ER.43 So far, the mode
of interaction between DO and DM remains poorly char-
acterized. We have recently shown that DM binds the
DOa1 domain, probably by stabilizing the N-terminal
regions of DO to allow ER egress.44 In the present study,
using a conformation-dependent DO-specific antibody,
we confirm that DM binding impacts on the conforma-
tion of DO.
Materials and methods
Plasmids and complementary DNAs
RSV.3DR18/DOb, pBSDOa.9, RSV.5neo DRa, pBudCE4-
A, pBud DOab, pBud DM, pBud DRb and RSV.5gptDN1
have been previously described.44–46 The DOb comple-
mentary DNA (cDNA) from the 721.45 cell line.47 was
excised with BamHI and the 13-kilobase fragment was
cloned into the RSV.5neo plasmid to generate RSV.5neo
DOb. Then, RSV.5neo DR18/DOb (cDOb) was generated
by inserting the MluI–EcoRV fragment of RSV.3 DR18/
DOb into RSV.5neo DOb. The DR18/DOa chimeric
cDNA (cDOa) was made by overlap extension polymer-
ase chain reaction (PCR) as described.45 using the DRa
cDNA cloned in the BamHI site of pBlueScript (Strata-
gene, La Jolla, CA), and RSV.5gptDN1 (DOa) as tem-
plates. The sequences of the oligonucleotides used for
PCR are available upon request. The SalI–PvuII fragment
encompassing the junction between DR and DO was sub-
cloned into RSV.5gptDN1. The nucleotide sequence was
confirmed by DNA sequencing. A 2-kilobase pair BamHI
fragment was either cloned into the BglII site of
pBudCE4-A DRb to generate pBudDR18/DOa
+DRb or
cloned into SRapuro to generate SRapuroDR18/DOa.
The DM variant devoid of its YxxL motif (DMY) was
generated by mutating the tyrosine 230 in the DMb cyto-
plasmic region. PCR overlap reactions were performed on
pBS 1-DMb.1.45 and the products were mixed in a final
PCR using flanking primers. This PCR product was
digested with SacI and HindIII, cloned into pBS 1-DMb.1
and sequenced (pBSDMbY230A). A SalI–XbaI fragment
was subcloned into pBud DMa46 to generate pBud DMY.
Antibodies
Monoclonal antibodies (mAbs) L243 (DRa-specific),
XD5.117 (XD5; DRb-specific), MAP.DM1 (DM-specific)
as well as the rabbit sera against DOa, calnexin and
DMb have been described previously.45,46,48,49 Anti-actin
(immunoglobulin G1; IgG1) is specific for the N-terminal
of the molecule (Chemicon International, Temecula, CA).
HKC5 is an IgG1 mouse mAb specific for the cytoplasmic
tail of DOb49 Mags.DO.5 mAb was generated from mice
 2008 Blackwell Publishing Ltd, Immunology, 127, 408–417 409
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immunized with purified DO/DM complexes and was
described previously.50 Secondary antibodies were the
Alexa Fluor 488-conjugated goat anti-mouse IgG antibody
(Molecular Probes, Eugene, OR), peroxidase- and biotin-
coupled goat anti-rabbit antibody (Bio/Can Scientific,
Mississauga, Canada) and Texas red-coupled strepta-
vidin (Jackson ImmunoResearch, West Grove, PA). All
these antibodies were titrated and used at saturating con-
centrations.
Cell lines and transfections
HeLa DRa +DR18/DOb (DRa/cDOb), HeLa DO and
HeLa DM.5 were previously described.45,46 Raji and HeLa
cells were kindly provided by Dr R.P. Se´kaly. HEK293T
cells were obtained from Dr Eric Cohen. Cells were cul-
tured in Dulbecco’s modified Eagles’s minimal essential
medium (DMEM), 10% fetal bovine serum. HeLa cells
were cotransfected by the calcium phosphate precipi-
tation method.51 using 2–20 lg of each DNA or transfect-
ed with Fugene6 (Roche Diagnostics, Laval, Canada)
using 1 lg of each DNA.45 HeLa DM.5 cells were trans-
fected with Fugene6. HeLa cDO were sorted on magnetic
beads (Invitrogen, Toronto, Canada) after staining with
Mags.DO5. For transient expression, HEK293T cells were
transfected by the calcium phosphate precipitation
method using 2 lg of each DNA. Cells were analysed
2 days post-transfection.
Flow cytometry
Cells were harvested using trypsin, washed and stained
for surface expression. For intracellular staining, cells were
treated with formaldehyde for 20 min, then with 50 mM
NH4Cl for 15 min and permeabilized with phosphate-buf-
fered saline/bovine serum albumin containing 005%
saponin.45 Cells were analysed on a FACSCalibur (Becton
Dickinson, San Jose´, CA).
Fluorescence microscopy
HeLa cells were plated on coverslips in 24-well plates and
cultured for 2 days before intracellular staining as
described for flow cytometry analysis. Cells were analysed
by fluorescence microscopy on a Zeiss axioplan 2 imaging
microscope. Photographs were taken with a Sony DXC-
390P digital camera.
Immunoprecipitation, Western blotting and
endoglycosidase H treatment
Cells (107) were trypsinized, washed in phosphate-
buffered saline and lysed into Triton-X100.45 Post-nuclear
supernatants were prepared and analysed directly on
immunoblots or used for immunoprecipitations overnight
at 4 using primary antibodies bound to protein-G cou-
pled to sepharose 4B (GE Lifesciences, Piscataway, NJ).
Samples were analysed on Western blots.45 For EndoH
treatment, lysates containing 2 · 105 cells were directly
digested with Endoglycosidase H for 30 min at 37 (New
England Biolabs, Pickering, Canada) and resuspended in
reducing loading buffer. Samples were boiled and analy-
sed by Western blotting.
Adenovirus production and HeLa cells infection
Production of recombinant adenoviruses (Ad) was as
described.52 AdDO encode both DOa and DOb. A
mutant AdDO was obtained by the same strategy using a
DOb cDNA with substitutions at positions V184H,
V186K and E187K (AdDO VVE). The empty adenoviral
vector (Ad0) is a replication-deficient recombinant ade-
novirus derived from serotype 5 with the deletion of E1
and E3 regions.53
For adenovirus transduction, HeLa cells were distrib-
uted in flat-bottom, 24-well plates at 25 · 105 cells/well
in 250 ll DMEM without serum. Viruses were added at a
multiplicity of infection of 50 and incubated at 37 in the
presence of 5% CO2 for 3 hr. Complete medium was
added and cells were cultivated for 2 days.
Results
Mags.DO5 binds the HLA-DOb chain
In DM-negative cells, transfected DO was shown to be
retained in the ER.29 We postulated that DM assists the
folding of the DOab heterodimer, allowing its matura-
tion. To gain insights into a possible impact of DM
expression on the structure of DO, we made use of the
Mags.DO5 mAb obtained following immunization of
mice with DO/DM complexes purified from a human
B-cell line.50 Given our recent demonstrations that DM
binds to the a chain of DO44 and that Mags.DO5 recog-
nizes the DO/DM complex,50 we hypothesized that this
mAb binds to the DOb chain. This was verified using
mixed DR/DO pairs expressed in class II-negative HeLa
cells.54 These mixed heterodimers (DRa/cDOb and
cDOa/DRb) overcome ER retention and were made pos-
sible by exchanging the first 18 amino acids of DO for
the corresponding sequence of DR (Fig. 1a,b). The cell
surface expression of DRa/cDOb and cDOa/DRb was
controlled using DR-specific antibodies against the a and
b chains, respectively (Fig. 1c). Mags.DO5 recognized the
DRa/cDOb mixed pair expressed on HeLa cells but not
its cDOa/DRb counterpart. Although we cannot entirely
rule out that the DOa chain somewhat contributes to the
efficiency of antibody binding, these results suggested that
Mags.DO5 is specific for an epitope located on the DOb
chain. In support of this, although Mags.DO5 does not
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bind DR, we observed some competition between this
mAb and an anti-serum made against the DRa/cDOb
mixed pair (data not shown).
Mags.DO5 recognizes a conformational epitope
Mags.DO5 does not recognize denatured DOb (data not
shown) suggesting that the mAb recognizes a conforma-
tional epitope. This was confirmed by flow cytometry on
permeabilized cells. Mags.DO5 did not recognize the
DOa chain when expressed independently. However,
slight reactivity to the free DOb chain was detected and
this reactivity increased slightly by the expression of DOa
and DOb together (Fig. 2a). The equivalent binding of
HKC5, a mAb specific for a linear epitope on the DOb
cytoplasmic tail,49 confirms that the observed increased
binding of Mags.DO5 in the DOA/DOB transfectant was
not caused by an accumulation of b chain in the presence
of DOa (Fig. 2). Semi-quantitative Western blotting with
HKC5 confirmed that both transfectants express similar
levels of DOb chain (Fig. 2b). Collectively, these results
support the notion that Mags.DO5 recognizes a confor-
mational epitope located on DOb. The conformation
change may be subtle as some antibody reactivity is
observed on the isolated b chain.
Coexpression of DM with DO enhances Mags.DO5
reactivity
Although Mags.DO5 was generated following immuniza-
tion of mice with DM/DO complexes, the mAb is specific
for DO because it does not recognize DM50 (data not
shown). However, cotransfection of DM and DO together
into 293T cells clearly showed that Mags.DO5 reacted
more strongly to DO when complexed with DM (Fig. 3a).
These differences were not the result of differences in
DOb expression levels because HKC5 staining was identi-
cal in the absence and presence of DM (Fig. 3a). The
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positive impact of DM is most apparent when the mean
fluorescence values obtained by flow cytometry are
expressed as a ratio between Mags.DO5 and HKC5
(Fig. 3b). Importantly, DOb and DOa were produced
from a bi-cistronic vector to minimize transfection-
dependent variations in the relative expression of the two
chains. Indeed, immunoprecipitation of DOb revealed
that ab heterodimers were formed, even in the absence of
DM (Fig. 3c). The increased Mags.DO5 reactivity in the
presence of DM was also observed in transfected HeLa
cells (see below).
DO conformation change occurs in the ER
The possibility remained that the effect of DM was indi-
rect and simply the consequence of its ability to target
DO to acidic compartments. Indeed, Liljedahl et al.
demonstrated that DO undergoes a conformation change
at low pH.33 To evaluate if the Mags.DO5 reactivity pat-
tern described above depended on accumulation of DO/
DM complexes in acidic vesicles, we transiently expressed
DO with wild-type DM or with a DM variant (DMY)
devoid of its YxxL lysosomal sorting signal.44 DMY inter-
acts with DO and the complex accumulates at the plasma
membrane (Fig. 4a). Cells expressing DO with DM or
DMY were permeabilized and stained with Mags.DO5
(Fig. 4b,c). The results showed that the increase in the
reactivity of Mags.DO5 was independent of DO localiza-
tion to intracellular acidic compartments.
To test if DM interaction with DO in the ER promoted
the formation of the Mags.DO5 epitope, we examined
mAb reactivity for a DO molecule that bears a triple
mutation in the b2 domain (DO VVE) (Fig. 5a). These
mutations, originally described in DR, were shown to
affect the interaction with DM.27 When introduced sepa-
rately into DOb, these mutations did not affect the bind-
ing to DM. However, when introduced together, these
three mutations affected the integrity of DO and strongly
impaired ER egress (Deshaies and Thibodeau, unpub-
lished data). The mutant b chain was transduced together
with DOA into HeLa cells either expressing DM or not.
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DO VVE showed a reduced capacity to egress the ER and
to acquire complex EndoH-resistant carbohydrates in
both the presence and absence of DM (Fig. 5b). Although
the ER-retained DO VVE was expressed at levels similar
to wild-type DO, this mutant was not efficiently recog-
nized by Mags.DO5 in the absence of DM. Coexpression
of DM partially restored Mags.DO5 reactivity, supporting
the idea that assembly of DM with DO in the ER gener-
ates the epitope recognized by Mags.DO5. Moreover, cells
transfected in the presence of brefeldin A exhibited a
block in the ER exit of DO/DM complexes but the treat-
ment did not prevent DM from increasing Mags.DO5
reactivity (data not shown).
Relationship between folding of DO and the reactivity
of Mags.DO5
We postulated that Mags.DO5 would recognize properly
folded DO molecules independent of the presence of DM.
To test this hypothesis, we stably expressed a chimeric
DO (cDO) in which the first 18 amino acids of both
DOa and b chains were substituted for those of the cor-
responding DR chains (Fig. 1). As opposed to wild-type
DO which colocalizes with the ER marker calnexin, the
cDO heterodimer was able to egress the ER in DM-nega-
tive HeLa cells and to accumulate in Lamp-1+ vesicles
(Fig. 6a and data not shown). In contrast to wild-type
DO, the conformation-dependent Mags.DO5 mAb recog-
nized cDO as efficiently as HKC5 in stably transfected
HeLa cells (Fig. 6b). Such strong Mags.DO5 staining is
reminiscent of the pattern observed for DO in DM+ cells
(Figs 3 and 5).
Since Mags.DO5 reacted strongly with cDO in the
absence of DM, we postulated that the Mags.DO5
staining on correctly folded cDO molecules was optimal
and could not be improved by coexpressing DM. We
first ascertained that the modifications imparted to the
DO molecule through the fusion of the first 18 amino
acids of DR would still allow a strong interaction with
DM. Both DM and DO were transiently transfected in
293T cells and DO was immunoprecipitated from deter-
gent lysates. Western blot analysis showed that DM was
efficiently coimmunoprecipitated with cDO in both
CHAPS and Triton X-100. This suggests that the cDO/
DM interaction is representative of the one observed
for DO. This is different from the association of DM/
DO with DR, which dissociates from DM upon lysis of
Raji cells in Triton X-100 (Fig. 6c). However, as
expected, coexpression of DM did not increase the
reactivity of Mags.DO5 to cDO (Fig. 6d). Consequently,
the Mags.DO5 mAb recognizes properly folded DO
molecules.
DM binding discloses the Mags.DO5 epitope on DO
Braunstein and Germain carefully titrated the mAb con-
centration to determine if avidity or affinity of a class II-
specific mAb could explain the differential staining
observed between transfectants expressing mismatched
MHC heterodimers.55 The rationale behind such experi-
ments is that at limiting concentrations of the mAb, anti-
genic molecules of different intrinsic affinities toward the
mAb will show divergent staining intensities, even if
expressed at similar levels. On the other hand, in these
conditions, antigens with the same affinity will show simi-
lar binding (read out by flow cytometry as mean fluores-
cence value) even if expressed differentially. We used a
similar approach to determine if the enhanced reactivity
of Mags.DO5 for DO in the presence of DM was the
result of a difference in affinity or avidity.
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DO with or without DM was transfected into 293T
cells and stained with titrated amounts of Mags.DO5 after
permeabilization (Fig. 7). At low or saturating concentra-
tions of mAb, the staining was always more efficient on
cells coexpressing DM, suggesting that the affinity of the
mAb is different for DO or DO/DM complexes. As
expected, the control HKC5 showed similar staining pat-
terns independent of DM expression. These results sug-
gest that in the absence of DM, the Mags.DO5 affinity is
weak for DO. Upon DM binding, DO most probably goes
through a conformation change that fully unveils the
epitope.
Discussion
In transfected HeLa cells and in mouse B lymphocytes,
under the experimental conditions tested so far, DO or
H2-DO molecules did not egress the ER on their own.29
In the present study, we sought to determine if DM
affects the quaternary structure of DO upon formation of
the complex in the ER. Interestingly, Liljedahl et al.
showed by immunoprecipitation that DOa and b chains
interact in DM-negative cells.29 As the primary sequence
of the a or b chain do not display known ER retention
signals, we postulated that the conformation of DO was
not optimal and that the heterodimer was most likely
retained by ER chaperones. Consequently, DO does not
acquire post-translational modifications in the form of
complex Endo H-resistant sugars.29
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Early after their synthesis in the ER, MHC II a and b
chains must associate with Ii to avoid aggregation and
premature degradation. Although the exact sequence of
events is still a matter of debate, formation of the nona-
meric complex with Ii prevents aggregation of MHC II.56
Quality control chaperones like BiP, GRP94, calnexin, cal-
reticulin and ERp72 have been implicated in the ER
retention of class II molecules in the absence of Ii.1
Although binding to these proteins has yet to be demon-
strated, we can assume that DO will probably be under
the control of similar checkpoints. The association of DO
with such public chaperones probably persists until DM
intervenes to optimize folding into a more stable, lower
energy conformation and to generate a transport-compe-
tent multi-unit complex. The fact that the Mags.DO5
staining increases upon coexpression of DM indicated
that a conformation change occurs on DO. Although this
had been suggested previously from the fact that DM
allows DO egress from the ER,29,42 our results demon-
strate for the first time that DM acts on the conformation
of DO. We ruled out by flow cytometry that DM simply
increases the steady-state amount of DO because the
staining with the HKC5 mAb did not increase compared
to Mags.DO5. Also, immunoprecipitation experiments
revealed similar amounts of DO in DM-positive or -nega-
tive cells. The exact nature of the conformation change
has not been determined. The membrane distal domains
of DO are more hydrophobic than classical MHC II and
may need to be shielded by DM, even more so knowing
that the groove is empty. Also, the DM may be involved
in the oxidation of DO.37,57 We have tested on DO the
reactivity of increasing concentrations of Mags.DO5 and
HKC5 in DM+ and DM– HEK293T cells (Fig. 7).
Although DM clearly impacts on the staining of DO at
limiting Mags.DO5 concentrations, such titration experi-
ments may somehow be difficult to interpret in terms of
antibody affinity or avidity as we have not tested in paral-
lel a DM+ control cell line expressing various levels of
DO. Still, coupled to our immunoblot and immuno-
precipitation data showing equivalent amounts of DOb in
DM+ and DM– HEK293T cells (Figs 2b and 3c), these
results are in line with an increased affinity of Mags.DO5
for DO/DM complexes as compared to free DO.
Three complementary results allow us to conclude that
the conformational change on DO takes place early dur-
ing maturation and is not merely the consequence of
DM-induced transport to the Golgi or the endocytic
pathway. First, brefeldin A did not prevent the stronger
recognition of DO by Mags.DO5 in the presence of DM
(data not shown). Second, point mutations in DO that
clearly impair ER egress did not prevent the ability of
DM to increase Mags.DO5 binding. Finally, diverting the
flow of DO/DM complexes to the plasma membrane
instead of the lysosomal compartments by mutating
the YxxL motif of DM did not perturb Mags.DO5
recognition. Altogether, the data strongly suggested that
the DM-induced conformation change on DO occurs as
early as in the ER and they rule out an indirect role of
DM in increasing Mags.DO5 reactivity following glycan
modification in the Golgi or protonation in acidic vesicles.
Studies on mixed pairs suggested a cis-coevolution of a
and b chain polymorphisms favouring pairing of mole-
cules from a given haplotype.58 A role for Ii in facilitating
ER egress of mismatched heterodimers has been
described.59 Although DO behaves very much like a mis-
matched pair, Ii does not seem to affect its sorting.29 Our
results show that DM acts as a chaperone and may give
some clues as to the mechanism by which it allows DO
to egress the ER. We have recently discovered a point
mutation that resulted in some DO egress independent of
DM.44 We proposed that this DOaP11V mutation might
improve the folding of the N-terminal regions of DOab
and reduce the need for DM. This contention is sup-
ported by the demonstration that cDO reactivity with
Mags.DO5 is maximal and independent of DM. In line
with this hypothesis, using the Mags.DO5 conformational
mAb, we demonstrated here that DM affects the confor-
mation of DO.
Mags.DO5 was made by immunizing mice with puri-
fied DO/DM complexes and we found that the epitope
recognized by this mAb is located on the DOb chain. The
possibility that DM contributes to the epitope is unlikely
considering that the Mags.DO5 reactivity toward cDO
was not increased in the presence of DM (Fig. 6) The fact
that amino acid changes in the N-terminal regions of
DOa and b improved Mags.DO5 reactivity may indicate
that the epitope is located in the membrane-distal b1
domains. Accordingly, DM improved Mags.DO5 binding
on the DO VVE mutant, which most likely suffers from a
severe conformation defect in its b2 domain. The DM-
induced conformation change may be somewhat drastic
but still, it could not override the negative impact of the
DO VVE mutations on ER egress.
A chaperone role for DM in the ER was suggested by a
study showing that in the absence of invariant chain, DM
can improve the transport of MHC II.60 However, the
conformation change described here is more reminiscent
of the appearance of the 16.23 epitope on DR3 molecules
having encountered DM. Verreck et al. showed that this
effect on the fine structure of the DR3 was independent
of CLIP removal or of the peptide editing capabilities of
DM.61 Also, the well-characterized stabilization of pep-
tide-free MHC II molecules points to a chaperone role of
DM that is not directly related to its catalytic activity.17
In this respect, DM would recognize DO just like any
other empty MHC II.62
Whether DO affects the structure of DM remains to be
established. The inhibition of DM by DO is certainly in
line with a reciprocal effect of the two molecules on their
respective fine structures. This could also explain the
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apparent increase in H2-DM half-life in the presence of
H2-DO.35 Comparing the crystal structures of isolated
versus associated DO and DM would shed light on the
interplay between the two chaperones.
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Chapter 4 : Directed evolution 
4.1. Yeast Display of DO single chain 
 In order to get insights about the mechanism underlying DO function, we 
generated a library of DO mutants (Esteban and Zhao, 2004). A single chain DO  
(DOsc) was generated (Error! Reference source not found.1), mutagenized and 
expressed in Saccharomyces cerevisiae. A library of 2.1x106 unique clones was 
obtained and selected for surface expression, as the DOsc would not escape the 
ER. I selected yeast that stained positive for both Mags.DO5 mAb and the HA-tag, 
appended at the C-terminal end of the β chain. 
 
Figure 4.1. Yeast display design and sorting 
a) Schema of the DO single chain construct. The α chain is linked to the β chain by a linker of 15 aa 
(Esteban and Zhao, 2004) and the latter to the Aga2 protein (Boder and Wittrup, 2000) as a single 
polypeptide. b) Histograms showing the fluorescence of cells displaying the DOsc after one, two 
and three rounds of sorting using both Mags.DO5 and the anti-HA mAbs.  
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 After three rounds of enrichment, selecting only the highest DOsc 
expressing yeast, I isolated and sequenced 18 individual yeast clones. These 
mutants are presented in Table 4.1 and included between three to five point 
mutations and some silent ones. Figure 4.2 and Figure 4.3 locate those mutants on 
DO model and the DO-DM structure (Figure 4.5). 
Table 
4.1: 
Mutation 
identified 
from 
sequenc
ed 
clones 
after 
yeast 
sorting 
*This 
mutant 
abrogat
es DOβ 
glycosyl
ation 
site 
 
  
 Of the 41 unique mutants obtained, five occurred in others DO species. For 
example, G17D is present on the Gorilla DOα sequence (Error! Reference 
source not found.). On the one hand, given the use of DOsc, in which the linker 
clone DOα DOβ 
1 G10aA, A11P *T21S 
2 V87S, T122I, G127D - 
3 P61T, D161E F122S, V158M, T164N 
4 H8L, S82C, H169Y, G171D - 
5 - T90S, K130T, F132S 
6 G17D - 
7 - P97S, G141V 
8 F12L, V167L V186M 
9 - Q60L, V91E 
10 - R34C, Y83N, A191D, S193T 
11 - P104L 
12 - R39C, S71S, Y83N, A190D, S192T 
13 A65G T120N 
14 G49Q P56R, R70K 
15 I112S S185T 
16 L70P, R79L Q25Q, G141V 
17 - E166E, E187K 
18 V34V, L45Q, G58S, V109A, N111N, A172G L115Q 
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connects the α2 domain to the β1 domain, the potential linker site would be on the 
solvent expose face of the α2 domain, on the C-terminal end of the groove. Hence, 
it seems reasonable to link DOα isolated mutation to a linked artefactual effect. On 
the other hand, many of the mutations are localized in two hot spots in the α1 and 
β1 domain (Table 4.2). Those two regions, located in the first beta-sheet 
connecting the α and β chain and at the P1 pocket vicinity, are crucial for the 
heterodimer pairing and stability (Deshaies et al., 2005; Natarajan et al., 1999a; 
Starwalt et al., 2003).  
 
Figure 4.2. DO mutants obtained after directed evolution 
Model of DO based on IAk and DQ2 (I-TASSER) showing the 41 single mutants isolated after 
sorting a 2.1x106 mutants library. The three mutants situated on the α1 first β-strand (G10A, A11P 
and F12D) are shown on the enlargement of the β-sheet platted floor of the α:β1 domain. 
Noteworthy is the T120N mutation, at the α2:β2 interface, which has been describe has stabilizing 
on DR1 (Starwalt et al., 2003). 
 
 
 
α1:β1 α1 domain β1 domain β2 domain 
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GLY 10 ALA GLY 18 ASP HIS 5 LEU PRO 97 SER 
ALA 11 PRO LEU 45 GLN TYR 83 ARG PRO 103 LEU 
PHE 12 ASP GLY 49 GLN THR 90 SER PHE 122 SER 
 PRO 57 THR VAL 91 GLU SER 185 THR 
 GLY 58 SER THR 21 SER VAL 186 MET 
 ALA 65 GLY  GLU 187 LYS 
Table 4.2: Selected DO mutants 
 
Figure 4.3. Rationalized DO mutants obtained from Yeast Display 
Potentially important conformational DO residues. In teal and pink are shown the isolated mutants 
located at the DO-DM interface I and III (Guce et al., 2012; Pos et al., 2012). In blue are the mutants 
that also increase Mags.DO5 reactivity. 
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DO-DM MAGS-DO 
Interface I 
GLU 40 LEU 45 
TRP 43 GLY 49 
SER 53 PRO 57 
PRO 57 GLY 58 
Interface III 
96-100 PRO 97 
183-187 SER 185 
 VAL 186 
 GLU 187 
 Furthermore, 25% of the isolated mutants were localized at the DM-DO 
binding interface ( ) and 12% are at the solvent-exposed β1 domain, which can 
rationally be the Mags.DO5 epitope. However, it is hard to pinpoint which of the 
isolated yeast clone mutation was accountable for the increase Mags.DO5 
reactivity. So, to further evaluate every variant contribution, these point mutations 
were applied singularly and tested in cellular setting, examining both Mags.DO5 
reactivity ER-exit and DM inhibition. 
Figure 4.4. DO residues affecting both DM binding and MAGS-DO5 reactivity 
Selected mutants when shown on the DM-DO crystal structure (4I0P). The colors are as shown in 
Figure 4.4 
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4.1.1. Effect of DO mutations on the peptide exchange  
 Normalized to wt DO staining and to the total DO expression (HKC5 mAb, 
which recognizes DOβ cytoplasmic tail), only a handful of mutant had increased 
Mags.DO5 reactivity (Error! Reference source not found.5, orange bars). I also 
tested the ability of HLA-DO to inhibit HLA-DM and assayed for the amount of 
CLIP. Interestingly, most of the mutants showed a decrease inhibitory effect, 
supporting the notion that the intrinsic instability of DO is a required for its function. 
Finally, these results support the model in which DO competes against classical 
MHCII molecules by sequestering DM chaperone’s function. 
 
Figure 4.5. Characteristics of DO mutants 
Normalized MAGS.DO5, HKC5 and cerCLIP expression after transfection of DO mutants, stemming 
from directed evolution and yeast display selection, into 293T CIITA cells. The MFIs were 
normalized for HKC5 expression, allowing comparison between different transfections. Then, the 
obtained ratio was normalized to the one of wild type DO in order to compare the mutants to the 
normal DO behavior. Thus, a value of 1 means that a given mutants behaves similarly to the wild 
type. Higher and lower value means that this mutant is better or worst, respectively. Note that these 
data are preliminary and that the lack of MAGS-DO5 or CLIP inhibition must be interpreted with 
caution. The left and right histograms show the α and β mutants, respectively.  
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What is interesting here is that even when Mags-DO5 reactivity for DO 
increases, there is not a higher amount of CLIP-MHCII at the plasma membrane. 
Moreover, none of the mutant selected by yeast display showed improved 
capability to inhibit DM.  
 
Figure 4.6. DMY effect on DO mutants 
Expression of DMY increases Mags.DO5 staining at the plasma membrane. In yellow are the 
Mags.DO5 MFI without DMY expression and in orange are the Mags.DO5 MFI with DMY. Mutations 
selected by yeast display do not require DM assistance to disclose Mags.DO5 epitope and those 
mutants egress similarly to the PV mutant (Deshaies et al., 2005). 
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Chapter 5 : Iip35 isoform promotes formation of 
nonamers 
Experimental design: MC, JSF and JT 
Performed experiments: MC75%, JSF25%  
Writing: MC85%, JSF5% and JT10% 
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5.1. Abstract 
The invariant chain (Ii) trimerizes in the endoplasmic reticulum (ER) and 
associates with MHC class II (MHCII) molecules. However, the exact stoichiometry 
of the complex that egresses the ER remains debated. To shed light on this issue, 
we used a functional approach based on a single-chain dimer construct in which Ii 
was covalently linked to MHCII β chain (βSCD). In HEK293T transfected cells, 
nonamer-like complexes including three SCDs and three MHCII α chains 
(α+βSCD)3 were shown to egress the ER. Disrupting these pseudo-nonamers by 
co-expressing Iip33 showed that pentameric (Ii2(βSCD+α)1) and/or heptameric 
(Ii1(βSCD+α)2) complexes can also reach the plasma membrane. By co-expressing 
various Ii isoforms together with wild-type HLA-DR and/or a variant fused to a 
cytoplasmic di-lysine (DRKKAA) ER retention motif, we showed that the 
stoichiometry of Ii/MHCII complexes may vary and that Iip35 promotes formation of 
nonamers. Finally, we provide evidence for the existence of mixed complexes 
containing both DR and DQ isotypes. Altogether, our results demonstrate that Iip35 
affects the stoichiometry of the MHCII/Ii complexes that gain access to the 
endosomes.  
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5.2. ntroduction 
The invariant chain (Ii; CD74) is endowed with pleiotropic functions and is 
best characterized for its role as a chaperone for major histocompatibility complex 
class II molecules (MHCIIs) (1). In the ER, Ii functions as a scaffold protein, 
favoring the association of certain α and β MHCII allotypes and preventing the 
binding of ER peptides. A type II transmembrane glycoprotein, Ii’s N-terminal tail 
contains two cytoplasmic leucine-based endosomal sorting signals (2). Its luminal 
part is composed of a membrane-proximal disordered region, the class II-
associated Ii peptide (CLIP) segment and a C-terminal trimerization domain (3,4). 
According to the current model proposed by Roche et al., three MHCII αβ 
heterodimers associate with a preformed Ii trimer, forming the nonameric structure 
that then egresses the ER (5). Once in endosomes, Ii is sequentially degraded, 
leaving CLIP in the peptide-binding groove (6). The exchange of CLIP for a high-
affinity peptide is catalyzed by HLA-DM, a non-classical MHCII molecule that 
resides in the endocytic pathway (7).  
Mice express two Ii isoforms (p31 and p41), which result from alternative 
splicing (8). In humans, the corresponding isoforms are known as p33 and p41. 
Additionally, about 20% of the translation products originate from usage of an 
upstream start codon. This generates p35 and p43, two additional isoforms which 
bear a sixteen-amino acid cytoplasmic extension (9). This N-terminal region 
contains a strong di-arginine (RxR) ER retention motif (10). The current model 
underlying ER egress of p35 is based on phosphorylation of its serine 8 (11,12). 
This allows the binding of 14-3-3 proteins, which compete with β-COP in the 
ERGIC or cis-Golgi to prevent retrograde transport by COPI-coated vesicles (13). 
Earlier work from our group has shown that the “masking” of the RxR motif requires 
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the MHCII β chain cytoplasmic domain (14). The molecular mechanism by which 
MHCII overcomes the ER retention motif is still unknown.  
The existence of nonamers has recently been challenged and it was 
proposed that due to structural constraints, Ii/MHCII complexes can only form 
pentamers (αβ(Ii)3) (15). Given the divergent results obtained so far using 
biochemical techniques, we chose to shed new light on the stoichiometry of the 
complex using a functional approach in transfected cells. Our data reveal that 
although pentamers can egress the ER, the need to mask the RxR motif of p35 
favors the formation of higher order structures. 
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5.3. Material and Methods  
5.3.1. Plasmids and mutagenesis 
The pbud DRα+DRβ,  pbud DM and pLNCX DQ plasmids have been 
described previously (14,16). DRβ was subcloned into pcDNA 3.1 MSC myc to 
generate DRβmyc. DRβKKAA was generated by PCR. Iip33, p35 and p35LIML were 
subcloned into pcDNA3 from previously described constructs (14). The pcDNA3 
p33LIML mutant and p35LIMLS6,8A mutant were created by PCR overlap mutagenesis 
(14). To create the pbud αSCD and βSCD single-chain dimers, the luminal 
domains of the mature DRα  (aa 1-191) and DRβ (aa 1-199) were linked by PCR 
overlap to Iip33’s luminal region (aa 57-232) using a (Gly)3(Ser)1(Gly)3 linker. 
p35LIMLTRIM coding for aa 1-143 of p35LIML was generated by introducing a stop 
codon in pcDNA3 p35LIML. 
5.3.2. Antibodies and Western blotting 
The following mouse mAbs were described previously (14,16): BU45 (C-
terminal region of human Ii); Pin1 (cytoplasmic tail of human Ii); L243 (HLA-DR); 
XD5.117 (DRβ); DA6.147 (DRα cytoplasmic tail); CerCLIP.1 (CLIP); MaP.DM1 
(DM); HLA-DQ FITC (Life Science Inc., Memphis, TM); 9e10 (myc-tag) (Biolegend, 
San Diego, CA). The C-2-10 monoclonal anti-PARP antibody was a kind gift from 
Dr Guy Poirier (Université Laval, Québec)(17). Secondary Alexa-fluor-coupled 
antibodies (Invitrogen, Burlington, ON) were used for flow cytometry. For Western 
blotting, Peroxidase-AffiniPure Goat Anti-Mouse IgG (H+L) (Jackson 
Immunoresearch, West Grove, PA) and Mouse TrueBlot® Western Blot Kit 
(eBioscience, San Diego, CA) were used. For immunoprecipitations, cells were 
lysed at 4°C in 1% Triton-X100. Samples were subjected to SDS-PAGE 10%. 
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Proteins on immunoblots were detected by chemiluminescence (Roche Applie 
Science, Laval, Qué.).  
5.3.3. Sucrose gradient 
Sucrose gradients were prepared by gradually mixing 0.4M with 0.8M 
sucrose in 10mM Tris-buffered saline 0.5% Triton X-100 pH 7.5 (15). Cell lysates 
(1 mL) were loaded on top of the gradients and submitted to centrifugation at 100 
000g for 50h. Twenty-four fractions were collected from each gradient and 
analyzed on immunoblots. 
5.3.4. Cell lines and flow cytometry  
For transient expression, HEK293T cells were transfected using 
polyethyleneimine (Polyscience, Warrington, PA) and stained after 48h. To 
determine surface expression, live cells were stained on ice and analyzed by flow 
cytometry. To determine total expression of MHCII or Ii, cells were fixed in 4% 
paraformaldehyde, permeabilized, and stained, as described previously (16). In 
some experiments, cells were first surface stained before being permeabilized and 
stained with different mAbs. As compared to living cells, staining of fixed and 
permeabilized cells sometimes results in an apparent lower specific fluorescence 
intensity due to increased autofluorescence and the strong background caused by 
some combinations of primary and secondary antibodies. 
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5.4. Results 
5.4.1. Single-chain dimers between Ii and MHCII  
To shed light on the composition of MHCII/Ii complexes that gain access to 
the plasma membrane and endosomes, we designed a strategy by which free Ii 
monomers are allowed to trimerize with other Ii molecules that are already linked to 
MHCIIs via a covalent link. This strategy limits the availability of MHCIIs and favors 
the formation of mixed complexes in which one or more Ii subunits will not be 
directly associated to a DR molecule. To construct the MHCII/Ii single-chain dimer 
(SCD), the luminal C-terminus of the HLA-DRβ chain (βSCD) was fused to the N-
terminus of Ii (18) (Fig. 1). When expressed with the complementary MHCII α chain 
in HEK293T cells, βSCD accumulated at the plasma membrane just like full length 
DR/Ii molecules and was recognized by the conformation-sensitive L243 mAb (Fig. 
1A-E). Accordingly, Ii was detected at the plasma membrane using the 
conformation-sensitive BU45 mAb (Fig. 1E). As BU45 recognizes an epitope 
located within or next to the trimerization domain and since this mAb does not bind 
Ii monomers, our results suggest that βSCD and DRα can form pseudo-nonamers 
(DRα3βSCD3) (19-21). In this experiment, the two di-leucine endosomal sorting 
signals of the wild type (WT) Ii control were mutated (Iip33LIML) to facilitate its 
detection at the plasma membrane (Fig. 1B). Indeed, because this molecule is less 
efficiently internalized, it has a longer half-life and accumulates preferentially at the 
cell surface after passage through the Golgi (22,23). Interestingly, βSCD yielded 
some MHCII-CLIP complexes at the plasma membrane (Fig. 1B, E). As the CLIP 
fragment can only be detected in association with MHC II molecules and after 
cleavage of Ii in late endosomes (24), this result suggested that at least a fraction 
of the complexes recycled between the endocytic pathway and the plasma 
membrane. Finally, we found that CLIP was efficiently removed upon co-
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expression of HLA-DM (Fig. 1C, F). Altogether, these results demonstrate that the 
DRα/βSCD complex is structurally very similar to WT MHCII/Ii.  
Figure 5.1: Schematic representation and 
expression of SCD.  
(A) Schematic representation of wild-type 
DRα, DRβ and Ii. (B) Wild-type DRα, DRβ 
and p33LIML were transiently transfected in 
HEK293T cells. After 48h, cells were stained 
to detect MHCII, Ii and CLIP using L243, 
BU45 and Cer-CLIP.1 mAbs, respectively. 
(C) Cells were transfected as above as well 
as with HLA-DM and stained for surface 
CLIP and permeabilized to detect HLA-DM. (D) Schematic representation of DRα and βSCD. βSCD 
was designed as to have Ii and HLA-DRβ luminal domains linked by a flexible gly3/ser/gly3 
sequence. (E,F) Transfected cells were analyzed as above. Histograms are representative of at 
least five independent experiments 
5.4.2. The stoichiometry of SCD complexes can vary in the presence of free Ii  
To further characterize the Ii/MHCII complex, we investigated the trafficking 
of βSCD when co-expressed with Iip33LIML and p35LIML (Fig. 2A). First, HEK293T 
cells were transiently transfected with α+βSCD and surface stained to detect Ii. 
The same cells were then permeabilized and stained for DR to assess efficacy of 
transfection and overall expression of the complex. In absence of additional Ii, as 
shown above, the βSCD and CLIP were detected at the plasma membrane (Fig. 
2A, B, left panels). Separate cell aliquots were also stained to measure surface 
MHCII and total Ii, allowing a molecule’s surface expression to be compared to its 
total protein levels (Fig. 2B, middle and right panels). These normalized 
(surface/total) mean fluorescence values (MFV), which reflect the efficiency of 
forward trafficking, tend to be low for ER-retained molecules (14). 
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Then, we co-expressed βSCD with DRα and p33LIML. This combination led 
to strong Ii, CLIP and DR surface expressions (Fig. 2A, B). However, these results 
do not indicate if some MHCII/Ii complexes included both SCDs and p33LIML 
moieties. We reasoned that p35LIML, contrary to p33LIML, might prevent surface 
expression of mixed complexes since the SCD lacks a β chain cytoplasmic region 
capable of shielding the RxR motif. Indeed, co-expression with p35LIML prevented 
transport of βSCD to the plasma membrane (Fig. 2A, right panel). MHCII staining 
of permeabilized cells with L243 confirmed the expression of the βSCD and DRα. 
The absence of CLIP at the plasma membrane is in line with the intracellular 
retention of this complex (Fig. 2B). Thus, it appears that p35 subunits get efficiently 
incorporated into SCD-containing complexes, causing a dramatic reduction of cell 
surface expression. 
Figure 5.2: Nonameric and pentameric-like 
complexes can egress the ER 
(A) Cells were transfected with DRα and βSCD 
alone or together with p33LIML or p35LIML. 
Contour plots represent Ii surface expression 
relative to MHCII total expression. (B) The left 
panel shows the MFVs obtained for CLIP at the 
cell surface. The right panels show the ratio 
obtained for surface expression versus total 
expression. This ratio indicates the proportion 
of Ii or MHCII expressed at the plasma 
membrane. (C) Cells were transfected with DRα 
and βSCD alone or together with p33 or p35. 
Cell lysates (right lanes) and Ii 
immunoprecipitations (left lanes) were analyzed on immunoblots. The HLA-DRα chain was detected 
using the DA6.147 mAb specific to the cytoplasmic domain. Heavy chains of the immunoglobulins 
(Ig) used for immunoprecipitations are indicated. Mock samples are non-transfected HEK293T cells. 
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(D) Samples were analyzed using the XD5.117 mAb specific to DR’s luminal domain. Error bars 
indicate the SD from five independent experiments. 
Our results suggest that the heterotrimerization of full-length p33LIML or 
p35LIML with the βSCD-included Ii chain generates pseudo-pentamers 
(Ii1(α+βSCD)2) and/or -heptamers (Ii2(α+βSCD)1). We performed co-
immunoprecipitation assays to confirm the association of WT Ii with βSCD using 
the Pin.1 mAb, which recognizes the cytoplasmic tail of Ii (Fig. 2C). Because Pin.1 
is sensitive to mutations in the leucine-based sorting signals, these experiments 
were performed with WT Ii isoforms. Iip33- and p35-immunoprecipitated samples 
were analyzed on immunoblots for the presence of DR α and β chains. Results 
confirmed that both DRα and SCD chains were associated with p33 and p35. While 
DRα was revealed with the cytoplasmic tail-specific DA6.147 mAb (top panel), the 
SCD-included DRβ chain was detected at ~50 kDa using the β1 domain-specific 
XD5 mAb (Fig. 2D). Cell lysates were included as controls. When expressed alone, 
α+βSCD was not detected as the Ii cytoplasmic portion is deleted. Combined with 
the fact that p35 prevents expression of the βSCD complex at the cell surface, 
these results demonstrate that full-length Ii can heterotrimerize with the Ii moiety of 
SCDs to form pseudo-heptamers and/or pseudo-pentamers. Taken together, these 
results suggest that the stoichiometry of MHCII-Ii complexes is variable.  
 
5.4.3. Retention of βSCD by Iip35 requires its trimerization domain  
To confirm that Iip35 interacts with the Ii moiety of the βSCD, we created a 
mutant devoid of its trimerization domain (p35LIMLTRIM, Fig 3). To do so, the C-
terminal region including the three α-helices that mediate Ii trimerization (25,26) 
was deleted in Iip35 and replaced by a myc/his tag to compensate the loss of the 
BU45 epitope. As for p35LIML, this mutant requires the presence of DR to access 
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cell surface (Fig 3 A and B) and to unmask the CLIP fragment (data not shown). 
These results suggest that the overall structure of this Ii variant is not grossly 
altered. To test if the C-terminal trimerization domain was responsible for the 
intracellular retention of the βSCD by p35, βSCD was expressed with DRα together 
with p35LIML or p35LIMLTRIM. As observed previously in figure 2, in absence of 
additional Ii, the Ii and MHCII moieties of the SCD were detected at the plasma 
membrane (Fig 3C, middle and right panels). Some CLIP was also detected in 
these conditions (Fig 3C, left panels). Interestingly, while p35LIML caused the 
intracellular retention of βSCD, the p35LIMLTRIM variant was inactive and CLIP, 
MHCII and Ii were all detected at the plasma membrane (Fig. 3C). This data 
strongly suggest that the intracellular retention of SCD by p35 is trimerization-
dependent and implies the formation of pseudo-pentamers (Ii1(α+βSCD)2) and/or -
heptamers (Ii2(α+βSCD)1). In addition, these results demonstrate that Iip35 did not 
cause retention simply by displacing the covalently-linked Ii segment of the βSCD. 
 
Figure 5.3: C-terminal trimerization domain of full-
length Ii allows formation pseudo-heptamers 
and/or pseudo-pentamers  
(A) p35LIML or p35LIMLTRIM were transiently transfected 
in HEK293T cells. After 48h, cells were stained to 
detect surface and total Ii using BU45 (p35LIML) or anti-
myc tag mAb (p35LIMLTRIM) (B) Wild-type DRα, DRβ 
and p35LIML or p35LIMLTRIM were transiently transfected. 
Cells were stained to detect surface and total Ii. (C) 
Cells were transfected with DRα and βSCD alone or 
together with p35LIML or p35LIMLTRIM. The left panel 
shows the MFVs obtained for CLIP at the cell surface. 
The right panels show the ratio obtained for surface 
expression versus total expression of Ii and MHCII. 
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Error bars indicate the SD from five independent experiments. 
5.4.4. p35 forces the formation of high order complexes 
The results presented above suggested that βSCD can form pseudo-
nonamers and that free Ii can incorporate these complexes to form lower-order 
structures. In a recent study, Koch et al. have suggested that only one MHCII αβ 
heterodimer can associate with an Ii trimer (15). This conclusion was based, in 
part, from sedimentation of B cell lysate proteins in sucrose gradients. To gather 
evidence for the existence of nonamers in the context of non-cavalently linked wild-
type molecules, we performed similar experiments using lysates from HEK293T 
cells expressing HLA-DR and either p33 or p35 (Fig4 A and B). After centrifugation, 
fractions were collected and analyzed on immunoblots for the presence of DRα. 
Our results show that p35 and MHCII can generate complexes of an apparent 
molecular weight superior to those formed around p33. The same applies to the 
control βSCD and DRα complexes as some were found deep in the gradient (Fig 
4C). These data are in line with βSCD forming pseudo-nonamers and suggest that 
p33 and p35 behave differently, the latter generating larger complexes.  
 
Figure 5.4: DR assembly with p35 
and βSCD forms complexes of 
higher molecular weight than 
around p33 
HEK293T cells were transfected 
with DR and p33 (A) or p35 (B) 
isoforms as well as α+βSCD (C). Cells were analysed by flow cytometry (data not shown) and 
lysed. Sedimentation on sucrose gradient was performed and 25 resulting fractions were western 
blotted for DRα using DA6 antibody and parp1 (116kDa). Blots are representative of at least 3 
independent experiments 
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5.4.5. Evidence for the ER egress of Ii/MHCII complexes of variable 
stoichiometry 
The above-described data prompted us to evaluate the assembly and 
stoichiometry of Ii-MHCII complexes in the context of various Ii isoforms. We 
generated a DRβ molecule bearing its own ER retention motif in the form of a 
cytoplasmic Lys-Lys-x-x (KKAA) motif (Fig. 5A). The di-lysine signal acts as a 
strong retention motif for ER-resident type I transmembrane proteins. Recombinant 
reporter molecules that bear this sequence also localize in the ER (27). The 
rationale behind this strategy is that if heptamers and nonamers exist, the DRKKAA 
variant should trap in the ER a co-expressed WT MHCII. In contrast, if pentamers 
are the only possible structures, the DRKKAA/Ii complex should be retained in the 
ER without influencing the trafficking of other MHCIIs.  
 
Figure 5.5: Surface expression of 
DRmyc is not affected by ER 
retained DRKKAA 
(A) Schematic representations of 
DRmyc and DRKKAA. (B) HEK293T 
cells were transiently transfected 
with DRα together with either 
DRβmyc (DRmyc), DRβKKAA (DRKKAA) 
or with both β chains (right panel). 
Cells were stained with L243. (C) The MFVs obtained in panel B were plotted. (D) DRmyc, and 
DRmyc+ DRKKAA cells were stained to detect total DRmyc expression using 9e10. Error bars indicate 
the SD from five independent experiments 
 
We first confirmed the lack of surface expression of the transiently co-
transfected βKKAA and DRα chains. Cells were stained to detect surface expression 
of MHCII, while total expression was assessed after permeabilization (Fig. 5B). A 
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myc-tagged DR molecule (DRmyc) was used as control (Fig. 5A). In line with the 
presence of a functional ER retention motif, the data revealed that DRKKAA was 
mostly found intracellularly (Fig. 5C). Importantly, when co-expressed with DRKKAA, 
DRmyc was still detected at the plasma membrane (Fig. 5B, C). The relative 
proportion of MHCII at the surface was somewhat intermediate in these conditions 
as the DRKKAA was retained in the ER, increasing the pool of “total” molecules. 
Staining of permeabilized cells with anti-myc mAb revealed that expression of 
DRβmyc was similar whether DRβKKAA was present or not (Fig. 5D). 
We then repeated these experiments using three different forms of Ii. First, 
we tested a MHCII/Ii SCD based on the DRα chain (αSCD). Upon association with 
the control βmyc chain, αSCD was detected at the cell surface using Ii-, DR- and 
CLIP-specific mAbs (Fig. 6A-C). However, as predicted, the αSCD was not 
detected at the plasma membrane when paired with DRβKKAA. Since SCDs force 
the formation of nonamer-like structures, we could then ask whether βKKAA would 
influence the fate of βmyc. Interestingly, when both βmyc and βKKAA were co-
expressed with αSCD, cell surface expression of DRmyc decreased dramatically 
(Fig6. A,B). Yet, βmyc was expressed, as confirmed by intracellular staining (Fig. 
6D). As DRmyc, but not DRKKAA, has the potential to reach the plasma membrane, 
we also measured the amount of surface MHCII in the context of total βmyc. The 
results confirmed that βKKAA prevented βmyc expression at the plasma membrane in 
presence of αSCD (Fig. 6E).These results suggest that a trimeric αSCD randomly 
associated with the surrounding available β chains. As probaly one copy of 
DRβKKAA got incorporated into each pseudo-nonamer, all the molecules in the 
complex (including DRmyc) were prevented from reaching the plasma membrane. 
Accordingly, no CLIP was detected at the cell surface (Fig. 6C).  
These data suggest again that nonamers exist, at least for SCDs. However, 
this nonameric complex could be artefactual due to the absence of potential 
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structural constraints normally imposed by the TM regions of WT molecules (15). 
To rule out this possibility, we assessed the impact of the DRβKKAA in the context of 
full length DRα and p33 or p35. When the control βmyc was the sole source of β 
chains, DRmyc, Iip33 and CLIP were all detected at the plasma membrane (Fig. 6A-
C, E). In contrast, for βKKAA, MHCII and CLIP were absent at the plasma 
membrane. Low levels of p33 were detected but these Ii trimers are most likely free 
of MHCII. Interestingly, when both β chains were co-expressed with p33, Ii and 
MHCII were detected at the plasma membrane, albeit at low levels (again due to 
the intracellular accumulation of DRKKAA, which traps some Ii and increases the 
intracellular pool of MHCII). Still, the presence of CLIP at the plasma membrane 
confirmed that these MHCII molecules trafficked with Ii. Together, these findings 
suggest that in the presence of p33, βmyc-based MHCII heterodimers can most 
likely egress as pentamers (Ii3(αβ)1).  
Figure 5.6: DRmyc is retained by 
DRKKAA when p35 expression 
forces the formation of high 
order complexes with MHCII 
(A, B and C) HEK293T cells were 
transiently transfected with DRβmyc 
and/or DRβKKAA  together 
with  αSCD, p33LIML or p35LIML. 
After 48h, cells were analyzed by 
flow cytometry to evaluate Ii 
expression (A) and MHCII surface to total expression ratio (B) using BU45 and L243, respectively. 
(C) Surface CLIP expression was assessed by flow cytometry and the MFVs were plotted. (D) Cells 
expressing  αSCD with DRβmyc and/or DRβKKAA were stained to detect total DRβmyc using anti-myc-
tag. (E) Cells from A, B and C were analyzed for MHCII/myc surface to total expression ratio using 
L243 and 9e10, respectively. Error bars indicate the SD from at least three independent 
experiments. 
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We cannot formally rule out that DRmyc was part of nonamers devoid of any 
DRKKAA. However, it is highly unlikely that nonamers would not randomly include at 
least one competing DRKKAA subunit. To resolve this issue and to better define the 
stoichiometry of the complex, we repeated the experiments with Iip35, which 
cannot egress as a pentamer since all RxR motifs in the complex must be masked. 
Thus, if pentamers do not exist and some nonamers devoid of DRKKAA are formed, 
the results should be the same as for p33 and DRmyc should be found at the 
plasma membrane. On the other hand, if nonamers incorporate both DRmyc and 
DRKKAA, no MHCII will be found at the plasma membrane. To discriminate between 
these possibilities, we next assessed the impact of expressing DRβKKAA and βmyc in 
the context of a p35 homotrimer. When expressed together with DRmyc, p35 and 
CLIP were found at the plasma membrane. On the other hand, in presence of 
DRKKAA, p35 was retained intracellularly. As this isoform cannot egress on its own, 
Ii was not detected at the cell surface. Interestingly, when βmyc and βKKAA were co-
expressed, results were different than those described above for p33. No MHCII, Ii 
or CLIP was found at the cell surface (Fig. 6A-C, E). Based on these findings, we 
conclude that p35 trimers are retained in the ER until saturated with MHCIIs. 
However, since β chains are incorporated randomly, it is likely that each and every 
nonamer contains at least one βKKAA chain, thereby preventing ER egress and 
causing retention of the associated βmyc. Altogether, our results demonstrate that 
while pentamers can exit the ER, the presence of p35 and the need to mask its 
RxR motif are conditions that will most likely generate nonameric complexes.  
5.4.6. Iip35 generates nonamers composed of mixed MHCII isotypes. 
The ability of p35 to generate high-order structures suggests that different 
isotypes may be part of a given heptamer or nonamer. To test this possibility, we 
assessed the capacity of the DRKKAA mutant to retain HLA-DQ in the ER (Fig 7A, 
B). Cells were transfected with either DQ alone, DQ and DR or DQ and DRβKKAA in 
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presence of either p33LIML or p35LIML. First, when co-expressed with p33LIML or 
p35LIML, DQ was found at the plasma membrane and some CLIP was generated 
(Fig. 7A, B). Similar results were obtained upon co-expression of DR, suggesting 
that the two isotypes behave the same in this assay. Interestingly, when co-
expressed with DRKKAA, DQ expression was only reduced in the context of Iip35LIML 
(Fig. 7A). As shown above for βmyc, this suggests that DQ can egress as 
pentamers with Iip33 independently of the presence of DRKKAA. However, p35 
trapped some DQ molecules. Noteworthy, the expression of DQ was not totally 
abolished as compared to DRmyc in the same conditions (Fig. 6B and E). The fact 
that no CLIP was detected at the cell surface suggested that these cell-surface DQ 
molecules did not interact with Ii and trafficked on their own (Fig. 7B). To test this 
possibility, we compared the capacity of DR and DQ to escape ER retention by 
p35S6,8A, an unphosphorylated Ii variant which cannot exit the ER (12,28). Figure 
7C and D show that while DQ and DR are well expressed at the plasma membrane 
and produce CLIP with Iip33, only DQ was detected at the cell surface with 
p35S6,8A. As there was no trace of CLIP, we conclude that some DQ molecules 
egress the ER without Ii. Altogether, these results showed the existence of mixed 
nonamers containing different MHCII isotypes.  
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Figure 5.7: Different MHCII isotypes can associate 
with the same p35 isoform in nonameric complex 
(A and B) HEK293T cells were transiently transfected 
with DQ, DQ and DR or DQ and DRKKAA  together 
with p33LIML or p35LIML. (A) After 48h, cells were analyzed 
by flow cytometry to evaluate DQ surface to total 
expression ratio using anti-DQ specific antibody. (B) 
Surface CLIP expression was assessed by flow cytometry 
and the MFVs were plotted. (C and D) HEK293T cells 
were transiently transfected with DQ or DR together 
with p33LIML or p35LIMLS6,8A. (C) After 48h, cells were 
analyzed by flow cytometry to evaluate DQ and DR 
surface to total expression ratio using anti-DQ and L243 antibody respectively. (D) Surface CLIP 
expression was assessed by flow cytometry and the MFVs were plotted. Error bars indicate the SD 
from at least three independent experiments. 
5.5. Discussion 
 
The exact sequence of events leading to ER egress of the Ii/MHCII complex 
remains to be fully characterized. In B cell lines, p35 is usually underrepresented 
as compared to p33, allowing formation of some p33 homotrimers (12,21,29). In 
MHCII-negative T2 cells, Iip35-including trimers do not reach endosomes and have 
a long half-life. In contrast, homotrimeric p33 complexes acquire complex sugars in 
the Golgi and have a much shorter half-life (21). MHCII associate sequentially with 
Ii to form pentamers, heptamers and, ultimately, nonamers (5,29). However, 
pentamers were recently proposed to be end points and higher order structures 
dismissed as experimental artefacts (15). Considering the conflicting biochemistry 
data obtained so far, we chose to shed new light on the formation of the complex 
using a functional readout based on the capacity of Ii and MHCII to reach the 
plasma membrane in transfected cells.  
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We herein have presented strong evidence that functional high-order 
structures do arise in the ER. We have shown that SCDs, adopting a nonamer-like 
structure, are expressed at the plasma membrane and that third party MHCII 
molecules are retained in the ER in the presence of p35 and DRβKKAA. However, in 
the context of p33, similar experiments have demonstrated that some pentameric 
or heptameric complexes can successfully go through quality control mechanisms 
and exit the ER, destined for the endocytic pathway or the plasma membrane. 
Those observations were confirmed by biochemical data showing that MHCII-p35 
and SCDs form higher molecular weight structures than MHCII-p33. 
Our results are in line with a model in which the various nascent isoforms of 
Ii homo- and heterotrimerize following translocation in the ER. In the case of p33, 
MHCII α and β chains (either pre-associated or not) fold on Ii homotrimers to 
generate pentamers. Such a complex is then competent to egress the ER 
definitively. This undoubtedly happens under certain experimental conditions and in 
some cell types. The ratio of Ii and MHCII is likely to be a factor affecting the final 
stoichiometry. As Ii is often in vast excess and half of the Ii pool exists as p33 
homotrimers, some MHCII may fold on their exclusive Ii trimer and egress the ER 
as pentamers (12,30). What physiological conditions could favor the formation of 
such complexes? Inflammation could benefit from the rapid expression of MHCIIs 
resulting from an increase in Ii expression. Although Ii gene expression is co-
regulated with MHCII, it is also specifically induced by NF-κB (31). As suggested 
here, the p33/p35 ratio will also modulate the stoichiometry of the complex. Clearly, 
the relative proportions of these isoforms can somehow be regulated as 
overexpression of p35 has been reported in chronic lymphocytic leukemia (32). 
Whether p35 plays a role in tumor escape from the immune system by modulating 
the association of Ii and MHCII remains to be determined.  
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Anderson et al. have calculated that 48% of all Ii molecules are part of 
heterotrimers containing at least one p35 isoform (12). The presence of p35 in an Ii 
heterotrimer forces the sequential addition of MHCIIs until all RxR motifs are 
phosphorylated and masked by MHCII β chains. Thus, depending on which Ii 
subunit binds MHCII first, an heterotrimer containing one p35 should have a 33% 
chance of being released from the ER as a pentamer. As the sequential binding of 
MHCII on the Ii trimer was shown to be non-cooperative in vitro (33), Ii trimers most 
likely compete with newly formed pentamers for the available MHCII. 
Our results suggest that slowing down transport kinetics modulates 
stoichiometry of Ii/MHCII complexes. Recently, soluble forms of human Ii and 
MHCII co-produced in cell line were shown to be secreted in complexes of different 
stoichiometry but all built around the Ii trimer (34). Such constructs devoid of TM 
regions may exit the ER quickly, preventing the saturation of Ii. Also, we can 
speculate that the diversity of Ii/MHCII complexes will be dictated by the nature of 
the isotypes co-expressed in a given cell. Our results clearly demonstrated that 
heptamers and pentamers can include different isotypes of MHCII. However, we 
also showed that a pool of folded and trafficked independently of Ii. The allotype 
used here (HLA-DQA1*0102/DQB1*0602) confers protection against insulin-
dependent diabetes mellitus and was shown to form SDS-resistant compact forms 
in the absence of HLA-DM (35). If this increased stability is related to the Ii-
independent ER egress described here remains to be addressed experimentally. 
Conversely, it would be interesting to study the protective properties of this MHCII 
molecule in the context of its potentially inefficient incorporation into nonamers. We 
can speculate that other factors, such as the affinity for CLIP, may regulate the 
incorporation (or dissociation) of some allotypes in nonamers. As the trafficking of 
Iip35 is peculiar, it is possible that some MHCII allotypes are more influenced than 
others by this Ii isoform. Interestingly, variation of p35 expression was suggested to 
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result in differential Ag presentation and contribute to the development of type 1 
diabetes (36). 
Taken together, our results demonstrate that the stoichiometry of the 
MHCII/Ii complex that reaches the endocytic pathway is influenced by the relative 
expression of the different Ii isoforms and of MHCIIs. Other variables undoubtedly 
include MHC haplotypes and cell type intrinsic factors. Ii serves as a chaperone for 
molecules other than MHCII and the expression of p35 may affect other cellular 
processes as well. In addition, Ii appears to function as a plasma membrane 
receptor. Given that p35 regulates surface display of Ii trimers (37), it will be 
interesting to determine the impact of this isoform on the chaperone-independent 
functions of Ii. Studies addressing the transport and functional characteristics of 
p35 in health and disease are warranted. 
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Chapter 6 : Discussion & Conclusion 
6.1. The relation between DO and DM  
 DO requires DM for maturation and to exit the ER. In Chapter 3, the 
interaction between DO and DM was examined with the Mags.DO5 mAb. Using 
this strategy, we showed that DM stabilizes the interactions between the DO α1 
and β1 chains and that DM influences DO folding in the ER. Furthermore, following 
the work from Deshaies et al., this conformation can also be achieved via a point 
mutation in the α1:β1 β-strand interface, regardless of DM binding (Deshaies et al., 
2005). Thus, the Mags.DO5+ conformation correlates with DO egress from the ER.  
6.1.1. DO conformation and Mags.DO5 epitope 
 Like DQα, DOα possesses an insertion (position 10b, or 11) between the 
residue 10 and 11 (or 12), which forms a bulge that protrudes toward the groove 
(Error! Reference source not found.). However, in contrast to the GLY inserted 
in DQ, DO has a PRO which disrupts the HB network tying the α and β first β-
strands together (Guce et al., 2012). One must wonder why would certain MHCIIs 
have a conserved insertion/bulge at this position. One hypothesis is that it is to 
prevent pairing with certain β chains that bear a long side chain at position β78, 
which would sterically clashes with the bulge.  
 As discussed in section 3.5, DM most probably stabilizes the poor DOα:β 
pairing upon binding, as interchanging these two strands for those of DR disclosed 
the Mags.DO epitope. This epitope is one that is conformation-sensitive and 
located on DOβ chain. Three regions, defined as DR1 most flexible, are possible 
candidates for this mAb binding: i) the C-terminal end of the α-helix, ii) the most 
carboxy-distal β-strand of the Ig domain or iii) the association of the N-terminal end 
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of the α-helix and the loop between the first and second strands forming the groove 
platform (Painter et al., 2008). 
 It seems unlikely that the epitope is located on the Ig β2 domain as this 
flexible strand gets buried at the DM interface (Guce et al., 2012; Pos et al., 2012). 
Next, the βG86Y/M point mutant, where the Y/M fills the P1 pocked, highly 
increases Mags.DO5 reactivity (data not shown and Error! Reference source not 
found.3) in addition to make empty-state DR1 resistant to SDS denaturation 
(Natarajan et al., 1999b).  Although I do not have formal evidence confirming 
Mags.DO5, it seems safe to argue that it binds the β1 domain, most probably at the 
N-terminal end of the peptide binding groove.  
 
Figure 6.1. DO modelization based on DQ2.  
Highlights of the three potential Mags.DO epitopes and the insertion creating the bulge at the α1:β1 
interface. i) N-terminal end of the β1 α-helix; ii) last Ig strand of the β2 domain; iii) C-terminal end of 
the β1 α-helix, at the platform-helix junction. 
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6.1.2. Concluding remarks 
 DO necessitates DM for maturation and to exit the ER. Interestingly, a 
conformation change occurs in DO upon its binding with DM, which can be 
monitored by the Mags.DO5 mAb. Of the 41 unique mutants screened through 
directed evolution, 25% were localized at the DM-DO binding interface and 12% 
are at the solvent-exposed C-terminal β1 domain, a potential Mags.DO5 epitope. 
Most of the mutants showed a decrease DM-inhibitory effect, supporting the notion 
that the intrinsic instability of DO is required and that subtle conformation change 
are partially responsible for this function.  
DO is highly conserved between species, so its structure-function must 
depend on its sequence to exhibit such role. First, although DO has over 80% 
homology with classical MHCIIs, it cannot bind peptides, probably because of a 
lack of available HBs to bind the peptide backbone with enough kinetic stability. 
Interestingly, 8% of the mutants are observed in wt DO sequences of other 
species. This suggested that in human DO, some mutations have cumulative or 
subtractive "stabilization" effect. 
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Figure 6.2. DO sequence Logo. 
20 DOα and 13 DOβ sequences were aligned and are shown as a logo depiction. The size of the 
letters represents the residue conservation between species. The red and black stars indicate 
isolated residues from directed evolution that are or not present in other DO species, respectively. 
 
Second, DO must remain in a permissive DM-binding state, a state that, 
once lost, renders it unable to bind DM again (The Stern Lab, personal 
communication). This conformation transition could be the key to clearly 
understand DO function and its relation with DM. Whether DO-DM dissociation in 
the MIICs is ligand-dependent or triggered by an unknown event remain to be 
evaluated. Given the particular DO-DM complexes location compared to the one of 
unbound-DM in the MHCIIs, one can't exclude that accessory protein are also 
implicated. 
DOα 
DOβ 
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6.2. vSAG7 presentation 
The activity of vSAGs has been known since the 70s but still remains poorly 
defined. vSAGs are produced in vanishingly small quantities rendering structure-
function studies quite a challenge, as reflected by conflicting discoveries. Although 
there is no crystal structure available, I have nonetheless undertaken the 
characterization of the trimolecular complex between vSAG, MHCII and TCR. My 
results reconcile many caveats pertaining to the field and provide new insights 
about vSAGs mechanistic and MHC-TCR docking topology 
In Chapter 2, I addressed the question: what is the topology of the TCR 
signaling complex mediated by vSAGs? My key finding was that TCR 
concomitantly binds both the MHCII α chain and vSAG. Therefore, the pressure 
exerted by vSAG alters conventional TCR-MHCII interactions and indicates that the 
TCR-MHCII docking is almost canonical when coerced by vSAGs. Furthermore, my 
results demonstrate that vSAG binding to MHCII molecules is conformation-
dependent and abrogated by the CLIP amino-terminal residues extending outside 
the peptide-binding groove. In addition, they also suggest that vSAGs cross-link 
adjacent MHCIIs and activate T cells via a TGXY motif.  
 
6.2.1. Model 
 It has long been clear that vSAGs have two binding sites on MHCIIs, one on the 
α chain and the other on the β chain, both overlapping those of SEA (Delcourt et al., 
1997a; Mottershead et al., 1995; Torres et al., 1993). Given that C-vSAG binds to the 
MHCIIα chain and N-vSAG binds to the MHCIIβ chain, and that both moieties remain 
non-covalently associated upon maturation, one must carefully consider how these 
proteins interact together. First, vSAG must bind without hindering nominal Ag 
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interaction with the distinctive MHCII’s open groove, as vSAG presentation depends on 
the bound-peptide (Woodland et al., 1997). Thus, in order to bind to both MHCII 
chains, vSAG7 must either: i) skirt around one or the other ends of the peptide groove; 
ii) go over it; or iii) bind an adjacent MHCII (Error! Reference source not found.3).  
 
Figure 6.3. Possible ways vSAG can bind MHCIIs 
From left to right: vSAG binds the MHCII on the peptide C-terminal end; on the N-terminal ends; 
through the peptide groove; over the groove, at the membrane distal region; or binds adjacent 
MHCIIs.  
 
 We can easily discern that vSAG7 does not surround MHCIIs at the C-terminal 
end of the peptidic groove (according to the canonical peptide orientation) because of 
the linker joining the peptide to the MHCIIβ chain in the tested constructs, which is 
likely to create sterical clash. Also, the identified binding sites of both vSAG7 moieties 
are closer to the N-terminal end of the peptidic groove, limiting the likelihood of such 
binding (Delcourt et al., 1997a; Mottershead et al., 1995). As described in section 
2.3.3, vSAGs do not bind the MHCII peptide groove. Next, although it seems equally 
possible that N-vSAG encircles the N-terminal groove opening, many facts argue 
otherwise. Indeed, a panel of mutants located at this MHCII interface do not affect 
vSAG presentation (Error! Reference source not found.4) (Thibodeau et al., 1994). 
Furthermore, peptide extending outside the groove at this end would likely hinder such 
binding mode. Also, concomitantly expressing the βSCD with the αIi SCD in 293T 
allows the pairing of both SCDs, suggesting that C-vSAG does not cross over to the 
MHCII α chain when it is bound to the MHCII β chain (5).  
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Figure 6.4. MHCII α  or β  mutants affecting or not vSAG 
presentation 
Cartoon of CLIP-DR3 (16A6) showing in pink the residues 
implicated in C-vSAG binding and in purple those that do no 
affect its presentation. 
 
A model in which vSAG binds the membrane-most distal 
region of MHCIIs, i.e. in a TCR-like binding fashion, 
does not fit our results highlighting the requirement of 
the TCR conjoint binding to both the MHCII α chain as 
C-vSAG would prevent both Ag and vSAG stimulation. 
Lastly, as discussed in section 2.4.3, it is more likely that C-vSAG binds adjacent 
MHCIIs than the one to which its N-vSAG moiety is bound. 
 
 
Figure 6.5. Coexpression of α Ii and βvSAG7 
Histogram showing transfection of the αIi and βvSAG 
SCDs. BU45 and L243 positive stainings imply that Ii 
trimerized and that the MHCII α and β chain paired 
correctly. As both Ii and vSAG are linked to a MHCII 
chain, existence of such multimeric complexes suggests 
that Ii and vSAG have distinct binding sites, arguing 
against vSAG binding to the N-terminal end of the 
groove. 
 
 Based on sequence homology, no other crystallized protein (and bSAGs) show 
enough similarity to generate a model accurate enough to formally rule out that vSAGs 
do not have loops or regions able to be "sandwiched" between the TCR-MHCII 
interface. Given the short half-life of the vSAGs, the protein bulk may include its share 
of protruding loops and could fit into such a model. Using the PHYRE2 server, only a 
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part of C-vSAG gives a confidence value of over 30% and supports the fact that vSAG 
has a unique fold. In Error! Reference source not found.6, the predicted structure of 
the C-vSAG 195-258 stretch is given, based on the C-terminal domain of FAD-linked 
reductase fold (Kelley and Sternberg, 2009). Interestingly, even though the 
confidence of this model is only 34.3% based on a sequence homology of 15%, the 
β-stranded sheet including the TGXY motif - implicated in TCR contact - would 
complement the lateral face of the TCR Ig domain well.  
 
Figure 6.6. Part of C-vSAG predicted structure 
a) Predicted secondary structure of C-vSAG (aa 195-258). b) Three different views of C-vSAG 
cartoon structure modelized from the C-terminal domain of the FAD-linked reductase fold. In blue, 
are shown the sticks of the TGXY motif c) Mapping of the TCR region implicated in vSAG binding. 
According to the results presented in chapter 2, I proposed a new SAG-
mediated T cell activation complex. Stemming from seminal work by Kappler, 
Pullen and Woodland's groups, my model is fine-tuned to many intricacies 
described in reports published in the nineties. vSAG7 binds to both MHCII α chain 
and TCRβ chain, in an arrangement somewhat similar to that observed previously 
in structures of various complexes of bacterial superantigens, MHCII, and TCR, but 
with less disruption of the conventional MHCII-TCR interface. We named this 
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vSAG-mediated MHC-TCR binding "near-canonical" in reference to the expected 
interaction of MHC and TCR. Most of the well-characterized bSAGs bind in such a 
way that conventional MHC-TCR interactions are disrupted and replaced by 
MHCII-SAG and SAG-TCR interactions (Error! Reference source not found.7). 
However, the vSAG-MHCII-TCR architecture is not quite canonical, as many 
peptides can be tolerated in the center of the interaction. Furthermore, vSAGs exert 
a pressure on the MHCII-TCR contacts that leads to CDR3β-MHCIIα interactions 
instead of the traditional CDR3β-peptide interactions.  
 
Figure 6.7. Architecture of SAG-mediated T cell signaling complexes 
Cartoons of the major docking topologies between MHCII and TCR, whether or not mediated by 
SAG. From left to right are pictured the canonical, SEB, SEA, MAM and vSAG T cell signaling 
complexes. 
How can the peptide TCR-contacting side chain not influence the vSAG7-
mediated response? It is hard to link this effect simply on a near-canonical docking 
model and thus must also be dictated by the TCR V domain. Indeed, it is possible that 
different TCR would be sensitive to variation of the protruding side chain while others 
would be more permissive. My results stem from two Vβ6-bearing hybridomas, which 
only differ at the Vβ CDR3 and it is unknown if they are paired with the same Vα. 
Given how TCRα chain paring influence the conformation of the CDRs, the Vα could 
also allow further pressure (Stadinski et al., 2011). The role of non-germline-encoded 
structures (Jβ regions and CDR3s) has been disputed in the context of vSAG 
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recognition as Vβ3+ T cells that escaped thymic selection in vSAG1+ mice showed no 
bias in the structure of these regions (Pullen and Bogatzki, 1996). However, this may 
indicate that vSAGs are presented by a vast array of peptides and that these V(D)J 
combinations were not of high enough affinity to allow thymic deletion. Still, a large 
body of literature suggests that the β chain junctional region could influence TCR 
recognition of vSAGs (Candéias et al., 1991b; Cells, 1995; Ciurli et al., 1998; 
Woodland et al., 1993). Recently, Kilgannon and colleagues proposed a model in 
which vSAG presentation was highly dependent on the CDR3 (Kilgannon et al., 2010). 
Interestingly, they reported that highly pMHCII-specific TCR (Vβ6+) fail to respond to 
vSAGs that were cognate to this Vβ. Although this result may sound trivial, it strongly 
supports the near-canonical docking and represents events in which vSAG cannot 
eschew such promiscuous TCR-pMHCII interactions. Thus, we can speculate that 
vSAGs coerce MHCII-TCR binding that may normally be of weak affinity and reorient 
the topology into a functional T cell signaling complex (Error! Reference source not 
found.8).  
 
Figure 6.8. Close-up of the vSAG mediated T cell signaling complex 
From left to right: Canonical pMHCII-TCR, vSAG-mediated pMHCII-TCR complex and a close-up of 
the latter. C-vSAG binds the TCR FR3 and HV4 and the MHCIIα chain, the latter also interacting 
with the TCR CDR1 and CDR3. The MHCIIβ-TCRα contacts remain to be evaluated. 
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6.2.2. vSAG and the MHCII-associated peptide 
In section 2.3.1 and 2.4.1, I described the influence of the MHCII bound-
peptide on vSAG presentation and proposed that amino-terminal PFRs are 
responsible for the inability of these pMHCII complexes to present vSAG. 
Notwithstanding the CLIP81-87 extension, no other distinct PFRs were tested and an 
idiosyncratic CLIP effect cannot be ruled out. Indeed, as introduced in section 
1.3.3. CLIP’s mission, the CLIP peptide possesses features that could possibly 
account for the results observed with vSAG. However, a previous report by 
Rötzschke and colleagues seems to indicate that any peptide amino-terminal 
extensions would give similar results. They monitored pMHCII migration patterns 
on SDS-PAGE or native gels and noticed that MHCIIs loaded with peptides bearing 
amino-PFR migrated faster than those without extensions (Rötzschke et al., 1999). 
Interestingly, in SDS-resistant experiments, DR1 loaded with lCLIP81-105 but not 
cCLIP87-105, generated fast-migrating heterodimers, similar to what is observed 
when HA is appended at least 10 amino-terminal PFRs (Rötzschke et al., 1999). 
They also assayed randomly generated amino-terminal peptide flanking sequences 
to verify whether this effect was sequence specific. However, every tested 
sequence, except a (GSPS)3 sequence, still generated the fast migrating pMHCII 
complexes. Altogether, these results suggest that the effect of lCLIP on vSAG 
presentation is linked to the presence of amino-terminal PFRs. However, with 
limited results it remains difficult to pinpoint whether this is due to steric hindrance, 
in which the extension prevents vSAG binding or a conformation alteration that 
does not allow vSAG binding to DRα.  
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6.2.3. vSAG-MHCII cross-linking = activation in trans? 
The results presented in section 2.4.3 suggest that vSAG7s bind multiple 
MHCIIs and stimulate TCR in trans. A priori, this model is rationalized by the 
inherent ability of the vSAG moieties to bind two opposite faces on MHCIIs. Yet, it 
is further refined when we compared CIITA+ versus CIITA- cell lines which showed 
that the presence of endogenous pMHCIIs restored HA- and vSAG-specific T cell 
stimulation after transfection of the SCT (Error! Reference source not found.9). 
In other words, we believe that vSAG (both moieties) are transferred to the 
endogenous pMHCIIs. By consequence, the HA-DR1 portion of the SCT becomes 
available to HA-specific T cells and vSAG is presented by the endogenous 
pMHCIIs. Whether vSAG stimulation can arise from its two moieties remains to be 
evaluated. However, it was previously shown that vSAG paracrine stimulation is at 
least 50% less potent, which suggests that N-vSAG may have a role in stabilizing 
the trimolecular complex (Delcourt et al., 1997a). 
 
Figure 6.9. Trans activation by vSAGs. 
On CIITA- cells, the lack of endogenous pMHCIIs prevents both HAs and vSAG-specific stimulation. 
1) vSAG-specific stimulation is prevented because of the limited concentration of pMHCIIs and 
because the latter is bound to N-vSAG*. 2) HA-specific stimulation is also inhibited by the N-
vSAG7* moiety. 3) Even if the vSAG domain of the SCT is transferred to an adjacent pMHCII, which 
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should restore both HA- and vSAG-specific stimulation, our read-out does not seem to be sensitive 
enough. In contrast, in CIITA+ cells, the presence of an endogenous population of pMHCIIs allows 
for  vSAG transfer, freeing the SCT of the vSAG moiety, restoring HA stimulation (4). Upon transfer 
to a permissive endogenous pMHCII, C-vSAG - either bound or not to N-vSAG - can stimulate 
cognate T cells (5). 
 
6.2.4. Concluding remarks 
Altogether, my results reconcile a compendium of studies pertaining to the 
field but refute the model proposed by the Huber group indicating that vSAGs bind 
to the MHCII peptide-binding groove (Hsu et al., 2001). In addition to depicting a 
novel SAG-mediated TCR signaling complex, I answer a question that has 
remained unresolved for over 20 years, highlighting the plasticity of the TCR 
complementary determining regions. Given the puzzling nature of vSAGs and my 
description of a novel SAG-TCR-MHCII fold, I believe that my data brings a much-
anticipated finale to decades of research and will serve as a grounding reference 
for future work, likely seeding new ideas related to MMTV superantigens. 
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6.3. Single chain constructs 
Briefly introduced in section 1.1.8, single chain constructs have been used 
for almost 20 years to generate pools of MHC bearing the same bound-peptide and 
shaped our comprehension of pMHC-TCR interaction. Here, I engineered an array 
of SC constructs to further characterize Ii and vSAG7 relation with MHCIIs. I also 
generated a single chain DO (DOsc) in which DOα is linked to DOβ. This construct 
was used to express DO at the surface of yeast cells.  
 
 
Figure 6.10. Cartoon of the single chain constructs 
From left to right: pMHCII: a peptide is appended to the MHCIIβ chain (Kozono et al., 1994); Ii-SCD: 
the luminal domain of either MHCII chain is attached to Ii by a G3SG3 flexible linker; vSAG-SCD: the 
luminal domain of either MHCII chain is attached to vSAG by a G3SG3 flexible linker; SCT: the 
luminal domain of vSAG is attached to the a pMHCII; DOsc: DO α and β chain are covalently 
attached by a 15 aa GS flexible linker (Esteban and Zhao, 2004).  
6.3.1. vSAG-SCDs 
As shown in the Chapter 2 (S2 and Figure 2.2B), the linkage of vSAG to 
DRα failed to efficiently exit the ER and was rapidly degraded non-specifically. 
These results, although hypothetical, suggest that vSAG interacts closely with 
DRβ, which was not allowed enough freedom to reach or pair with the wt β chain 
upon co-expression given the length of the linker (7aa). However, unexpected 
vSAG-α chain interaction that prevented their pairing with DRβ cannot be excluded. 
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6.3.2. DOsc 
The strategy to link DO luminal domain with a 15 aa linker (Error! 
Reference source not found.1) stems from the study by Esteban & Zhao 
(Esteban and Zhao, 2004). However, after performing the directed evolution on 
such constructs, they were tested in 293T for expression and fail to give rise to 
Mags.DO5 positive DOsc. At this point other constructs were tested, some with 
longer linker (22 aa) or with the β chain upstream of the α chain (with both linker 
length). Again, no Mags.DO5 positive DOsc were observed, although the HA-tag 
stained positively intracellular. Thus, it seems that even in the yeast, DOsc could 
not exit the cell unless accumulating mutation allowing proper folding into the 
Mags.DO5 conformation. 
6.3.3. Ii-SCDs 
Presented in detail in Chapter 4, constructs in which Ii was appended to the 
luminal domain of either MHCII α or β chain allowed us to describe the variable 
stoichiometry of the multimeric complexes including up to three MHCIIs and the Ii 
trimer. This strategy ensures that every Ii isomer is bound to an MHCII and forms 
nonameric complexes. However, when co-expressed with full-length wt Ii, the latter 
forming mixed-trimers with the Ii SCDs, cannot pair with MHCIIs given the lack of 
one of the MHCII chain, the other being exclusively expressed as the SCD. These 
mixed-trimers are well recognized by a battery of mAbs. Also, the SCDs recycle 
between the plasma membrane and the endosomes and allowed for proper 
degradation of Ii into the CLIP peptide. Moreover, we found that CLIP was 
efficiently removed upon co-expression of HLA-DM. Altogether, we demonstrate 
that Ii-SCDs are structurally very similar to wt MHCII/Ii complexes and adopt a wt-
like traffic. 
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6.4. Conclusion, Perspectives & Contribution 
Improving Ag uptake and peptide loading onto MHCII molecules is one of 
the challenges limiting the full potential of immunotherapy. One way to achieve this 
is by investigating MHCIIs chaperoning and processing. The peptide occupancy 
state leading to the high kinetic stability of MHCIIs is a factor limiting the success of 
peptide-based vaccines. Interestingly, both Ii and HLA-DM induce MHCII 
conformational changes and so studying those changes could provide valuable 
clues as to how to trigger peptide loading, a necessary step in designing peptide-
peptide based vaccines. Also, superantigens offer a great tool to monitor those 
subtle conformation alterations in addition to increase the potency of pMHCIIs. 
It was recently proposed that Ii trimers could only bind a single MHCII 
heterodimer and that this interaction would lock the Ii scaffold, preventing binding 
of additional MHCIIs (Koch et al., 2011). This report contradicts seminal work in 
which nonameric complexes were observed (Roche et al., 1991b). As a co-author 
with Cloutier, M. (Annex I), I recently confirmed that Ii can bind multiple MHCIIs at 
once, but that different stoichiometry exists. Furthermore, the number of MHCIIs 
that bind Ii trimer increases with time in the ER, as a result of the Ii p35 isoform ER-
retention motif. As of now, it is still unclear how Ii is able to stabilize MHCIIs other 
than from its association to the peptide-binding groove. Indeed, the field is plagued 
by the lack of a crystal structure portraying MHCIIs bound to Ii. After many 
attempts, the Wiley group has demonstrated that upon binding to MHCIIs, the 
structure of Ii becomes only partially ordered and crystallization assays have failed 
(Jasanoff et al., 1999b). In light of our results showing that the occupancy state of Ii 
trimers with different numbers of MHCIIs varies, it is possible that heterogeneity of 
Ii-MHCII complexes suppressed crystallization. 
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To counter Ii’s disordered state and coerce formation of nonameric 
complexes, I have engineered an array of single chain dimer (SCD) fusions 
between the luminal domains of Ii and either MHCII chain, which will likely restrict 
the flexibility of Ii. Those straightforward constructs are possible because DR and Ii 
are type I and type II proteins, respectively, allowing fusion of the C-terminus of DR 
chains to the N-terminus of Ii.  
Further structural studies of those SCDs will determine the Ii binding site on 
MHCIIs and provide insights as to the peptide loading mechanism and how certain 
MHCII allotypes fail to efficiently pair with Ii. Painters et al. demonstrated that the 
MHCII α chain region connecting the α1 to the α2 domain undergo a conformation 
change upon peptide binding (Painter et al., 2011). Analogously, DM interaction 
with DO induces conformation changes at this region (Personal communication). 
Besides, a report by Neumann et al. suggests that Ii binds MHCII at the same 
interface as DM (Neumann and Koch, 2006). Thus, it is conceivable that both Ii 
and DM alter MHCII conformation similarly. Because both Ii and DM are required 
for vSAG presentation in HeLa cells, one must wonder if such effect on the MHCII 
structure is sensed by this family of SAG. The recent DO-DM and DR-DM co-
crystal provides grounding information to undertake rational-designed site-directed 
mutagenesis in order to verify whether Ii or vSAG also bind similar regions and if Ii 
and DM stabilize empty MHCIIs by targeting the α1-α2 connecting region using a 
similar mechanism. 
Altogether, I aimed to understand the interrelation between Ii, DM, DO and 
the MHCII heterodimers. My results should provide grounding on the peptide 
exchange mechanism, proposed to occur synergistically with MHCII conformation 
transitions and to the impact of the bound-peptide at a structure-function level. To 
date, only a small segment of Ii, the CLIP region, has been crystallized in 
association with MHCIIs. Ii fragments extending outside the peptide-binding groove 
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were disordered on the solved CLIP-MHCII structures. Interestingly, the N-terminal 
end of the Ii extending outside the peptide-binding groove triggers peptide self-
release and is used to enhance the efficacy of peptide-based vaccines (Xu et al., 
2012). Of note, two vaccines relying on this characteristic of Ii are currently in 
phase I clinical trials against breast and prostate cancer. Knowing how this 
extension is detrimental to both SEB and vSAG presentation one must wonder how 
it affects MHCIIs. Further studying the structures of the SCDs could provide a 
model as to how this region of Ii, also referred to as Ii-key, enhances peptide 
immunotherapy and how vSAGs bind DRα. Finally, one may argue that using 
crystallography is paradoxical in evaluating protein dynamism. However, amassing 
a wealth of MHCII structures, especially those in interaction with chaperones, 
provides different snapshots along the course leading to peptide exchange.  
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